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ABSTRACT 
Epigenetic control of gene expression involves covalent reversible modifications 
of DNA, RNA, and histones which lead to changes in chromatin structure and accessibility. 
The ability to maintain precise control over gene expression in cells and tissues is critical 
for ensuring normal cellular development and homeostasis. The most important epigenetic 
mark of DNA is methylation of cytosine at the C5 position (MeC). This stable epigenetic 
mark is introduced by de novo methyltransferases DNMT3a/b and maintained through cell 
division by maintenance methyltransferase DNMT1. Ten Eleven Translocation (TET) 
dioxygenases oxidize 5-methylcytosine (MeC) to 5-hydroxymethylcytosine (hmC), 5-
formylcytosine (fC), and 5-carboxylcytosine (caC), a process known to induce DNA 
demethylation and gene reactivation. A precise balance of DNA methylation and 
demethylation is important for establishing tissue specific gene expression patterns, 
maintaining cell identity, and guiding development. However, inflammation and exposure 
to exogenous agents can lead to changes in DNA methylation patterns or “epimutations” 
which together with genetic mutations can lead to the development of cancer. 
Chapter I of this Thesis provides an overview of the major mechanisms of 
epigenetic regulation including epigenetic marks of DNA, non-coding RNAs, and histone 
modifications. Chapter I then describes epigenetic dysregulation in cancer and other human 
diseases. We then go on to describe how epigenetic changes in DNA can be detected and 
quantified using antibodies and mass spectrometry-based approaches. After considering 
global quantitation of epigenetic DNA modifications, we discuss the methods available for 
mapping epigenetic modifications along the genome.  
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In Chapter II of this thesis, the effects of C5-cytosine substituents with increased 
steric bulk on catalytic activity of maintenance DNA methyltransferase (DNMT1) were 
examined. This protein specifically recognizes 5-methylcytosine (MeC) bases at 
hemimethylated CG sites in DNA and conducts maintenance methylation. Maintenance 
methyltransferase activity was the highest towards DNA containing the natural DNMMT1 
substrate, MeC. The enzyme was capable of performing maintenance methylation when 5-
ethyl-dC was the substrate, while the more rigid and bulky C5-alkyl substituents such as 
5-vinyl- dC, and 5-propyl-dC could not direct maintenance methylation.  
In Chapter III, we investigated the kinetics of maintenance DNA methylation 
towards DNA duplexes containing oxidized forms of MeC (hmC, fC, and caC). We also 
employed a molecular dynamics simulation of the enzyme with the DNA to understand the 
interactions of oxidized forms of MeC with the DNMT1 enzyme. We found that methyl 
transfer rates were reduced when MeC was oxidized to hmC, fC, and caC, consistent with 
the model that Tet mediated oxidation contributes to passive DNA demethylation. 
In Chapters IV and V, we investigated inflammation-mediated epigenetic changes 
in the lung using A/J mouse model of smoking induced lung cancer. In collaboration with 
NuGEN (Santa Carlos, CA), we developed a novel reduced representation bisulfite 
sequencing (RRBS) methodology to map both MeC and hmC genome-wide. Our studies 
provide evidence that inflammation of the lung induces both global and site-specific 
epigenetic changes in DNA methylation and hydroxymethylation, alters global histone 
acetylation, and deregulates gene expression. These studies also provide evidence that 
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exposure to cigarette smoke can alter site-specific DNA methylation and 
hydroxymethylation of genes that are associated with the cancer phenotype.  
The final chapter of this dissertation (Chapter VI) employs affinity proteomics to 
identify protein readers of epigenetic marks of DNA in the lung. DNA duplexes 
functionalized with C, MeC, hmC, fC, and caC were attached to solid support and 
incubated with nuclear protein extracts from human bronchial epithelial cells (HBEC). 
Proteins specifically recognizing DNA epigenetic marks were identified using Orbitrap 
Velos mass spectrometer and quantified using 8-plex TMT tags. This chapter details the 
development of a method for carrying out the affinity proteomics experiments, including 
solid phase synthesis of DNA targets, peptide tagging, sample clean-up, fractionation, and 
nanoHPLC-ESI+-MS2 based methodology for protein identification and quantification. 
Overall, during the course of the studies described in this thesis, we have 
investigated the specificity and kinetics of human maintenance DNA methyltransferase 
(DNMT1), employed animal models to characterize epigenetic changes in the lung caused 
by inflammation and exposure to cigarette smoke, and examined novel mechanisms of 
epigenetic regulation at oxidized forms of MeC. Overall, this work contributes to current 
understanding of epigenetic regulation in normal cells and epigenetic deregulation in 
cancer.  
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I. LITERATURE REVIEW 
 
Adapted in part from: 
Seiler, C.L.; Fernandez, J.; Han, Q.; and Tretyakova, N.Y.; Experimental methodologies 
for detection and mapping of epigenetic DNA marks, Springer Chapter, submitted March 
19, 2018. 
 
This thesis chapter is an expansion of a book chapter submitted to the Springer 
publishing group, which was a collaborative effort between Christopher Seiler, Jenna 
Fernandez, and Qiyuan Han, under the direction of Prof. Natalia Tretyakova. Christopher 
Seiler wrote sections 1.1, 1.2, and 1.7. Christopher Seiler, Jenna Fernandez, and Qiyuan 
Han wrote sections 1.3, 1.4, and 1.6. Qiyuan Han wrote section 1.5. Christopher Seiler and 
Jenna Fernandez edited the text and prepared the original figures.   
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1.1 Epigenetic regulation of gene expression 
1.1.1 What is epigenetics? 
Generally, epigenetics is defined as changes in gene expression that do not result 
from changes in the gene sequence.1 Epigenetic regulation can be achieved through 
reversible covalent modifications of DNA, RNA, and histones.1 DNA epigenetic 
modifications are primarily found as cytosine methylation, its oxidized forms, and may 
also employ methylation of adenine (see section 1.1.2 for more information).1 Epigenetic 
modifications of histones include lysine acetylation, which can reduce the charge on 
histones, and methylation, which can occur as mono-, di-, or tri-methylated forms (see 
section 1.1.3 for more information).1 Epigenetic regulation of RNA occurs through 
individual RNA species such as miRNA as well as covalent modification of mRNA 
transcripts (see section 1.1.4 for more information).1 Epigenetic changes are critical in 
cellular development and differentiation, as well as for normal cellular processes.1 
Epigenetic deregulation is increasingly recognized as a critical event in the development 
of cancer and other diseases including asthma,2 autism, and diabetic cardiomyopathy.3-4  
 
1.1.2 DNA epigenetic marks 
Epigenetic control on DNA primarily presents as methylation of C5-position of 
cytosine.5 The human genome contains 3 billion base pairs.6 Of these, nearly 27 million 
cytosines exist in the CpG sequence context, making them potential targets for DNA 
methyltransferase (DNMT) activity.7 Cytosine methylation can also be found in CHH and 
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CXG contexts, where H is A or T. It is currently unknown what enzymes in mammals may 
be responsible for methylating cytosine in these contexts. 5-Methylcytosine (MeC in 
Figure 1.1) is a key epigenetic modification of DNA with important roles in gene 
regulation, genetic imprinting, X-chromosome inactivation, and genome stabilization.8 
Methylated CpG sites are recognized by methyl-CpG binding proteins, leading to the 
recruitment of histone deacetylases, chromatin remodeling, and in most cases, reduced 
levels of gene expression.9-10 DNMTs introduce MeC into the genome by catalyzing the 
transfer of a methyl group from S-adenosylmethionine (SAM) to the C-5 position of 
cytosine in DNA.10-11 DNMT3 A/B are responsible for de novo DNA methylation, a 
process mediated by the DNMT3L scaffolding protein.12 Once established, DNA 
methylation patterns are faithfully maintained by specialized DNA methyltransferase, 
DNMT1, which recognizes hemi-methylated CpG sites and methylates the newly 
synthesized strand.10 This preserves cell identity and maintains tissue specific gene 
expression patterns following semi-conservative DNA replication.  
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Figure 1.1. Structures of epigenetic modifications of DNA including 5-methyl-2ʹ-
deoxycytidine (MeC), 5-hydroxymethyl-2ʹ-deoxycytidine (hmC), 5-formyl-2ʹ-
deoxycytidine (fC), 5-carboxyl-2ʹ-deoxycytidine (caC), N6-methyl-2ʹ-deoxyadenosine 
(N6MedA), and 4-methyl-2ʹ-deoxycytidine (4mC). 
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Recent studies have shown that cytosine methylation marks are reversible. Ten 
eleven translocation family of proteins (TET 1-3) iteratively oxidize MeC to generate 5-
hydroxymethylcytosine (hmC), 5-formylcytosine (fC), and 5-carboxylcytosine (caC) 
(Figure 1.1 and Figure 1.2).13-16 TET enzymes utilize active site non-heme iron and α-
ketoglutarate to split molecular oxygen and sequentially oxidize MeC.13, 17-18 During the 
oxidation of MeC to hmC, fC, and caC, hydrogen atom abstraction from the C5 methyl 
group is the rate limiting factor.17 In the reaction mechanism, a hydrogen atom needs to be 
directed toward the active site iron for the oxidation reaction to proceed.17-18 The C-5 
methyl group of MeC is able to rotate and position its hydrogen atoms efficiently in the 
active site of the protein. Once MeC is oxidized to hmC and fC, the abstraction of hydrogen 
atoms from C5 becomes progressively more difficult, slowing the enzymatic activity of 
Tet.17 When fC is present in the active site, the C5-carbonyl oxygen and N4-exocyclic 
amine form an intramolecular hydrogen bond, which keeps the remaining C5-hydrogens 
4.98 Å away from the active site iron.17 The hydroxymethyl group of hmC can also form 
an intramolecular hydrogen bond with the exocyclic amine of the pyrimidine. However, 
this nucleoside can exist in two conformations in one of which the C5-hydrogen atom is 
oriented toward the catalytic iron, allowing for oxidation to occur, at a slower rate.17  
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Figure 1.2. Enzymatic pathways that generate MeC, hmC, fC, caC, and N6MedA in 
genomic DNA. Cytosine is methylated by DNA methyltransferase in the presence of S-
adenosylmethionine. MeC can then be iteratively oxidized by the TET family of enzymes 
to produce hmC, fC, and caC. N6MedA is introduced by a yet undiscovered methylase and 
can be demethylated by Alkbh1.  
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TET-mediated oxidation of MeC to hmC, fC, and caC leads to passive DNA 
demethylation since DNMT1 activity is reduced in the presence of oxidized forms of  MeC 
.19-20 Both fC and caC can also be removed via thymine DNA glycosylase (TDG) and 
replaced with C via the base excision repair pathway, leading to active DNA 
demethylation.16 Oxidized forms of MeC can also be enzymatically removed by 
Srap1endonuclease (SOS associated peptidase 1).21  
In addition to their roles in DNA demethylation, oxidized forms of MeC have been 
proposed to possess their own epigenetic functions by directly participating in epigenetic 
signaling.22-25 Mass spectrometry based proteomics studies have identified a number of 
proteins that specifically interact with MeC, hmC, fC, and caC, suggesting that each of 
these epigenetic marks is recognized by a unique set of “readers”.26-27 For example, Mbd2 
specifically binds MeC, Thy28 specifically binds hmC, while Uhrf1 preferentially binds 
MeC and hmC, and Srap1 binds hmC, fC, and caC.21, 26  Genome-wide distributions of 
MeC, hmC, fC, and caC bases further suggest that they play different roles in gene 
regulation.28 For instance, hmC is preferentially enriched at distal regulatory elements such 
as enhancers in mouse and human embryonic stem cells, whereas fC or caC tend to 
accumulate at poised enhancers and promoters, respectively.28-29  
MeC and its oxidized forms are present in all mammalian tissues examined, but in 
different amounts. MeC makes up 4.30  0.22% of dG.30 hmC levels vary between 0.03% 
and 0.69% of dG depending on tissue type (Figure 1.3).30 In most tissues, fC and caC are 
present in much lower amounts, with fC concentrations approximately three orders of 
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magnitude lower than the levels of hmC, and the levels of caC approximately 10-fold lower 
than the amounts of fC.31  
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Figure 1.3. Tissue specific amounts of MeC and hmC determined by mass spectrometry. 
A. hmC abundance is tissue-dependent, with the highest levels observed in tissues of the 
central nervous system. The lowest levels of hmC are observed in the pituitary gland, liver, 
spleen, and testes. This roughly correlates with cell proliferation rates, with higher levels 
of hmC found in tissues with the lowest proliferation rates. B. Values of MeC expressed as 
percentage of dG. Levels of MeC appear to stay relatively consistent across all tissue types. 
Adapted from Globisch D et al. (2010) Tissue distribution of 5-hydroxymethylcytosine and 
search for active demethylation intermediates. PLoS One. Dec 23;5(12):e15367. doi: 
10.1371/journal.pone.0015367. Used in accordance with CC BY license 
(http://creativecommons.org/licenses/by/4.0/)." 30 
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Recently, several additional modifications of DNA were discovered including N6-
methyl-2ʹ-deoxyadenosine (N6MedA) and N4-methyl-2ʹ-deoxycytidine (4mC) (Figure 
1.1), which may play a role in epigenetic regulation. These DNA modifications have long 
been known to exist in prokaryotes, where N6mdA and 4mC are the most prevalent DNA 
modifications and are primarily used for distinguishing host DNA from foreign pathogenic 
DNA.32-33 First indirect evidence for the presence of N6MedA in mammals dates to 1983.34 
Although subsequent studies by Ratel et al. were unable to confirm the presence of 
N6MedA in mammalian genomes,35 more recent reports confirmed the observation of 
N6MedA in mouse and human genomes.33, 36 N6MedA is widely distributed across the 
genome, although depleted in exonic regions.33 Furthermore, N6MedA is preferentially 
found at TAGG sites and has been implicated in gene repression.33, 36 Recently, N6MedA 
in mouse brain has been shown to be mediated by environmental stress, although the 
biological significance of this finding remains to be elucidated.37 Many biological features 
of N6MedA in mammals require further study, including the nature of N6MedA writers, 
erasers, and readers.33  
N4-methyl-2ʹ-deoxycytidine (4mC) has been observed in DNA of thermophilic 
bacteria and many bacteria mesophiles.38 In bacteria, 4mC is generated by N-4 cytosine 
specific DNA methyltransferases.39 4mC is a part of a bacterial restriction modification 
system used to defend against foreign DNA, with several 4mC methyltransferases and 
4mC-sensitive restriction endonucleases identified in various bacterial strains.40 However, 
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additional biological functions of 4mC have not been fully elucidated, and its possible 
function in eukaryotes remains to be established.  
DNA epigenetic marks have distinct relationships with the levels of gene 
expression as indicated by the varied genomic locations determined by DNA-Sequencing 
(See section 1.4 for more information). MeC is consistently increased in promoter CpG 
islands of inactive genes and in inactive promoter regions with low CpG density.41 hmC is 
enriched in TSS and gene bodies and is associated with active gene transcription, a reversal 
of MeC repression.42 fC and caC are associated with active gene transcription.43-44 
However, fC and caC are associated with reduced rates of RNA polymerase II catalyzed 
transcription and substrate specificity.45 
 
1.1.3 Histone epigenetic marks 
 Mammalian DNA is packaged in the nucleus, where it exists in complex with 
histone proteins to form chromatin.1 Approximately 147 base pairs of DNA is wrapped 
around a histone octamer comprised of two copies of each histone H2A, H2B, H3, and H4 
or their variants.46 The presence of epigenetic marks on histones has been known since 
1964.47 These marks occur on the highly basic lysine rich tails of the histones and alter the 
chromatin structure and interacting proteins.46 Histone tail lysines are modified with acetyl 
and methyl groups with the methylation occurring as a mono-, di-, or tri-methylated.48 
Generally, histone acetylation removes the positive charge on histone tails by converting a 
primary amine group (-NH2) to an acetamide (-NH-C(O)-CH3). This change reduces 
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charge-charge interactions of histones with the negatively charged phosphodiester 
backbone of DNA, allowing for chromatin opening and active transcription.49 Histone 
epigenetic marks are introduced by a group of enzymes termed writers (histone acetyl 
transferases, HAT, histone methyltransferases, HMT), interpreted by readers for 
acetylation (bromodomains) and methylation (chromodomains), and removed by erasers 
(histone deacetylase, HDAC, histone lysine demethylase, LSD).46, 50 
 Addition of acetyl groups to histones by HATs utilizes the acetyl group from acetyl-
CoA and requires a catalytic glutamate residue in the enzyme active site.51 The effect of 
histone acetylation of H3K9, H3K14, and H4K12 on chromatin structure has been 
investigated using chromatin immunoprecipitation sequencing (ChIP-Seq).52 Histone 
acetylation is correlated with actively transcribed genes.46 In particular, H3K9 acetylation 
is associated with transcriptional start sites. Similarly, acetylation of H2AK5, H3K14, and 
H4K12 is common in gene bodies of highly expressed genes.48 Many HATs are present in 
multiprotein complexes which influence and direct their activity.53 HDACs oppose the 
activity of HATs by removing the acetyl groups from lysine, restoring the positive charge 
on histones and generally acting as transcriptional repressors.46, 48 Similarly to HATs, 
HDACs can also function in protein complexes containing additional HDACs, which 
modulates the activity and specificity of the HDACs in the complex.46, 48, 54 Bromodomain 
family of protein readers is implicated in many regulatory pathways, including cell 
signaling and chromatin remodeling.46 Examples of bromodomain proteins include BRDT, 
BRD2, BRD3, and BRD4.46  
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 Histone methylation is catalyzed by histone lysine methyl transferases (HKMT).48 
These proteins function by transferring the methyl group from SAM to an ε-amino group 
of lysine. HKMT proteins tend to be quite specific for their substrates and in some cases 
can catalyze the formation of di- and tri-methylated lysine.48, 55 The ability of HKMT 
proteins to catalyze the formation of trimethylated lysine is typically controlled by the 
presence of phenylalanine in their active site, and replacement of the Phe with Tyr prevents 
formation of trimethylated lysine.55-56 Histone lysine methylation, e.g. H3K27, H3K9, 
H3K4, H4K20, H3K79, and H2BK5, affects the levels of gene expression.57 Interestingly, 
the exact methylation state of the lysine is very important: H3K27 trimethylation being 
associated with repression, while H3K27 monomethylation associated with activation.58-59 
Additionally, repression of transcription by trimethylation of H3K27 is associated with an 
increase in CpG methylation.60 
Histone demethylation is catalyzed by lysine specific demethylases (LSD).48, 57 
LSD1 recognizes mono- and di-methylated H3K4 in free histones, however, LSD1 can 
also recognize nucleosomes when it is a part of the Co-REST system.48, 61 Co-REST is a 
protein complex that functions as a corepressor of the REST (RE1 silencing transcription 
factor).62 LSD1 is part of the KDM1 family of lysine specific demethylases.63 KDM1 
proteins are able to demethylate mono- and di-methylated lysines via a catalytic 
mechanism that includes the formation of an imine intermediate (Scheme 1.1A).48, 64-65 The 
imine is subsequently hydrolyzed, giving rise to free Lys and releasing formaldehyde.64 
The need to form an imine intermediate prevents KDM1 family demethylases from 
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demethylating trimethylated lysines. The second family of LSDs has a mechanism distinct 
from that of LSD1 and instead contain a Jumonji C domain that performs an oxidative 
demethylation reaction to remove methyl groups from lysine (Scheme 1.1B).66 The 
Jumonji C domain uses Fe(II) and α-ketoglutarate to oxidize the methyl group to a 
hydroxymethyl which spontaneously breaks down to a free amine and liberates 
formaldehyde.48, 66 
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Scheme 1.1. Histone lysine demethylation by LSD1 (A) and Jumonji C protein JHDM (B). 
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1.1.4 RNA epigenetic marks 
 Cellular RNA exists in multiple forms including mRNA, miRNA, lncRNA, 
snoRNA, snRNA, rRNA and tRNA.67 Several RNA species are involved in the epigenetic 
regulation of gene expression. mRNA is heavily modified post transcription with over 160 
known modifications.68-69 These post-transcriptional modifications can act to alter RNA 
splicing, mRNA translation rates, and the longevity of mRNA in the cell.68-69 Further 
control is imposed by micro RNA species (miRNA). miRNA (an RNA species about 22 
nucleotides in length) act by binding to the 3ʹUTR of target mRNA species to inhibit 
translation and to increase its degradation.70-71 Many mRNA contain multiple miRNA 
binding sites, allowing for a complex regulatory network.67 miRNA are widespread and 
conserved regulatory molecules, although some are tissue specific.72-73 In addition, miRNA 
have been shown to control a diverse group of processes including pluripotency, epithelial-
mesenchymal transition, and metastasis among others.73-75 Recently, long noncoding RNA 
(lncRNA, a non-protein-coding RNA transcript greater than 200 nucleotides) emerged as 
a component of cellular differentiation.4, 67, 76-77 Epigenetic regulation by lncRNA is 
achieved through multiple pathways including recruitment of chromatin modifying 
complexes, targeting DNA for methylation, and enhancing the expression of neighboring 
cognate genes.76, 78-79 These effects are mediated through lncRNA in complex with 
chromatin modifying complexes such as HMTs.80-81 
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1.2 Epigenetic deregulation and human disease 
1.2.1 Role of epigenetic deregulation in disease  
Epigenetic control of gene expression allows for a regulated expression of proteins 
and signaling molecules necessary for cells and tissues to perform their unique functions. 
Genetic mutations found in tumors can alter a protein’s sequence that affects function and 
dysregulated epigenetic signaling can affect the expression and levels of proteins in the 
cell. Epigenetic changes, or “epimutations”, are increasingly recognized as critical events 
in the development of cancer and other diseases.3 Specifically in cancer, changes in DNA 
methylation patterns can lead to silencing of tumor suppressor genes and activation of 
protooncogenes, which represents an early critical event in tumor development.3 Aberrant 
cytosine methylation is implicated in many additional human diseases including asthma, 
autism, and amyotrophic lateral sclerosis.2, 82-83 Drugs that inhibit DNA methylation have 
been successful for treating many types of cancer.84 DNMT inhibitors such as 5-
azacytidine, 5-aza-2′-deoxycytidine (decitabine) and pyrimidin-2-one ribonucleoside 
(zebularine) are used as single agents and in combination with classical chemotherapeutic 
agents in treatment of various tumors including myelodysplastic syndromes.85-89 
DNA hydroxymethylation is also implicated in many diseases. Elevated levels of 
hmC are observed in patients with systemic lupus erythematosus,90 autism,82 and bronchial 
asthma.91 In contrast, the levels of hmC are substantially lowered in human cancers, with 
a 50% to 90% reduction of hmC in breast cancer, liver cancer, lung cancer, and other tumor 
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types.92 There are currently no drugs targeting the TET enzymes available on the market 
and no TET specific inhibitors.  
Epigenetic modifications of histones have also been assessed for their role in human 
disease. HDAC inhibitors have been used as anticancer agents in combination with other 
therapeutics, this includes FDA approved drugs Vorinostat and Panobinostat.93-94  
Inhibitors of the histone acetylation readers, bromodomain proteins, have been explored as 
possible therapeutics for a variety of conditions including cancer, inflammatory and 
infectious diseases.48 The most well-known bromodomain inhibitor, JQ1, has been shown 
to have promising anticancer effects.95 
Noncoding RNA, especially miRNA, has been associated with a variety of diseases 
including cancer, myocardial infarction, and autoimmune disease.96-97 RNA regulation can 
be achieved by transcribing pseudogenes, which are chromosomal regions that are an 
imperfect copy of a functional gene but will often carry the same miRNA binding sites.98 
The transcription of a pseudogene’s mRNA in the cell function as a miRNA decoy for the 
cognate gene and can reverse the repression of those cognate genes by intercepting the 
repressive miRNAs.98 miRNA targets have been suggested as potential therapeutic targets 
using strategies such as introduction of mature miRNA duplexes to increase levels.97 These 
approaches have similar difficulties to gene therapy approaches such as selective targeting 
and transient expression, although some easily accessible sites like the lungs and the eye 
have been successful.99-100 
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1.2.2 Epigenetic changes in lung cancer 
 
Lung cancer is anticipated to kill over 150,000 Americans this year and is 
responsible for 30% of cancer deaths worldwide.101 Cigarette smoke contains over 60 
known carcinogens including tobacco specific nitrosamines and butadiene as well as co-
carcinogens such as the bacterial endotoxin lipopolysaccharide (LPS).102-105 These 
carcinogens and co-carcinogens can induce genetic and epigenetic alterations.104, 106 
Among epigenetic changes detected in smoking-induced lung tumors, DNA methylation, 
histone acetylation, and micro RNA expression are often dysregulated, leading to silencing 
of tumor suppressor genes and activation of oncogenes such as Kras.104 In particular, 
methylation of key genes such as MGMT, Rassf1a, DAPK1, p16, hMLH1 correlates with 
malignant phenotype.107-108 Rassf1 promoter hypermethylation has been shown to be 
present in invasive cancers.109 For lung adenocarcinoma, Tsou et al. identified a panel of 5 
genes (p16, EX2, CDX2, HOXA1, and OPCML) whose methylation state could selectively 
distinguish cancerous and non-cancerous tissue.110 p16, EX2, CDX2, HOXA1, and 
OPCML are identified as having a high frequency of DNA methylation and a significant 
increase in methylation in tumors compared to adjacent normal tissue.110  A total of  28 
loci were tested in matched tumor and adjacent normal tissue to find the most predictive 
biomarkers.110  
In addition to changes in DNA methylation, the levels of histone modifying 
enzymes are altered in lung cancer.111 This includes the methyltransferase EZH2, which 
methylates H3K27 and is associated with silencing CDH1, p27, and BRCA1.111-113 HMT 
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G9a is also capable of methylating H3K37 and promotes lung cancer invasion and 
metastasis by silencing Ep-CAM.114-115 Histone lysine acetylation marks are also 
deregulated in lung cancer, especially hypoacetylation of H3K18.116-117  
Some miRNAs can act as oncosuppressors, while others, such as miR-21 or miR-
663, act as oncogenes and are overexpressed in cancer.118-119 miR-21 in particular has been 
is frequently amplified in non-small cell lung cancer (NSCLC).120 miRNA-663 reduces 
apoptosis by limiting the permeability of the mitochondria outer membrane by inducing 
p53 translocation to the mitochondria.119 miR-663 depletion was enough to cause cell death 
in NSCLC in vivo.119  
Advances in the treatment of lung cancer over the past 25 years have increased the 
5-year survival rates from 12.3% (1975-77) to 16.3% (2001-7).121 Many new treatments 
have been approved by the FDA, including angiogenesis inhibitors, antimetabolites, 
antimicrotubular, EGFR inhibitors, kinase inhibitors, PD-1 blockers, and a 
photosensitizing agent. Unfortunately, initial clinical trials have failed to achieve a 
significant response in lung cancer patients with epigenetic drugs.122-126 New agents 
targeting additional epigenetic pathways are needed to help improve lung cancer treatment. 
 
1.2.3 Inflammation and increased cancer risk 
 Tissue inflammation is a necessary process employed in the innate immune system 
and during wound repair.127 However, chronic inflammation is strongly associated with the 
pathogenesis of cancer.128-129 Specifically, chronic inflammation in the lung such as in 
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chronic obstructive pulmonary disease (COPD) increases the risk for lung cancer, while 
colitis and Crohn’s disease are associated with colon cancer.130 COPD patients are at 5-
fold higher risk for lung cancer, while Crohn’s disease can increase colon cancer risk 
between 4 and 20-fold.131-132 Chronic inflammation caused by H. pylori infection in the 
stomach  is associated with gastric cancer, while HPV can cause cervical cancer, and 
hepatitis viruses - liver cancer.129 
 
1.2.4 Animal models of lung cancer initiation  
Various animal models have been used for studying lung cancer initiation, with the 
two most common being murine systems.133 Rat models of smoking induced lung cancer 
have the advantage of little to no spontaneous background tumor formation. Female rats 
exposed to mainstream cigarette smoke had a significant increase in lung tumorigenesis.134 
One of the key animal models of smoking-induced lung cancer is the A/J mouse.135 A/J 
mice are susceptible to the formation of spontaneous and induced lung tumors and have 
been widely used to observe lung tumorigenesis following exposure to environmental 
tobacco smoke.133, 135 Multiple studies of A/J mice exposed to mainstream smoke for 5 
months with 4 months post-exposure have shown a positive correlation of exposure with 
lung tumorigenesis.136-138 In these smoke exposure studies, whole body exposure to 
mainstream smoke as opposed to nose only exposure produced positive tumorigenesis 
results.136 Life-time exposure to cigarette smoke has also been examined in female B6C3F1 
mice. Hutt et al. found a significant increase in the lung tumorigenesis after life-time 
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exposure (over 900 days) to mainstream cigarette smoke.139 The exposure of A/J mice to 
cigarette smoke starting 12 hours after birth for 4 months followed by 5 months post 
exposure resulted in an increase in the number of lung tumors in exposed mice.140 This 
tumorigenic effect was reduced in mice which were simultaneously dosed with anti-
inflammatory agents such as acetylsalicylic acid, supporting a critical role of inflammation 
in smoking-induced lung cancer.140 
Animal models have also been used to explore the carcinogenicity of individual 
tobacco carcinogens such as tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) and cocarcinogens such as lipopolysaccharide (LPS).141-143 
Using the A/J mouse model, Melkamu et al. observed that the inflammatory agent LPS can 
increase both the size and multiplicity of NNK-induced tumors, supporting the hypothesis 
that lung inflammation promotes tumorigenesis.141 A further study with lung inflammation 
by LPS in the A/J mouse found that this effect could be attenuated by dietary supplements 
of indole-3-carbinol and silibinin.142 Given individually to A/J mice by intragastric gavage, 
NNK and benzo[a]pyrene were found to induce lung tumor formation following 8 week 
long exposures, but the tumorigenicity could be reduced by pre-dosing with 
chemopreventative agents benzylisothiocyanate  and phenethylisothiocyanate.144 
Overall, previous studies using rodent models have established that lung tumors 
can be induced by exposures to tobacco smoke and to single tobacco carcinogens such as 
NNK, and that this effect can be enhanced by inflammation. These investigations have 
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confirmed that lung tumors can be caused by exposure to cigarette smoke or its 
components, consistent with epidemiological evidence.  
 
1.3 Methods for detection and quantification of epigenetic modifications within the 
genome 
1.3.1 Initial detection of MeC and its oxidized forms via paper chromatography and 
thin layer chromatography 
  Paper chromatography and thin layer chromatography experiments played a key 
role in the initial discovery of epigenetically modified DNA bases.145 In paper 
chromatography, a compound mixture is spotted on a strip of chromatography paper, which 
is then hung in a development chamber, and dipped into a solution of volatile alcohols in 
which to develop the chromatogram. Compounds that are more soluble in the alcohol 
mobile phase move up the paper strip during development. Paper chromatography was 
used for the initial detection of MeC in eukaryotic DNA.145 Calf thymus DNA was 
hydrolyzed with acid, and the resulting free bases were separated by paper chromatography 
using butanol. The resulting chromatographic spots were extracted with alcohol and 
identified by comparing their UV spectra to those of standard nitrogenous bases. Paper 
chromatography has since been replaced by newer techniques such as thin layer 
chromatography (TLC).  
TLC was instrumental for the initial discovery of hmC in Purkinje cells and 
cerebellum tissue146 and the identification of TET family of enzymes responsible for the 
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oxidation of MeC to hmC.13 To determine the components of DNA by TLC, the DNA was 
digested to nucleosides and radiolabeled with 32P, followed by 2D-TLC in which an 
additional spot was observed on the TLC plate.146 The new TLC spot, corresponding to 
hmC, was detected in both cell types, but was twice as abundant in Purkinje cells as 
compared to granule cells.146 TLC was also used to identify hmC as the oxidation product 
of MeC in HEK293 cell DNA.13 Following transfection of HEK293 cells with a plasmid 
containing TET1, cellular DNA was isolated and cleaved with MspI. Following 
radiolabeling with 32P, DNA fragments were enzymatically digested to nucleotides, which 
were run out on a cellulose TLC plate using a mixture of isobutyric acid, water, and 
ammonia and imaged using a phosphoimager.13 The TLC showed a small spot that was 
only visible when cells had been transfected with TET1 and cleaved with MspI (Figure 
1.4).13  
The strength of TLC in studies aiming to identify new epigenetic modifications of 
DNA lies in its high sensitivity following 32P end labeling of native and modified 
nucleosides. A key weakness of TLC is the necessity for a secondary confirmation of the 
identified spot, which is most often done through mass spectrometry. Additionally, TLC is 
not scalable to a high throughput format and thus is not well suited for large studies.  
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Figure 1.4. Identification of hmC in brain cells and its formation by TET1 via 32P TLC. A. 
The 2D-TLC of Purkinje cells and Granule cells indicated a new spot marked X, which 
comigrates with hmC mono phosphate. From Kriaucionis, S., and Heintz, N. (2009) The 
nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. 
Science 324, 929-930. Reprinted with permission from AAAS.146 B. DNA was isolated 
from HEK293 cells after transfection with TET1 plasmid. DNA was digested with MspI, 
32P end labeled, and digested to nucleosides. HEK293 DNA revealed an additional 
nucleotide in the presence of TET1, both full length (FL) and catalytic domain (CD), but 
not in the mutants of either. From Tahiliani, M. et al. (2009) Conversion of 5-
methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. 
Science 324, 930-935.13 Reprinted with permission from AAAS. 
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1.3.2 Antibody based detection of epigenetic marks in DNA  
 Antibodies that specifically recognize epigenetic marks of DNA are commonly 
used to quantify their global levels. In 1980, Sano et al. developed an antibody against MeC 
which could recognize methylated sites in purified DNA.147  In brief, DNA fragments were 
separated by agarose gel electrophoresis and transferred to nitrocellulose paper. The 
membrane was incubated in the presence of purified antibody raised in rabbits against 
MeC, followed by incubation with 125I-labeled goat anti-rabbit IgG. The MeC was then 
visualized by autoradiography. This methodology was capable of detecting 20 fmol of MeC 
in immobilized restriction fragments of DNA.147 A more sensitive MeC antibody, as well 
as an antibody specific for N6MedA, were developed a few years later and utilized for their 
detection in human and Drosophila DNA.34 This more sensitive MeC antibody enabled the 
detection of a minimum of 5 fmol amounts in nanogram quantities of DNA.34  
Today, antibody-based detection of DNA epigenetic marks is a commonly used 
technique, and antibodies for many epigenetic DNA modifications are commercially 
available. These antibodies have frequently been used in an enzyme-linked immunosorbent 
(ELISA)-type assay (Figure 1.5).148-149 Commercially available ELISA-based kits for 
global DNA methylation profiling are available from a number of companies including 
Zymo and EpiGentek. Generally, these kits capture DNA on an ELISA plate. MeC is 
detected through sequential incubations with a primary antibody against MeC, followed by 
a secondary antibody linked to luciferase or a similar enzyme, and finally using 
colorimetric or fluorometric detection reagents.148 The development of antibodies specific 
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for hmC and fC allowed for their quantitation using similar commercially available kits 
(e.g. EpiGentek MethylFlash Global DNA hydroxymethylation (5-hmC) ELISA Easy Kit; 
Active Motif Global 5-hmC DNA Quantification Kit; EpiGentek MethylFlash 5-
Formylcytosine (5-fC) DNA Quantification Kit). These ELISA-based assays are easy to 
perform, require equipment that is readily available at most research laboratories, and work 
best for the identification of large changes in global DNA methylation. However, it should 
be noted that ELISA-based methods are prone to high variability, do not allow for absolute 
quantitation, and are best suited for detecting large changes in global levels of hmC or fC.  
 Dot blotting is another simple and rapid antibody-based method to quantify global 
levels of epigenetic modifications of DNA. In this method, genomic DNA is spotted on a 
membrane.   The membrane is sequentially incubated in blocking buffer, antibody solution, 
and rinsing buffer. Using an antibody specific for a specific epigenetic modification allows 
for detection of overall global genomic levels. After chemiluminescence imaging, the 
intensity of the signal can be used to compare the levels of epigenetic modifications 
between samples. Generation of antibodies specific for different epigenetic modifications 
has permitted the quantification of MeC, hmC, fC, caC, and N6MedA in both human and 
mouse tissues by dot blot.33, 150-151 As is the case for ELISA-based detection, dot blots do 
not allow for absolute quantification and suffer from high variability. 
 Antibodies have also been used to elucidate the biological functions of DNA 
epigenetic marks by studying their tissue-specific levels and distribution. Global levels of 
epigenetic DNA marks can be evaluated by staining cells or tissues with a specific 
28 
 
monoclonal antibody.152 Globisch et al. utilized immunostaining experiments with a 
commercially available hmC-specific antibody to map the distribution of hmC in cells and 
tissues. They found that hmC was localized in the cell nuclei and that virtually all cells 
contained hmC. Furthermore, the use of immunostaining allowed these authors to confirm 
that the highest levels of hmC are found in the brain, followed by kidney and nasal 
epithelia.30 
Antibodies specific to epigenetic marks can also be used for affinity enrichment of 
DNA regions. Antibodies can be used to immunoprecipitate modification-containing DNA 
fragments, allowing for their enrichment. This technique can then be coupled to 
methylation-specific oligonucleotide (MSO) microarrays, locus specific PCR, or whole 
genome approaches such as next generation sequencing or microarrays, to enable for low 
resolution mapping of epigenetic marks within the genome (see sections 1.4.4 and 1.4.5). 
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Figure 1.5. Scheme of ELISA methodology. In an ELISA the methylated DNA is coated 
onto the surface of a well-plate, incubated with a MeC specific antibody. Following binding 
of the primary antibody, a secondary antibody directed toward the primary antibody is 
added, which is conjugated to a dye or fluorophore. The amount of methylation can then 
be visualized by the level of absorbance or fluorescence intensity.  
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1.3.4 High performance liquid chromatography and mass spectrometry 
Global levels of MeC, hmC, fC, caC, N6MedA, and 4mC in genomic DNA can be 
accurately quantified by isotope dilution liquid chromatography mass spectrometry. In this 
approach, DNA is enzymatically digested using nucleases and phosphatases, and the 
resulting nucleosides are analyzed by HPLC-ESI-MS/MS. HPLC with UV detection can 
be used for measuring MeC in biological samples due to its high content (4-5% of all 
cytosine bases),153 while other epigenetic modifications (hmC, fC, caC, N6MedA, and 
4mC) are significantly less abundant  and require more sensitive methods such as HPLC-
ESI-MS/MS.153  
HPLC-ESI-MS/MS is widely accepted as the most accurate technique for 
quantification of global levels of MeC and its oxidized forms.153 In this approach, DNA is 
digested to individual nucleosides. Epigenetically modified DNA nucleosides are detected 
based on their characteristic molecular weights (Table 1.1), HPLC retention times, and 
MS/MS fragmentation (Figure 1.6). MeC, hmC, fC, caC, and N6MedA can be readily 
identified by mass spectrometry based on their distinct mass to charge ratios and MS/MS 
fragmentation.153 Absolute quantitation is performed using stable isotope labeled 
analogues of each nucleoside that are spiked into samples (Figure 1.6), or by using external 
calibration curves. This methodology makes it possible to accurately quantify global 
amounts of each epigenetic mark of DNA, although it does not provide their distribution 
along the genome.154 
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Table 1.1. Molecular weights and main MS/MS fragments of canonical and 
epigenetically modified DNA nucleosides.  
Nucleoside [M + H]+ [M + H - deoxyribose]+ 
dC 228.0979 112.0505 
dG 268.1040 152.0567 
T 243.0975 127.0502 
dA 252.1091 136.0618 
MeC 242.1135 126.0662 
hmC 258.1084 142.0611 
fC 256.0928 140.0455 
caC 272.0877 156.0404 
N6MedA 266.1248 150.0774 
4mC 242.1135 126.0662 
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Figure 1.6. Quantitation of epigenetic modifications via mass spectrometry. A. Mass 
spectrometry analyses begin with DNA that is spiked with internal standards and 
enzymatically digested to nucleosides. The hydrolysate is enriched for the target analytes 
prior to LC-MS analysis. B. Example of LC-MS/MS trace for the epigenetic modifications 
of cytosine, MeC, hmC, fC, and caC. Standards of MeC, hmC, fC, and caC, 100 fmol each 
were separated using a Luna Omega C18 column (Phenomenex, Torrance CA) which was 
eluted with a gradient of 0.1% acetic acid in water and pure acetonitrile. The mass 
spectrometric analysis was performed using a Thermo Fisher Scientific TSQ Quantiva 
mass spectrometer operating in SRM mode. The fragmentation conditions were optimized 
to give only the loss of deoxyribose as the primary fragmentation.  
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Methods that employ HPLC-ESI-MS/MS techniques to quantify epigenetic 
modifications have been developed for a variety of applications and instruments.155-157 Due 
to the large number of methods that have been published for analyzing a combination of 
MeC, hmC, fC, and caC, only a few of them will be discussed here.  
Earlier approaches employed offline analyte enrichment prior to HPLC-ESI-
MS/MS analysis to minimize interference and improve detection sensitivity. The sample 
clean-up steps can include offline HPLC15, 158 or solid phase extraction20 In one example, 
DNA digests were subjected to offline HPLC clean-up, followed by HPLC-ESI-
MS/MS/MS method on a LTQ linear ion trap.158 The methodology of Liu et al. used 30-80 
µg of genomic DNA and the limits of detection for hmC, fC, and caC were reported to be 
2-3 modifications per 105 cytidines.158 
More recent applications of HPLC-ESI-MS/MS for epigenetic marks of DNA have 
done away with offline sample clean-up steps or performed the enrichment online in a two-
dimensional HPLC (2D-LC) tandem mass spectrometry method. A general method for 
analysis of MeC, hmC, fC, and caC was reported by Liu et al. which could be used at either 
analytical or nano HPLC flow rates.153 DNA samples are enzymatically digested, followed 
by ultrafiltration to remove digestion enzymes. A column switching nano-HPLC 
methodology using two HPLC columns was used to allow for inline sample cleanup prior 
to high resolution MS/MS analysis using a Q-Exactive hybrid quadrupole-Orbitrap mass 
spectrometer.153 Using this methodology, MeC, hmC, fC, and caC can be quantified at low 
femtomole levels.153 A similar methodology was reported by Gackowski et al.159  2D-LC 
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allowed for isolation of peaks of interest (hmC, fC, and caC) as they eluted off the first 
HPLC column and directing them to a second column, which was connected to a Waters 
Xevo TQ-S mass spectrometer. Using this approach, a high level of sensitivity was 
achieved for hmC (LOQ: 3 fmol, LOQ: 10 fmol), fC (LOQ: 0.3 fmol, LOQ: 0.8 fmol), and 
caC (LOQ: 0.05 fmol, LOQ: 0.13 fmol) and the amounts of each were quantified in 
matched cancer and normal human colon tissue samples.159 By minimizing sample 
processing and analyte clean-up steps, 2D-LC methodologies significantly simplify sample 
analyses, minimize the cost, allowing for high throughput quantification of large numbers 
of samples. 
Although the vast majority of mass spectrometry based techniques do not allow for 
mapping epigenetic marks along the genome, a report by Lin et al. employed a MS 
approach to determine local concentrations of MeC at specific genes.160 Following 
endonuclease cleavage with BbvI, DNA sequences of interest were captured by 
hybridization to complementary sequences immobilized on streptavidin beads.160 The 
captured DNA was heated in formic acid to release MeC as a free base, which was detected 
using an LTQ mass spectrometer. Lin et al. used this method to probe methylation status 
of four promoter regions: GSTP1, BCL2, ESR1, and HIC1 in DNA from clinical prostate 
tissue samples digested with BbvI.160 The capture methodology was able to effectively 
distinguish cancer tissue from normal tissue based on the level of promoter methylation of 
GSTP1, BCL2, ESR1, and HIC1.160 
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Biological samples from clinical studies are often precious, requiring method 
minimization to reduce DNA input. Le et al. have developed an HPLC-MS/MS method for 
the analyses of MeC and hmC in 50 ng of DNA.161 This effort employed an Agilent 6460 
QQQ, an Agilent Eclipse C18 (2.1 x 50 mm, 1.8 µm particle size) column eluted at a flow 
rate of 100 µL/min. External calibration curves were constructed using known 
concentrations of MeC and hmC. This method was able to quantify 0-10% MeC and 0-2% 
hmC.161  
 The recent discovery of N6MedA (Figure 1.1) in mammalian embryonic stem cells 
was accomplished by offline HPLC separation of enzymatic DNA digests, followed by 
HPLC-ESI-MS/MS analysis on a Waters UPLC coupled to a TSQ Quantum Ultra triple-
quadrupole mass spectrometer.36 Quantitation of the N6MedA was performed with 
external calibration curves, and the identity of the novel nucleoside in embryonic stem cells 
was confirmed using high resolution mass spectrometry.36 
HPLC-ESI-MS/MS analysis of 4mC is not only challenging because it is present in 
relatively low amounts, but it also has the same molecular mass and similar biophysical 
properties as MeC (Figure 1.1 and Table 1.1), making it difficult to detect it separately. 
HPLC resolution of 4mC and MeC was achieved by gradient elution of a C18 column 
under acidic conditions.40 This allowed for 4mC quantification in the bacteria C. 
kristjanssonii which contains high concentrations of 4mC.40 
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1.4 Sequencing of epigenetic modifications in the genome 
1.4.1 Indirect methods to map epigenetic DNA modifications along the genome 
Mapping epigenetic DNA marks along the genome is essential for our 
understanding of their biological roles, interrelationships, and dynamics. The majority of 
techniques used currently employ bisulfite conversion, modified bisulfite conversion, or 
antibody capture to help locate epigenetic DNA modifications. Although the readouts from 
these techniques are indirect, they have yielded a wealth of important information over the 
years. Novel methodologies such as nanopore sequencing and single molecule real-time 
(SMRT) sequencing allow for a direct sequencing of modified DNA and are discussed in 
Section 1.5. 
 
 
1.4.2 Bisulfite conversion to distinguish between C and MeC 
Early studies of chemical reactivity of native and modified DNA nucleosides have 
revealed an important difference between C and MeC.162-163 Upon treatment with bisulfite, 
cytosine is readily deaminated to uracil, while a much slower reaction is observed for MeC. 
The bisulfite reaction with cytosine proceeds through a C-6 sulfonate intermediate, which 
undergoes hydrolysis in the presence of base to release uracil (Figure 1.7A).162 Unlike C, 
MeC is resistant to the deamination under the same conditions.164 Therefore, bisulfite 
treatment of genomic DNA can be used to distinguish between methylated and 
unmethylated cytosines in the genome. Following bisulfite treatment, cytosine will be 
deaminated and subsequently read as T, while MeC will resist deamination and will be read 
37 
 
as C (Figure 1.7A). This unique property has been used by various sequencing 
technologies that employ bisulfite conversion to determine the locations of MeC bases in 
the genomes of various species including mammals, plants, and bacteria.165-166 
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Figure 1.7. Effects of bisulfite treatment on MeC and hmC in DNA and the sequencing 
results. A. Bisulfite-mediated deamination of cytosine. HSO3− adds across the 5,6-double 
bond of cytosine, promoting deamination and conversion to 6-sulfonyluracil. 6-
sulfonyluracil is desulfonated to uracil (U) at higher pH. MeC is also deaminated to 
thymine by bisulfite conversion, but the rate is approximately two orders of magnitude 
slower than that of cytosine. Bisulfite quickly converts 5-hydroxymethylcytosine to form 
cytosine-5-methylenesulfonate (CMS), which does not readily undergo deamination. B. 
Shown are examples of Sanger sequencing traces of hmC-containing DNA before and after 
bisulfite treatment. hmC resists bisulfite induced-deamination and is thus read as cytosine. 
The control C-containing oligonucleotide, on the other hand, shows complete conversion 
of all C's in the top strand (highlighted sequences) to T's (lower panel). Adapted from 
Huang Y et al. (2010) The behavior of 5-hydroxymethyl-cytosine in bisulfite sequencing. 
PLoS One. Jan 26;5(1):e8888. doi: 10.1371/journal.pone.0008888. Used in accordance 
with CC BY license (http://creativecommons.org/licenses/by/4.0/).167 
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1.4.3 Microarray technology for sequencing 
A DNA microarray is a collection of DNA segments of known sequence attached 
to a solid surface in a known pattern. DNA to be sequenced is fragmented and modified 
with fluorescent tags incorporated through PCR. DNA fragments present in DNA samples 
are hybridized to specific sites on the array and can be fluorescently imaged.168 The extent 
of enrichment can be quantified from the intensity of the fluorescent signal.168 An upstream 
enrichment step is a necessary component in using DNA micro arrays. As such, micro 
arrays are often coupled to antibody enrichment, or used with cDNA to explore RNA 
abundance under different treatment conditions. The microarray methodologies require 
small sample input and are easily replicated for multiple samples.  
In 2002, Gitan et al. developed the first methylation-specific oligonucleotide 
(MSO) microarray for DNA methylation analysis.169 In this technique, DNA samples are 
treated with bisulfite to convert cytosine to uracil, whereas MeC remains unchanged 
(Figure 1.7A). Specific CpG containing regions of the genome are then amplified by PCR 
and labeled using fluorescent dye-conjugated primers and hybridized to oligonucleotide 
probes attached to a glass surface. The oligonucleotide probes are specifically designed to 
discriminate between bisulfite converted and unconverted sequences containing known 
CpG sites. The quantitative differences in hybridization, which can be assessed by the 
fluorescent intensity, indicate the methylation status of a particular genomic locus. This 
first use of a MSO microarray successfully mapped methylated CpG sites within the 
estrogen receptor gene CpG island in cultured breast cancer cells and clinical samples.169  
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 Further developments in the MSO microarray methodologies have led to a creation 
of gene-specific, multiplex systems that can be used to simultaneously examine 
methylation across multiple CpG sites of numerous genes. This method provides both 
qualitative and quantitative DNA methylation data.170 Due to these advantages, the MSO 
microarray technology was commercialized and is now widely used to study cytosine 
methylation along the genome. 
 A variety of commercially available methylation microarrays are available from 
companies such as Illumina, Affymetrix, Agilent, and Roche NimbleGen. One such 
commercially available microarray is the Infinium Human Methylation 450 BeadChip 
(Infinium Methylation 450K) by Illumina. The Infinium 450K makes it possible to assess 
the methylation status of more than 480,000 cytosines distributed over the entire human 
genome.171 This microarray utilizes a similar technique as the MSO microarray developed 
by Gitan et al. in 2002 and can determine the methylation status of  96% of CpG islands 
and 99% of known human genes using ~500 ng DNA.148 The CpG sites being interrogated 
include promoter regions, 5ʹ-UTRs, gene bodies, 3ʹ-UTRs, and intergenic regions.171 The 
Infinium 450K is also applicable to both cell and tissue samples, however this array lacks 
coverage of distal regulatory elements.172 
 Although the Infinium 450K had been widely used by the epigenetics research 
community, the technology has presented some technical challenges.172 It was reported that 
many of the probes in the Illumina 450k array either cross-hybridize to non-targeted 
genomic regions or target loci that contain known single nucleotide polymorphisms 
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(SNPs), both of which interfere with analysis of DNA methylation levels.173 Because of 
this, sites of differential DNA methylation identified using the Illumina 450k array must 
be confirmed using a second independent assay, especially the sites targeted by the cross-
reactive probes or that contain known SNPs. This led Illumina to release a new technology, 
the Infinium MethylationEpic (EPIC) BeadChip. This new array was specifically designed 
to target enhancer regions. It contains over 850,000 probes, which cover more than 90% of 
the sites on the Infinium 450K, plus more than 350,000 CpGs at regions identified as 
potential enhancers by FANTOM5 and the ENCODE project.174-175 In this array, probe 
sequences are designed to be complementary to specific 50 base regions of bisulfite 
converted genomic DNA with a CpG site at the 3ʹ end of the probe. Following hybridization 
to bisulfite converted DNA, single-base extension of the probe incorporates a fluorescently 
labelled ddNTP at the 3ʹ CpG site to distinguish between the C/T conversion that results 
from bisulfite treatment.172  
 Methylation array methodologies described above represent a cost-effective and 
high-throughput technology to quantify the methylation level of half a million cytosines all 
over the genome. Furthermore, these arrays have low input DNA requirements, making 
them a powerful tool to study DNA methylomes. However, there are potential biases with 
this technology. As with all bisulfite-based methods, incomplete bisulfite conversion can 
affect quantitation of methylation differences. In addition, single nucleotide 
polymorphisms (SNPs) can interfere with methylation level detection, and commercial 
arrays are limited to human samples only. No commercial arrays are now available to map 
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methylation of the murine genome, hindering the application of this methodology to the 
wide range of valuable animal models of disease.176-177 Despite these limitations, 
Needhamsen et al. recently reported the use of the Infinium Human MethylationEPIC 
BeadChip to study DNA methylation in mouse DNA samples.177 This study identified over 
19,000 EPIC probes which aligned to the bisulfite converted reference mouse genome.177 
Another limitation of this technology, is its inability to differentiate methylation from 
hydroxymethylation.167 
 Recent work by Nazor et al, combines TET-assisted bisulfite (TAB) conversion 
with Illumina 450K DNA methylation arrays. This method, termed TAB-array, provides a 
low-cost, high-throughput approach that distinguishes hmC from MeC signals at base 
resolution.178 This technique requires that the genomic DNA from each biological sample 
is split in two fractions for different downstream processing steps. One fraction undergoes 
normal bisulfite conversion which identifies cytosines as methylated or not methylated, 
without distinguishing between MeC and hmC. The other fraction undergoes TAB 
conversion in which DNA is first glucosylated to protect hmC, and then oxidized by TET1, 
followed by bisulfite treatment. This allows hmC to be distinguished from MeC and 
quantified at the CpG sites included in the 450K array.178 
 
 
1.4.4 Next generation sequencing technology 
Next generation sequencing includes techniques that utilize polymerase synthesis 
of complimentary DNA strand to determine the sequence of input DNA. The technology 
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used by Illumina (San Diego, CA) immobilizes DNA fragments onto a chip by hybridizing 
them to synthetic DNA oligomers that were seeded on the chip during manufacturing. The 
immobilized DNA is then amplified on the chip to create clusters of identical DNA 
fragments, which will increase the recorded signals from DNA synthesis. Following 
amplification, the DNA clusters are sequenced by synthesis of the complementary DNA 
using engineered DNA polymerases and specially modified nucleic acids.179 Each 
nucleotide has a fluorescent tag and is reversibly blocked modified at the 3ʹ end to allow 
for only a single incorporation.179 Following single nucleotide addition, a camera images 
the chip to record a fluorescent signal and records the sequence being made, followed by 
deprotection of the 3ʹ end for continued synthesis.179 These steps for elongation are 
repeated until the desired read length is achieved. This technology can be combined with 
antibody/enrichment-based sequencing (Section 1.4.5), whole genome sequencing 
(Section 1.4.6), reduced representation sequencing (Section 1.4.7), and modified bisulfite 
sequencing (Section 1.4.8) as detailed below. 
 
 
1.4.5 Antibody/Enrichment-based sequencing  
Low resolution data for genome wide distribution of DNA methylation marks can 
be obtained using antibody-based techniques such as Methylated DNA 
Immunoprecipitation (MeDIP). In this assay, MeC targeted antibody is used to specifically 
immunocapture methylated genomic fragments.180 The enriched DNA fragments can then 
be input into high throughput DNA detection methods such as DNA microarray (MeDIP-
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ChIP) or next generation sequencing (MeDIP-seq). Through genome-wide peak calling of 
the microarray or the respective sequencing results, methylated regions along the whole 
genome can be identified.180-181 The advantages of this method are its low cost and the 
ability to rapidly identify DNA methylation regions within the genome. 
Similar immunoprecipitation (IP) based methodologies have been developed for 
oxidized forms of MeC (including hmC, fC, and caC), since the corresponding antibodies 
against them are now readily available.42, 182 This approach has been used in multiple 
studies to identify regions of hmC enrichment such as CpG rich transcription start sites and 
fC and caC enrichment at pericentric heterochromatin, as well as at distal regulatory 
elements.42, 182 
Apart from direct antibody enrichment techniques, a number of chemically assisted 
techniques have been developed for mapping hmC and fC. In anti-cytosine-5-
methylenesulfonate (anti-CMS Seq) technique, hmC is converted to cytosine-5-
methylenesulfonate (CMS) by bisulfite treatment, followed by enrichment of CMS-
containing DNA fragments via CMS-targeted antibody and their sequencing.183 This 
methodology has a lower background and lower reliance on hmC density in the fragment 
as compared to direct antibody pull-down of hmC containing fragments.183-184  
In GLIB-seq (Glucosylation, periodate oxidation, biotinylation Sequencing), hmC 
is glucosylated in the presence of β-glucosyltransferase, and the resulting glucosyl 
derivatives are oxidized with sodium periodate to yield two aldehyde groups.183 The latter 
are derivatized with biotin-containing aldehyde reactive probe (ARP), and the derivatized 
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fragments are enriched via streptavidin beads and sequenced, allowing for mapping of hmC 
marks along the genome.183 Another chemically assisted enrichment method for hmC is 
hMeSeal-seq (hydroxymethyl selective chemical labeling).185 In this method, an 
engineered glucose moiety containing an azide group is enzymatically added to the 
hydroxyl group of hmC by T4 bacteriophage β-glucosyltransferase. The azide group can 
then be chemically modified with biotin for detection, affinity enrichment, and sequencing 
hmC–containing DNA fragments.186  
Similar mapping methodologies have been developed for fC.43, 187 Since fC 
contains an inherently reactive aldehyde group, it can be directly modified with biotin-
containing aldehyde reactive probe, followed by enrichment of fC containing DNA 
fragments using streptavidin beads.43 Another method for mapping fC involves 
enzymatically blocking hmC with unmodified UDP-Glc.187 This is followed by fC 
reduction to hmC with NaBH4 and hMeSeal-seq to localize the newly formed hmC sites as 
fC fragments.187 
The main limitation of all enrichment-based methods is their low resolution (100-
300 bp).188 This can be a major problem, especially for studies utilizing multiple epigenetic 
marks. Another limitation is that these methods are unable to quantify absolute methylation 
levels because each enriched fragment may have variable numbers of epigenetic marks. 
Additional common concerns include antibody cross-reactivity, low capture efficiency, 
and the limitations of downstream DNA detection methods (microarrays and sequencing) 
used to determine the enrichment. However, these techniques are still widely used as they 
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provide a rapid, comparatively less laborious and inexpensive way to study genome wide 
methylation. 
 
1.4.6 Whole genome bisulfite sequencing  
 Studies of DNA methylation were initially restricted to localized CpG-rich regions 
of the genome.189 However, several methods now exist which can map DNA methylation 
genome wide. Whole-genome bisulfite sequencing (WGBS) was developed in 1992 by 
Frommer et al. to measure CpG methylation genome-wide at a single-base resolution.190 
This method utilizes bisulfite-induced modification of genomic DNA to convert cytosine 
to uracil, the latter is converted to thymine during PCR amplification. MeC residues 
however, are not converted and remain as cytosines after PCR amplification.190 The 
development of high-throughput sequencing has facilitated the generation of genome-wide, 
single-base resolution DNA methylation maps from bisulfite-converted DNA.191 The first 
methylome was generated in 2008 from the Arabidopsis thaliana genome.192-193 The first 
human methylome was reported by Lister et al. in 2009 from human embryonic stem cells 
and fetal fibroblasts.194 These studies revealed the genome wide context of DNA 
methylation. Extensive differences were found between the methylomes of two human cell 
types, revealing the dynamic nature of this modification. Due to the high genomic coverage 
of WGBS (95%), this method is preferred for building reference methylomes.195 
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1.4.7 Reduced representation bisulfite sequencing (RRBS)  
 Although WGBS allows for the greatest coverage of DNA methylation genome-
wide, it is time consuming and requires significant financial investment in sequencing to 
reach the effective depth required for accurate DNA methylation mappings; this hinders its 
application to large-scale DNA methylation studies.196 Reduced representation bisulfite 
sequencing (RRBS) is an efficient and high-throughput technique used to analyze 
methylation profiles at a single-nucleotide level from regions of high CpG content.197-198 
This technique utilizes a methylation-insensitive restriction enzyme, such as MspI, which 
cuts at 5′-CCGG-3′ sites, enriching for CpG rich regions of the genome such as CpG islands 
by leaving CpG rich regions at the ends of fragments being sequenced.191 This portion of 
the genome is then sequenced using NGS to generate single-base pair resolution DNA 
methylation maps. RRBS captures 85% of CpG islands and 60% of gene promoters, 
requiring small sample input (0.01-0.03 µg of DNA).191, 199 By combining different 
restriction enzymes, CpG coverage across the genome can be altered to include or exclude 
certain regions of interest such as CpG island shores, which are the two kilobase regions 
adjacent to CpG islands and are known to play an important role in various biological 
processes including cellular differentiation.200-201 
One of the main advantages of RRBS over WGBS is the overall reduction of the 
size of DNA regions to be sequenced, therefore requiring fewer reads for accurate 
sequencing reducing the cost and allowing for deep sequencing.191 An important 
disadvantage of RRBS is that it does not capture all CpG islands and/or promoters. While 
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WGBS can access ~95% of the genome, RRBS only reaches 3.7% genome coverage.191 
However, RRBS enjoys much better coverage depth than WGBS and the concordance of 
DNA methylation levels between the two methods is high.196 Due to these advantages, 
RRBS has become popular when high-throughput, low cost methylation analysis is needed 
such as in clinical applications.202 It is important to note however, that RRBS has been 
mostly applied for DNA methylation profiling of CpG sites within mouse and human 
genomes, and  the ability of MspI coupled RRBS to cover non-CpG methylation has not 
been demonstrated.196 
 
 
1.4.8 Modified bisulfite sequencing to facilitate detection of hmC, fC and caC by next 
generation sequencing 
         The discovery of hmC, fC, and caC as oxidation products of MeC generated by 
TET enzymes has spurred a flurry of speculation about possible biological roles of these 
additional epigenetic marks.203 In addition to their role as demethylation intermediates, 
these oxidized forms of MeC may serve as unique epigenetic marks in their own right, 
interacting with a distinct group of protein readers and eliciting a unique epigenetic 
response.26-27 Therefore, it is of great interest to map the locations of hmC, fC, and caC 
along the genome. Similarly to MeC, hmC resists bisulfite mediated deamination, thus the 
two marks cannot be distinguished by standard bisulfite methodology (Figure 1.7).164, 167 
167, 204 Therefore, previous studies that employed bisulfite conversion to map MeC actually 
detected both hydroxymethylation and methylation together. In contrast, fC and caC 
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readily undergo deamination upon treatment with bisulfite and thus cannot be distinguished 
from C (Figure 1.8).15-16, 205 In addition, fC also undergoes deformylation which is 
mediated by sulfonation of the C6 position of the nucleoside to generate the corresponding 
alcohol (Figure 1.8). Base catalyzed deprotonation of the alcohol and β-elimination 
produce cytosine.16 Determining the levels and positions of epigenetic modifications in the 
genome is important to understanding the biological function of these DNA marks. 
Therefore, novel sequencing methodologies were needed to separately map all four 
epigenetic marks.  
        The first method for distinguishing between MeC and hmC during bisulfite 
sequencing utilized an additional chemical reaction on the genomic DNA. The oxidative 
bisulfite sequencing (oxBS-Seq) includes DNA treatment with potassium perruthenate 
(KRuO4) to selectively oxidize the hmC to fC (Figure 1.8).205 After the oxidation, the DNA 
is treated with bisulfite to deaminate cytosine. Booth et al. coupled oxBS-Seq to RRBS to 
increase the sequencing depth at potentially interesting CG repeats by reducing the amount 
of DNA that could be sequenced. hmC was identified primarily at CG sites located within 
low density CpG islands (CGIs).205 In addition to chemical oxidation to distinguish 
between MeC and hmC enzymatic oxidation can used (TET Assisted Bisulfite Sequencing, 
TAB-Seq).206  The latter technique utilizes T4 β-glycosyl transferase and UDP-glucose to 
protect the primary alcohol on hmC, followed by oxidation of MeC to caC using 
recombinant TET1 protein (Figure 1.8).207 This is coupled with bisulfite treatment and 
sequencing of the original sample and Tet treated DNA to provide data for MeC and hmC 
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location. Using the technique on the whole genome, hmC was found to be almost 
exclusively found at CG sites, and nearly half of all hmC sites were present in distal 
regulatory elements.206 TAB-Seq has been applied to identify changes in MeC and hmC in 
intergenic regions of kidney tumors208 and to identify sites of 4mC in bacterial DNA.40 
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Figure 1.8. Methodologies for distinguishing epigenetic modifications in DNA using 
bisulfite treated DNA. A. Diagram of the Bisulfite coupled sequencing technologies used 
for mapping the positions of MeC, hmC, fC, and caC. B. Sample preparation scheme for 
differentiating MeC and hmC in TAB-Seq206 and oxBS-Seq.205 C. fC is deaminated and 
deformylated by treatment with bisulfite. Protection of fC by reaction with O-
ethylhydroxylamine in fCAB-Seq prevents the deamination and deformylation that 
typically occur when fC is treated with bisulfite.187 In redBS-Seq, fC is reduced with 
sodium cyanoborohydride to hmC which will resist deamination.209 fC in the original 
sample can be determined by comparison of fCAB-Seq or redBS-Seq data with DNA that 
had undergone standard bisulfite sequencing. D. Because fC and caC deaminate when 
treated with bisulfite, MAB-Seq utilizes the methylase M.SssI to methylate unmodified 
cytosines. Following bisulfite treatment, MeC and hmC will be identified as C, while fC 
and caC are deaminated and identified as T their levels and position in the genome.210 
caMAB-Seq first reduces fC to hmC and then follows MAB-Seq in order to specifically 
map caC.210 
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Mapping fC along the genome was accomplished in part by modification of the 
previous techniques to distinguish between MeC and hmC. The first reported method for 
fC was formylcytosine chemical assisted bisulfite sequencing (fCAB-Seq).187 In this 
approach, chemical labeling of fC is conducted with O-ethylhydroxylamine to protect fC 
from conversion during DNA treatment with bisulfite (Figure 1.8).187, 205 DNA sequencing 
is performed on paired samples that had undergone fCAB protection plus bisulfite 
treatment and standard bisulfite treatment. Through the mapping of standard bisulfite 
sequencing results and fCAB-Seq data to the genome, sites specifically modified with fC 
could be identified. Cytosine formylation amounts at these sites can be estimated by 
subtracting the percent cytosine methylation determined in the bisulfite only treated sample 
(which is the sum of MeC and hmC) from the percent of cytosine methylation in the fCAB-
Seq sample data (which is the sum of MeC, hmC, and fC).187 Because fC is a minor 
component of DNA, each region of DNA was sequenced an average of 1000 times, which 
allows estimation of fC levels to +/- 0.1%. Sequencing of DNA from mouse embryonic 
stem cells showed that fC levels were increased at poised enhancers sequences, while MeC 
was also reduced at those same enhancers, indicating MeC oxidation by TET could 
function in epigenetic priming.187 Another chemical method for identification of fC is 
reduced bisulfite sequencing (redBS-Seq). The redBS-Seq method employs sodium 
cyanoborohydride to reduce fC to hmC in genomic DNA (Figure 1.8).209 The DNA is then 
treated with bisulfite to deaminate cytosine and both redBS and standard bisulfite treated 
DNA samples are sequenced. Cytosine formylation levels are determined as in fCAB-Seq 
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above. Using this technique, fC was shown to be present in CpG sites asymmetrically with 
hmC, where one strand contains fC and the opposite strand hmC.209  
An additional method for determination of oxidized forms of MeC by sequencing 
is modification-assisted bisulfite sequencing (MAB-Seq) (Figure 1.8).210 Detection of caC 
and fC is simultaneously possible by treatment of the DNA with bacterial methylase 
M.SssI, which methylates all unmodified CG dinucleotides to give MeCG. Following 
methylation to protect all unmodified cytosine in a CG context, bisulfite treatment of DNA 
will lead to deamination of fC and caC. This results in sequencing output that can identify 
the locations of fC and caC together. MAB-Seq is reliant on quantitative conversion of C 
to MeC by M.SssI and is limited to detection of fC and caC only in the CG context. MAB-
Seq was further developed to be specific for caC (caMAB-Seq) (Figure 1.8), which takes 
advantage of the reduction of fC by sodium borohydride prior to performing the steps of 
MAB-Seq.210 Using MAB-Seq and caMAB-Seq, fC and caC have been mapped at single 
base resolution to regions with higher chromatin accessibility, and therefore TET 
accessibility, despite TET stalling on hmC during oxidation.18 The sequencing profiles 
obtained via MAB-Seq and caMAB-Seq indicate that there might be preferential locations 
for TET activity, either through chromatin accessibility or sequence dependent removal of 
fC and caC by TDG.210  
 The first sequencing of 4mC in the genome was reported using a modification of 
the TAB-Seq methodology.40 This is possible because 4mC undergoes deamination at a 
rate between C and MeC.40  To allow for 4mC detection, the bisulfite conditions were 
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optimized to ensure the retention of 4mC in the genome while deaminating TET-generated 
caC. Using this methodology, 4mC was mapped in C. kristjanssonii, a bacterium with 
similar levels of MeC and 4mC.40 This methodology, 4mC-TAB-Seq, is well suited for 
identification of 4mC in genomes which have high concentrations of 4mC at particular 
sites, especially in bacteria which utilize 4mC as part of their restriction-modification 
systems.38 Application of this methodology to mammalian cells and tissues is limited by 
the incomplete retention of 4mC after bisulfite conversion (40-55%), making accurate 
identification of sites possessing less than complete methylation nearly impossible.40    
 Mapping N6MedA can also be accomplished using restriction enzyme-based 
sequencing (6mA-RE-Seq).211 This sequencing technique takes advantage of previous 
information gained from antibody enrichment methods, which found that N6MedA was 
found in CATG and CATC motifs in the C. reinhardtii genome, a green algae.211 Focusing 
on these two motifs, 6mA-RE-Seq employs digestion of DNA by CviAII or DpnII, 
sonication to fragment the DNA, end repair, adenylation, and ligated to adapters.211 The 
methylated sequences will resist enzymatic digestion, allowing indirect detection of 
N6MedA based on the location of the motif in the sequencing read. The motif at the end 
of a read indicates a lack of methylation, while a read with the motif in the middle indicates 
the presence of N6MedA. The amount of N6MedA can be calculated from the relative 
number of sequencing reads where the specific adenosine is located at the end of a read 
(unmethylated) or at an internal position (methylated). Using this technique, N6MedA was 
identified at 3-4% of all available motifs in the C. reinhardtii genome.211 When N6MedA 
57 
 
containing sites identified by 6mA-RE-Seq were compared to those from 
immunoprecipitation (IP), 28% of sites identified by IP were not identified by 6mA-RE-
Seq and did not contain the motifs used in 6mA-RE-Seq. Using 6mA-RE-Seq and IP 
sequencing Fu et al. found that N6MedA was enriched in the regions of DNA linking 
nucleosomes possibly used for positioning these nucleosomes on DNA.211  
 
1.5 Direct detection and mapping of epigenetic modifications in DNA 
Unlike methodologies described above and summarized in Table 1.2, third 
generation sequencing methods allow for reading the nucleotide sequences at the single 
molecule level without additional modification reactions like bisulfite conversion, making 
it possible to directly distinguish between C, MeC, and its oxidized forms during the 
sequencing step. These methodologies are currently under active development. 
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Table 1.2. Brief description of techniques for performing base resolution sequencing 
of MeC, its oxidized forms, 4mC, and N6MedA. 
Sequencing 
Technique 
Description 
WGBS Bisulfite treatment and sequencing are carried out on the whole 
genome. Reads both MeC and hmC as C after bisulfite conversion.  
RRBS CpGs are recognized and cut by specific enzymes. Traditional bisulfite 
sequencing is carried out on this enriched CpGs region. Reads both 
MeC and hmC as C after bisulfite conversion. 
TAB-Seq hmC is converted to 5gmC by the β-GT enzyme. This protects hmC 
from TET oxidation, which is used to convert MeC to caC. hmC is 
detected after bisulfite sequencing. MeC is determined by subtracting 
hmC from standard BS-Seq.  
oxBS-Seq hmC is treated with potassium perruthenate and converted to fC. This 
will cause fC to be read as T after bisulfite conversion. hmC identified 
by subtracting the signal for MeC from traditional BS-Seq. 
redBS-Seq fC is reduced to hmC with sodium borohydride. This will cause fC to 
be read as C in BS-Seq. The sites of fC can be determined by 
subtracting BS-Seq methylation from redBS-Seq.  
fCAB-Seq fC is reacted with EtONH2, which protects fC from bisulfite mediated 
deamination. This allows fC to be read as C in BS-Seq. The location of 
fC can be identified by subtracting BS-Seq methylation from fCAB-
Seq.  
MAB-Seq Unmodified CpGs are methylated by M.SssI. fC and caC can then be 
identified in BS-Seq by C to T transition in the sequencing data relative 
to the reference genome. 
caMAB-Seq fC is reduced to hmC with sodium borohydride. Unmodified CpGs are 
methylated by M.SssI. caC can then be identified in BS-Seq by C to T 
transition in the sequence relative to the reference genome. 
 
  
59 
 
1.5.1 Single molecule real-time (SMRT) sequencing 
As DNA sequencing methodologies entered the third generation, single molecule 
real-time (SMRT) technology has become a new favorite since it has longer read lengths 
(10,000 bp up to 60,000 bp) produces higher consensus accuracy, and is characterized by 
a lower degree of bias as compared to second generation sequencing.212 Unlike the 
aforementioned sequencing methods, SMRT-seq can directly read different base 
modifications via the kinetics of nucleotide incorporation during the normal course of 
sequencing of an intact DNA.213 In SMRT-seq, kinetics signatures of MeC and hmC are 
very subtle, presenting an accuracy challenge for detection, whereas fC and caC show very 
distinct kinetics signatures.214 More recently, it was shown that glycosylation of hmC 
significantly enhances its kinetics signature, making simultaneous mapping of all three 
oxidized forms of MeC possible.215  
 
1.5.2 Nanopore sequencing  
Another emerging third generation sequencing technology is Nanopore sequencing, 
which can directly read out different bases using distinct current signals generated as DNA 
translocates through a protein nanopore.216 Generally, a protein nanopore is set in an 
electrically resistant polymer membrane and an ionic current is passed through the 
nanopore by setting a voltage across this membrane. When DNA passes through the pore 
or near its aperture, this event creates a characteristic disruption in the current. 
Measurement of that current makes it possible to identify the molecule in question. 
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Previous study has shown the ability of discriminating between all 5 cytosine variants by 
a low-throughput nanopore sensors,217 although high throughput nanopore sequencing can 
only discriminate cytosine, MeC and hmC.218  
 
1.6 Challenges of using sequencing to identify epigenetic modifications at single base 
resolution 
        As described above, application of DNA sequencing techniques can provide base 
resolution maps of DNA epigenetic marks, allowing for elucidation of their biological 
functions.205-206, 210 However, significant challenges remain in applying sequencing 
strategies to map non-canonical DNA bases. Sequencing cost is the first factor that needs 
to be considered when planning a new study. Although the cost of whole genome 
sequencing has decreased significantly in recent years, it remains around $1000 per 
genome according to the National Human Genome Research Institute,219 making this 
approach non-practical for large studies involving hundreds of samples (Figure 1.9).220 
One possible solution to the high cost of whole genome sequencing includes RRBS, 
however RRBS introduces an additional challenge with a more limited coverage of CpG 
regions.196 MspI is a restriction enzyme commonly used in RRBS methods, however 
theoretically it can only cover 10% of the genomic regions.199 More targeted capture based 
approaches are available for sequencing specific regions, such as the SeqCap Epi (Roche) 
and SureSelect (Agilent) systems.221-222 These capture methods focus on predetermined 
genomic regions in order to reduce sequencing complexity, but are by design limited 
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around specific genomic regions which may or may not include the regions of interest. 
Custom capture libraries can be created if certain regions are not part of the original capture 
systems.223  
Secondly, for the methods relying on bisulfite sequencing, the conversion rate of 
the target bases remains to be improved. Without excellent, specific conversion the 
uncertainty in mapping target bases will significantly affect the estimation of their 
abundance in particular regions. In addition, these methods usually involve several rounds 
of sequencing under different conditions, which increases the cost, labor, as well as 
requiring increased DNA sample input. Due to the deamination of cytosine to uracil during 
the sample preparation, these methods also pose additional challenges after sequencing 
including read alignment and bioinformatics analysis. 
Lastly, third generation sequencing technologies such as single molecule real-time 
(SMRT) sequencing and Nanopore sequencing permit longer reads and direct detection of 
epigenetic modifications of DNA. Because these methods do not rely on DNA conversion 
with bisulfite or enzymatic processes and allow for longer reads, read alignment is 
simplified. Despite these positives, third generation sequencing still needs to improve, 
especially in regard to the signal intensity for some specific epigenetic marks, the overall 
accuracy, and larger DNA input requirements. These limitations prevent the application of 
this technology to whole genome sequencing without some form of enrichment.36 
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Figure 1.9. The effectiveness of various sequencing technologies at discriminating 
between epigenetic modifications in DNA and the relative cost of their application. The 
ability of a method to identify MeC (Blue), hmC, (green, both MeC and hmC (blue and 
green stripes), fC (yellow), caC (orange), both fC and caC (yellow and orange stripes), and 
N6medA (red). The relative cost is depicted as filled circles, least expensive ( ) to 
most expensive ( ). 
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1.7 Summary and thesis goals 
 Epigenetic regulation of gene expression is central to controlling physiological 
processes in cells and is mediated through covalent DNA, histone, and RNA modifications 
and non-coding RNAs.1 The DNA epigenetic modifications include MeC, hmC, fC, caC, 
and N6MedA (Figure 1.1). Epigenetic DNA modifications are placed at specific sites 
enzymatically. These epigenetic modifications affect the transcription of genes and need 
to be faithfully maintained through replication cycles.1 Patterns of epigenetic 
modifications, which are responsible for stable gene expression and cell identity can be 
altered by cigarette smoke exposure and by inflammation.141, 224 These epigenetic DNA 
modifications can be quantified post-exposure to measure the magnitude of change in the 
global epigenetic levels, providing an overview of how the whole genome was affected. 
The oxidation of MeC to hmC, fC, and caC by TET proteins provided potential new 
epigenetic marks; an identity that has been supported by additional reports.26-27 However, 
the kinetic effects of these epigenetic DNA modifications on DNMT1 activity had not been 
explored. Thus, the initial goal of this thesis was to develop a kinetic assay of DNMT1 to 
investigate its activity when presented with alternative substrates.  
 We developed an in vitro, kinetic assay using isotope dilution tandem mass 
spectrometry for the quantitation of MeC formation in digests of synthetic DNA duplexes 
incubated with DNMT1. Passive demethylation, where DNMT1 fails to properly methylate 
the newly synthesized DNA has been suggested as a mechanism to facilitate DNA 
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demethylation. We tested whether DNMT1 would effectively recognize the oxidized forms 
and methylate the duplex accordingly.  
 Additional studies were focused on animal models of smoking induced lung cancer. 
We developed an isotope dilution, capillary-LC tandem mass spectrometry method to 
quantify global epigenetic changes in mice treated with NNK, LPS, and both NNK and 
LPS. The exposure of A/J mice to cigarette smoke is hypothesized to capture the tumor 
initiation pathway of smoking in humans. The type II alveolar cells are hypothesized as 
sites of lung cancer initiation due to their proliferative ability.225 We tested this hypothesis 
by determining the gene expression profile of isolated type II cells from A/J mice and 
performing oxoRRBS to site specifically assign changes in DNA methylation and 
hydroxymethylation in mice exposed to cigarette smoke.  
 To further our understanding of the processes and proteins associated with the 
oxidized forms of MeC in DNA we began development of a protein pull-down assay to 
identify epigenetic readers in the lung.   
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II. HUMAN DNA METHYLTRANSFERASE ACTIVITY IN THE PRESENCE OF 
5-METHYLCYTOSINE ANALOGUES WITH EXTENDED ALKYL SIDE CHAIN  
Adapted from: 
 
Kotandeniya, D.; Seiler, C. L.; Fernandez, J.; Pujari, S. S.; Curwick, L.; Murphy, K.; 
Wickramaratne, S.; Yan, S.; Murphy, D.; Sham, Yuk Y.; and Tretyakova, N. Y.; Can 5-
methylcytosine analogues with extended alkyl side chain guide DNA methylation? Chem. 
Commun. 2018, 54, 1061-1064. 
 
This work was performed in collaboration with Dr. Delshanee Kotandeniya, Jenna 
Fernandez, Dr. Suresh S. Pujari, Lauren Curwick, Kristopher Murphy, Dr. Susith 
Wickramaratne, Shuo Yan, Dan Murphy, and Dr. Yuk Y. Sham, under the direction of Dr. 
Natalia Tretyakova. Delshanee Kotandeniya and Christopher Seiler performed the kinetics 
experiments for cytosine, ethyl, propyl, and methylcytosine containing DNA. Christopher 
Seiler performed the kinetics experiments for vinylcytosine containing DNA. Delshanee 
Kotandeniya, Christopher Seiler, Suresh Pujari, Kristopher Murphy, Shuo Yan, and Dan 
Murphy synthesized compounds on the way to making phosphoramidites. Susith 
Wickramaratne and Suresh Pujari took compound identification spectra including NMR. 
Christopher Seiler took HRMS of the synthesized molecules. Christopher Seiler 
synthesized the stable isotope labeled internal standard. Delshanee Kotandeniya, 
Christopher Seiler, and Lauren Curwick synthesized, purified, and characterized DNA 
oligos. Jenna Fernandez performed the computational modeling with direction from Yuk 
Y. Sham.  
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2.1 Introduction 
  5-Methylcytosine (MeC) is the most abundant endogenous modification of 
DNA known to date, with approximately 5% of all cytosine bases carrying the C-5 
methyl group.13 The majority of MeC residues are found within 5′-CG-3′ 
dinucleotides (CpG sites), where both cytidine nucleotides are methylated. 
Methylated CpG sites are recognized by methyl-CpG binding proteins (MBP),226 
which in turn recruit histone-modifying proteins, ultimately leading to chromatin 
remodeling and gene silencing.11, 227  
  Methylation status of gene promoter regions largely determines which groups 
of genes are actively expressed in a given tissue.228 Cytosine methylation patterns 
are stable in adult cells for many generations and are transmitted to progeny cells 
upon cell division.229  The hemi-methylated 5′-CG-3′ sequences arising as a result 
of semiconservative replication are recognized by maintenance DNA 
methyltransferase (DNMT1), which places a methyl group on the C-5 position of 
cytosine of the newly synthesized strand opposite MeCG of the template strand, 
thereby preserving DNA methylation patterns.11 Any errors in DNMT1 action would 
lead to aberrant gene expression, which in turn can contribute to malignant 
transformation (Chapter I of this thesis).230 
  It has been shown that DNMT1 fidelity can be compromised by structural 
modifications within 5′-CpG-3′ sites.19, 231 For example, 5-halogenated cytosines 
mimic 5-methylcytosine, leading to erroneous methylation of CpG sites by 
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DNMT1.19, 231-232 In contrast, oxidation of the C-5 methyl group of MeC to 5-
hydroxymethyl-dC, 5-formyl-dC, and 5-carboxy-dC interferes with DNMT1 
mediated methylation of the cytosine in the opposite strand, ultimately leading to 
the removal of DNA methylation marks (Chapter III of this thesis).233 
  The goal of the present work was to probe the ability of C5-alkylated 
cytosines with extended C5 side chain to direct DNMT1-catalyzed DNA 
methylation. The novel C5-alkyl-cytosine analogs (5-ethyl-dC, 5-propyl-dC, and 5-
vinyl-dC, Scheme 2.1) were placed within a CpG site derived from the p53 tumor 
suppressor gene, and the resulting synthetic DNA duplexes were incubated with 
human recombinant DNMT1 protein. A mass spectrometry-based assay was used to 
study the kinetics of cytosine methylation in the presence of native MeC and its 
homologues with extended C5 alkyl chain. Furthermore, DNMT1 interactions with 
structurally modified DNA were investigated using molecular modeling. Our results 
indicate DNMT1 can the flexible, extended C5 side chain of 5-ethyl-dC but is unable 
to methylate DNA duplexes containing the more rigid 5-vinyl-dC or larger C5 side 
chain of 5-propyl-dC. Molecular modeling indicates the reduced activity toward the 
extended C5 alkyl side chains are due to a steric clash with the target recognition 
domain of the protein.  
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Scheme 2.1. Structures of MeC, EthyldC, PropyldC and VinyldC. 
  
  
69 
 
2.2 Materials and Methods 
Materials:  
All nucleoside phosphoramidites, solvents, and solid supports required for the solid 
phase synthesis of DNA were acquired from Glen Research Corporation (Sterling, VA). 
Recombinant human DNA-methyltransferase 1 was purchased from New England Biolabs 
(Ipswich, MA). Phosphodiesterase I, phosphodiesterase II, and DNase I were obtained 
from Worthington Biochemical Corporation (Lakewood, NJ). Bovine intestinal alkaline 
phosphatase was procured from Sigma Aldrich Chemical Company (Milwaukee, WI) 
while 2′-deoxycytidine hydrochloride was from Berry & Associates Inc. (Dexter, MI). 
Stable isotope labeled thymidine was purchased from Cambridge Isotope Laboratories 
(Tewksbury, MA). The rest of the chemicals were purchased either from Fisher Scientific 
(Fairlawn, NJ), Sigma-Aldrich (Milwaukee, WI) or Alfa Aesar (WardHill, MA) and used 
without further purification unless noted otherwise. NMR was performed on a 500 MHz 
Bruker system. Accurate mass measurements were obtained on a LTQ Orbitrap Velos 
(Thermo Scientific, Pittsburgh, PA) and mass fragmentation data were collected on an 
Agilent 1100 LC/MSD Ion trap (Agilent Technologies, Santa Clara, CA). 
 
Methods: 
5-Iodo-2′-deoxycytidine (1) (Scheme 2.2) 
2′-deoxycytidine hydrochloride, 4.0 g (15.2 mmol), was suspended in 3.0 mL of 
carbon tetrachloride, 4.5 mL of water, and 12.0 mL of glacial acetic acid. To the 
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suspension, was added I2 2.3 g (9.06 mmol, 0.60 equiv) and iodic acid, 1.4 g (8.0 mmol, 
0.53 equiv). The reaction mixture was stirred at 40 oC for 90 min after which 45 mL of 
water was added followed by cooling to room temperature. The mixture was filtered under 
vacuum, and the filtrate was extracted with benzene (10 x 100 mL) and reduced under 
vacuum resulting in a yellow residue. The residue was dissolved in 100 mL of methanol 
and evaporated under vacuum to remove excess acetic acid. This process was repeated 5 
times to remove additional acetic acid, resulting in a yellow solid. The solid was dissolved 
in a minimum amount of deionized water and the pH adjusted to pH 10 with 10 N NaOH. 
This liquid was frozen at -20 ℃ overnight, warmed to a room temperature and then filtered. 
The filtrate was reduced to half its volume by heating, refrozen, warmed to room 
temperature, and filtered to yield a second crop of crystals. The crystals were combined 
and recrystallized in methanol to yield plate-like crystals of 1 (3.3 g, 61% yield). ESI+-
MS/MS: m/z 353.9 [M + H+]+ → m/z 238.0 [M + H+ – deoxyribose]+, Exact mass calc: 
353.9945 [M + H+]+, Exact mass obs: 353.9939 [M + H+]+ (error 1.7 ppm); 1H NMR 
(DMSO-d6, 500 MHz): δ 8.28 (s, 1H), 7.79 (br s, 1H), 6.58 (br s, 1H), 6.07 (dd, 1H, J = 
6.5, 6.5 Hz), 5.19 (d, 1H, J = 4.0 Hz), 5.09 (t, 1H, J = 5.0 Hz), 4.20 (ddd, 1H, J = 10.0, 4.0, 
4.0 Hz), 3.78 (ddd, 1H, J = 6.5, 3.5, 3.5 Hz), 3.62 (ddd, 1H, J = 12.0, 5.0, 4.0 Hz), 3.54 
(ddd, 1H, J = 12.0, 4.5, 4.0 Hz), 2.13 (ddd, 1H, J = 13.0, 6.0, 4.0 Hz), 1.99 (m, 1H). 13C 
NMR (DMSO-d6, 125 MHz): δ 163.7, 153.9, 147.3, 87.4, 85.3, 69.9, 60.8, 56.5, 40.8. 
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5-iodo-3′,5′-t-butyldimethylsilyl-2′-deoxycytidine (2) (Scheme 2.2) 
A flask containing compound 1, 0.50 g (1.42 mmol), and imidazole, 0.77 g (11 
mmol, 8 equiv), which was dried under high vacuum for 2 days. Anhydrous 
dimethylformamide (DMF) under vigorous stirring was bubbled with Ar for 30 min. 10 
mL of the DMF was added to the nucleoside/imidazole mixture in an Ar-glove bag. To this 
mixture was added t-butyldimethylsilyl chloride (TBSCl), 0.85 g (5.7 mmol, 4 equiv), 
under an atmosphere of Ar. The reaction was stirred under Ar at room temperature for 48 
h. The reaction was monitored by TLC (12:1 CH2Cl2:MeOH on silica plates). The reaction 
was reduced under vacuum and then taken up in CH2Cl2 (50 mL). The organic layer was 
washed with water (5 x 50 mL) and then dried using Na2SO4. The product was purified on 
a silica column eluted with 12:1 CH2Cl2:methanol to yield the final product 2 as a white 
solid (0.75 g, 91% yield).  ESI+-MS/MS: m/z 582.1 [M + H+]+ → m/z 237.9 [M + H+ – 
deoxyribose]+, Exact mass calc: 582.1675 [M + H+]+, Exact mass obs: 582.1663 [M + H+]+ 
(error 2.1 ppm); 1H NMR (CDCl3, 500 MHz): δ 8.08 (s, 1H), 6.24 (dd, 1H, J = 6.5, 6.5 
Hz), 4.20 (ddd, 1H, J = 6.0, 3.0, 3.0 Hz), 3.98 (d, 1H, J = 2.5 Hz), 3.88 (dd, 1H, J = 11.5, 
2.5 Hz), 3.75 (dd, 1H, J = 11.5, 2.5 Hz), 2.45 (ddd, 1H, J = 13.5, 5.5, 3.0 Hz), 1.96 (m, 
1H), 0.93 (s, 9H), 0.88 (s, 9H), 0.13 (d, 6H, J = 5.5 Hz), 0.06 (d, 6H, J = 3.5 Hz). 13C NMR 
(CDCl3, 125 MHz): δ 163.7, 155.2, 146.8, 88.4, 87.0, 72.4, 63.0, 56.2, 42.8, 26.3, 25.9, 
18.6, 18.1, -4.5, -4.7, -5.0, -5.1. 
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5-(Trimethylsilyl)-ethynyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (3) (Scheme 
2.3) 
A flask containing compound 2 (1.5 g, 2.6 mmol) was dried under vacuum for two 
days.  The dried solid was transferred to a flame-dried flask and the solid was dissolved in 
100 mL 3:1 dry, deoxygenated solution of DMF:Et3N (deoxygenated by bubbling with Ar 
for 30 min). To the solution, 2 molar equivalents of trimethylsilylacetylene (0.73 mL, 5.2 
mmol), 0.2 mol eq. of CuI (0.098 g, 0.52 mmol), and Pd(PPh3)4 (0.30 g, 0.26 mmol) were 
added sequentially to the flask in an Ar-glove bag. The flask was capped, and the reaction 
mixture was stirred for 2 days at room temperature under an atmosphere of Ar, under dark 
conditions. The mixture was diluted with 400 mL EtOAc and the organic layer was washed 
with water (100 mL x 3) and brine (twice) followed by drying the organic layer with 
anhydrous Na2SO4. The product was purified by two successive silica columns using a 
gradient of 100% CH2Cl2 to 16:1 CH2Cl2:2-propanol to give compound 3 in 35% yield. 
ESI+-MS/MS: m/z 552.2 [M + H]+ → m/z 208.1 [M + H – deoxyribose]+, Exact mass calc: 
552.3104 [M + H]+, Exact mass obs: 552.3093 [M + H]+ (error 2.0 ppm); 1H NMR (CDCl3, 
500 MHz): δ 8.23 (br s, 1H), 8.07 (s, 1H), 6.24 (dd, 1H, J = 6.0, 6.0 Hz), 5.76 (br s, 1H), 
4.35 (ddd, 1H, J = 6.3, 3.3, 3.3 Hz), 3.95 (d, 1H, J = 2.5 Hz), 3.91 (dd, 1H, J = 11.5, 2.0 
Hz), 3.75 (dd, 1H, J = 11.5, 2.0 Hz), 2.43 (ddd, 1H, J = 13.0, 6.0, 4.0 Hz), 2.00 (m, 1H), 
0.92 (s, 9H), 0.87 (s, 9H), 0.21 (s, 9H), 0.13 (d, 6H, J = 6.5 Hz), 0.05 (d, 6H, J = 3.0 Hz). 
13C NMR (CDCl3, 125 MHz): δ 164.9, 154.4, 144.1, 101.2, 96.2, 91.1, 88.2, 86.8, 71.7, 
62.6, 42.8, 26.2, 25.9, 18.6, 18.1, 0.0, -4.5, -4.8, -5.1, -5.3. 
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5-Ethynyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (4) (Scheme 2.3) 
Compound 3 (0.7 g, 1.3 mmol) was dissolved in 10 mL anhydrous MeOH, and the 
solution was cooled on ice for 5 min.  To this was added 3 mL of 1N KOH, and the mixture 
was stirred at room temperature for 3 hours. The reaction was monitored by TLC using 
12:1 dichloromethane (DCM):MeOH. Once the starting material appeared to have been 
consumed, the pH of the solution was brought up to pH 7 by dropwise addition of 1N HCl.  
The solvent was then evaporated under reduced pressure, and the product was purified on 
a silica column (DCM:MeOH) to afford a light beige foam 0.55 g (90% yield). ESI+-
MS/MS: m/z 480.3 [M + H]+ → m/z 136.0 [M + H – deoxyribose]+, Exact mass calc: 
480.2708 [M + H]+, Exact mass obs: 480.2699 [M + H]+ (error: 1.9 ppm); 1H NMR (CDCl3, 
600 MHz): δ 8.21 (s, 1H), 6.26 (dd, 1H, J = 6.5, 6.5 Hz), 6.11 (br s, 1H), 5.63 (br s, 1H), 
4.36 (m, 1H), 3.95 (m, 1H), 3.93 (dd, 1H, J = 9.7, 2.3 Hz), 3.77 (dd, 1H, J = 9.5, 1.5 Hz), 
3.32 (s, 1H), 2.48 (m, 1H), 2.04 (ddd, 1H, J = 10.7, 5.3 Hz), 0.92 (s, 9H), 0.88 (s, 9H), 0.13 
(d, 6H, J = 6.0 Hz), 0.06 (d, 6H, J = 3.0 Hz). 
 
5-Ethyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (5) (Scheme 2.3) 
Compound 4 (0.548 g, 1.14 mmol) was dried overnight under high vacuum and was 
dissolved in 20 mL of anhydrous MeOH by gently warming it in a water bath. The flask 
was capped, and the solution was purged with Ar by bubbling. To this was quickly added 
0.35 mol equivalents of 10% Pd-C (0.042 g, 0.4 mmol) and the reaction was stirred under 
hydrogen for 24 h at room temperature. The reaction was monitored by TLC, using 12:1 
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DCM:MeOH as the mobile phase. The crude reaction mixture was then passed through a 
Celite® column to remove the Pd-catalyst, and the column washed with MeOH to collect 
the product. MeOH was evaporated under reduced pressure to yield 0.547 g of white foam 
(99% yield). ESI+-MS/MS: m/z 484.3 [M + H]+ → m/z 140.0 [M + H – deoxyribose]+, 
Exact mass calc: 484.3021 [M + H]+, Exact mass obs: 484.3008 [M + H]+ (error 2.7 ppm); 
1H NMR (CDCl3, 500 MHz): δ 7.50 (s, 1H), 6.31 (dd, 1H, J = 6.5, 6.5 Hz), 4.34 (ddd, 1H, 
J = 6.0, 3.0, 3.0 Hz), 3.93 (d, 1H, J = 3.5 Hz), 3.83 (dd, 1H, J = 11.5, 3.5 Hz), 3.75 (dd, 
1H, J = 11.5, 3.0 Hz), 2.40 (ddd, 1H, J = 13.0, 5.5, 3.0 Hz), 2.27 (q, 2H, J = 7.5 Hz), 1.93 
(m, 1H), 1.15 (t, 3H, J = 7.5 Hz), 0.91 (s, 9H), 0.88 (s, 9H), 0.09 (s, 6H), 0.06 (d, 6H, J = 
3.0 Hz). 13C NMR (CDCl3, 125 MHz): δ 165.1, 155.9, 137.4, 107.2, 87.8, 86.1, 72.1, 63.1, 
42.2, 26.1, 25.9, 21.0, 18.5, 18.1, 13.0, -4.5, -4.7, -5.3.  
 
4-N-Benzoyl-5-ethyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (6) (Scheme 2.3) 
Compound 5 (0.125 g, 0.258 mmol) which was dried overnight under high vacuum 
was co-evaporated three times with 5 mL each of anhydrous pyridine. The residue was 
dissolved in 5 mL of anhydrous pyridine, and the flask was immediately capped with a 
rubber septum under Ar atmosphere. To the mixture was added 60 µL (0.516 mmol, 2.0 
equiv) of benzoyl chloride over a period of 5 minutes at room temperature and the reaction 
was stirred.  The reaction was monitored by TLC (30:1 DCM:MeOH) every ½ hour. Since 
the reaction still had a lot of starting material remaining after 2 hours, another 40 µL (0.34 
mmol, 1.3 equiv) of benzoyl chloride was added and reaction was monitored for another 2 
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hours, until all starting material was consumed. At the end of the reaction the solvent was 
removed under reduced pressure, the crude product was taken up in DCM, and the organic 
layer was washed three times with 50 mL water followed by drying with anhydrous Na2SO4 
and the solvent removed under reduced pressure. The crude product was purified on a silica 
column, using 30:1 DCM:MeOH. After evaporation of solvent, a few drops of MeOH were 
added to the resulting oil to produce white needle like crystals 0.129 g (85% yield). ESI+-
MS/MS: Exact mass calc: 588.3284  [M + H]+, Exact mass obs: 588.3267 [M + H]+ (error 
2.9 ppm);  1H NMR (CDCl3, 500 MHz): δ 13.4 (s, 1H), 8.30 (dd, 2H, J = 8.5, 1.5 Hz), 7.62 
(s, 1H), 7.52 (m, 1H), 7.44 (dd, 2H, J = 7.5, 7.5 Hz), 6.34 (dd, 1H, J = 7.5, 5.5 Hz), 4.41 
(m, 1H), 3.98 (ddd, 1H, J = 5.0, 2.5 Hz), 3.98 (dd, 1H, J = 11.5, 3.0 Hz), 3.78 (dd, 1H, J = 
11.5, 3.0 Hz), 2.57 (m, 2H), 2.34 (ddd, 1H, J = 13.5, 6.0, 2.5 Hz), 2.02 (ddd, 1H, J = 13.5, 
7.5, 6.0 Hz), 1.25 (t, 3H, J = 7.5 Hz), 0.94 (s, 9H), 0.90 (s, 9H), 0.12 (d, 6H, J = 2.0 Hz), 
0.09 (d, 6H, J = 4.0 Hz). 13C NMR (CDCl3, 125 MHz): δ 179.7, 159.5, 147.9, 137.5, 136.4, 
132.4, 130.0, 128.2, 117.5, 88.2, 85.7, 72.5, 63.2, 41.7, 26.1, 25.9, 21.6, 18.6, 18.1, 13.9, -
4.5, -4.7, -5.3. 
 
4-N-Benzoyl-5-ethyl-2′-deoxycytidine (7) (Scheme 2.3) 
Compound 6 (0.046 g, 0.078 mmol) was dried overnight under high vacuum and 
then co-evaporated three times with 5 mL each of anhydrous pyridine. The flask was 
immediately fitted with a rubber septum and purged with Ar (1-2 min) and 1.3 mL of dry 
and degassed DCM was added under an atmosphere of Ar. To the solution, 102 µL (0.63 
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mmol, 8 equiv) of triethylamine-trihydrofluoride (Et3N•3HF) was added dropwise to the 
flask over a period of 30 min using a syringe. The reaction was stirred under an atmosphere 
of Ar at room temperature for 16 h. During this time, the reaction was monitored every 2 
h by TLC (30:1 DCM:MeOH, if a lot of starting material is remaining, more Et3N.3HF is 
added). Upon total consumption of starting compound 6 by TLC, product (7) was isolated 
by purification on a silica column using a gradient of DCM and 30:1 DCM:MeOH resulting 
in a white solid 0.027 g in 96%, yield. ESI+-MS/MS: m/z 360.2 [M + H]+ → m/z 244.1 [M 
+ H – deoxyribose]+, Exact mass calc: 360.1554 [M + H]+, Exact mass obs: 360.1553 [M 
+ H]+ (error 0.3 ppm); 1H NMR (MeOD/DMSO-d6, 500 MHz): δ 7.47 (d, 2H, J = 5.5 Hz), 
7.33 (s, 1H), 6.78 (t, 1H, J = 7.3 Hz), 6.69 (t, 2H, J = 7.5 Hz), 5.52 (dd, 1H, J = 6.8, 6.8 
Hz), 3.64 (m, 1H), 3.17 (d, 1H, J = 3.0 Hz), 3.03 (dd, 1H, J = 12.0, 3.0 Hz), 2.96 (dd, 1H, 
J = 11.8, 3.3 Hz), 1.81 (q, 2H, J = 7.5 Hz), 1.54 (m, 1H), 1.48 (m, 1H), 0.46 (t, 3H, J = 7.5 
Hz). 13C NMR (CDCl3, 125 MHz): δ 180.6, 160.7, 149.5, 139.4, 138.5, 133.6, 130.8, 129.3, 
118.0, 89.2, 87.0, 71.9, 62.5, 41.7, 21.9, 13.7. 
 
4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-ethyl-2′-deoxycytidine (8) (Scheme 2.3) 
Compound 7 (4-N-benzoyl-5-ethyl-2′-dC, 0.130 g, 0.361 mmol) was dried under 
vacuum overnight and co-evaporated three times with 6 mL each of anhydrous pyridine. 
The flask was immediately capped, purged with Ar, and transferred to a glove bag filled 
with Ar. Anhydrous pyridine (kept over activated 4Å molecular sieves) was degassed with 
Ar for 20 min.  All additions were performed in an Ar glove bag. Anhydrous, degassed 
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pyridine (2 mL) was added to the flask containing dried nucleoside. Dimethoxytrityl 
chloride (DMTrCl), 0.147 g (0.434 mmol, 1.2 equiv), was added to the nucleoside-pyridine 
solution. Upon addition of all reagents, the flask was taken out of the glove bag, and the 
reaction was stirred for 16 h at room temperature away from light. The reaction was 
monitored using 5:47.5:47.5 TEA:EtOAc:Hexane on TLC plates soaked in 95:5 
hexane:TEA. The reaction mixture was quickly dried under high vacuum. To this was 
added 30 mL of DCM and the organic layer was washed two times with 25 mL each of ice 
cold water. The reaction mixture was dried using anhydrous Na2SO4, and the solvent was 
removed under reduced pressure. The resulting solid was purified on a short silica-flash 
column packed in 95:5 Hexane:TEA using solvent gradient below: 95:5 Hexane:TEA, 
5:25:70 TEA:EtOAc:Hexane, 5:47.5:47.5 TEA:EtOAc:Hexane, 95:5 EtOAc:TEA. Upon 
evaporation of the solvent, the resulting oily product was dissolved in 1 mL of anhydrous 
DCM and dried under high vacuum overnight to get a white foam 0.155 g of 65% yield. 
ESI+-MS/MS: m/z 662.6 [M + H]+ → m/z 303.1 [dimethoxytrityl cation]+, 244.0 [M + H – 
deoxyribose]+, Exact mass calc: 684.2680 [M + Na]+, Exact mass obs: 684.2680 [M + Na]+; 
1H NMR (CDCl3, 500 MHz): δ 8.20 (dd, 1H, J = 7.0, 1.0 Hz), 7.64 (s, 1H), 7.51 (m, 1H), 
7.42 (m, 4H), 7.30 (m, 7H), 6.84 (m, 4H), 6.40 (dd, 1H, J = 6.0, 5.0 Hz), 4.57 (ddd, 1H, J 
= 5.0, 2.5, 2.5 Hz), 4.07 (ddd, 1H, J = 3.0, 3.0, 3.0 Hz), 3.50 (dd, 1H, J = 9.0, 3.0 Hz), 3.39 
(dd, 1H, J = 8.7, 2.7 Hz), 2.60 (br s, 1H), 2.47 (dq, 1H, J = 11.0, 2.5 Hz), 2.32 (m, 1H), 
2.23 (m, 1H), 2.09 (m, 1H), 1.00 (t, 3H, J = 6.3 Hz). 
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4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-ethyl-2-deoxycytidine-3′-[(2-cyanoethyl)- 
(N,N-diisopropyl)]-phosphoramidite (9) (Scheme 2.3) 
Into a flame dried round bottom flask was added compound 8 (0.075 g, 0.113 
mmol), which was dried in an Ar filled glove bag under high vacuum overnight. Anhydrous 
DCM (kept over activated 4Å molecular sieves) was degassed with argon for 20 min. All 
additions below were performed sequentially in an Ar glove bag: 197 µL of anhydrous 
N,N-diisopropylethylamine (1.13 mmol, 5 equiv as phosphitylating reagent), 2 mL of 
anhydrous and degassed DCM and 51 µL of 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite (0.23 mmol, 2 equiv). The flask was capped, and the 
reaction stirred for 16 h under an Ar atmosphere at room temperature away from light. 
After 16 h, 250 µL of anhydrous MeOH was added to prevent the oxidation of the 
phosphoramidite and 200 µL of Et3N was added to ensure that the product does not get 
hydrolyzed during the work-up steps.  To this solution was added 30 mL of EtOAc. The 
organic layer was extracted three times with ice-cold brine, dried using anhydrous Na2SO4, 
and the solvent was removed under reduced pressure. The resulting solid was dissolved in 
a few mL of 5:95 TEA:EtOAc and a short silica-flash column was run to isolate the product 
using the gradient elution described below: 95:5 Hexane:TEA, 5:25:70 
TEA:EtOAc:Hexane, 5:47.5:47.5 TEA:EtOAc:hexane, 95:5 EtOAc:TEA. Evaporation of 
the solvent resulted in compound 8 as a white foam (0.059 g, 62% yield). 1H NMR (CDCl3, 
400 MHz): δ 8.28 (d, 2H, J = 7.6 Hz), 7.67 (s, 1H), 7.51 (t, 1H, 8.0 Hz), 7.42-7.27 (m, 
11H), 6.85 (m, 4H), 6.41 (dd, 1H, J = 13.8, 7.6 Hz), 4.66 (m, 1H), 4.18 (m, 1H), 3.79 (s, 
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6H), 3.63-3.48 (m, 4H), 3.35-3.30 (m, 2H), 2.62 (t, 2H, J = 6.4 Hz), 2.41 (dd, 1H, J = 6.4, 
6.4 Hz), 2.31 (m, 1H), 2.17 (m, 1H), 1.25-1.16 (m, 12H), 0.96 (t, 3H, J = 8.4 Hz). 31P NMR 
(CDCl3, 162 MHz): δ 147.70, 147.29.  
 
5-Propyn-1-yl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (10) (Scheme 2.4) 
5-Iodo-3′,5′-TBS-2′-dC (2) (2 g, 3.44 mmol) was dried under vacuum for two days.  
The dried solid was transferred to a flame-dried two-necked flask inside an Ar-glove bag.  
To the flask was added 0.397 g of Pd(PPh3)4 (0.344 mmol, 0.1 equiv) and 0.033 g CuI 
(0.172 mmol, 0.05 equiv). The flask was capped, and 50 mL of anhydrous, deoxygenated 
solution of DMF:Et3N (4:1) was added, along with constant purging of propyne gas.  The 
pressure inside the flask was kept at a constant of 8 psi throughout the reaction.  The 
reaction was stirred for 48 h at room temperature, away from light. At the end of the 
reaction, the solvents were evaporated, and crude product was taken up in 150 mL of DCM. 
The organic layer was washed five times with 75 mL each of water and twice with 50 mL 
each of brine, followed by drying organic layer with anhydrous Na2SO4. The product was 
purified by two successive silica columns with solvent gradient from 100% DCM to 9:1 
DCM:MeOH to afford light a beige solid in (1.44 g) 85% yield. ESI+-MS/MS: m/z 494.3 
[M + H]+ → m/z 150.1 [M + H – deoxyribose]+, Exact mass calc: 494.2865 [M + H]+, Exact 
mass obs: 494.2849 [M + H]+ (error 3.2 ppm); 1H NMR (CDCl3, 500 MHz): δ 8.44 (br s, 
1H), 8.00 (s, 1H), 6.25 (dd, 1H, J = 6.0, 6.0 Hz), 5.81 (br s, 1H), 4.34 (m, 1H), 3.90 (m, 
2H), 3.74 (dd, 1H, J = 12.0, 3.0 Hz), 2.40 (ddd, 1H, J = 13.5, 6.5, 4.5 Hz), 2.00 (m, 4H), 
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0.92 (s, 9H), 0.86 (s, 9H), 0.12 (d, 6H, J = 8.0 Hz), 0.04 (s, 6H). 13C NMR (CDCl3, 125 
MHz): δ 165.2, 154.5, 142.9, 91.8, 91.7, 87.9, 86.4, 71.3, 71.1, 62.5, 42.6, 26.1, 25.8, 18.5, 
18.1, 4.5, -4.5, -4.8, -5.4, -5.5. 
 
5-Propyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (11) (Scheme 2.4) 
To a flask containing 0.075 g of dry 5-propyn-1-yl-3′,5′-t-butyldimethylsilyl-2′-
deoxycytidine (10) was added 5 mL of anhydrous MeOH.  The flask was capped, and the 
solution was purged with Ar by bubbling for 5 min.  To this was added 20 weight % of 
10% Pd-C catalyst (0.015 g, 0.14 mmol). The reaction mixture was kept under hydrogen 
gas and stirring at room temperature, away from light for 2 days. The reaction was 
monitored by TLC, using 12:1 DCM:MeOH as the mobile phase.  The crude reaction was 
then passed through a Celite® column to remove the Pd catalyst, and the column washed 
with MeOH to collect product 11.  The solvent was evaporated under reduced pressure to 
yield white crystals (0.068 g) in 90% yield. ESI+-MS/MS: m/z 498.2 [M + H]+ → m/z 154.1 
[M + H – deoxyribose]+, Exact mass calc: 498.3178 [M + H]+, Exact mass obs: 498.3163 
[M + H]+ (error 3.0 ppm); 1H NMR (CDCl3, 500 MHz): δ 7.46 (s, 1H), 6.30 (dd, 1H, J = 
6.8, 6.8 Hz), 4.33 (m, 1H), 3.91 (ddd, 1H, J = 6.0, 3.0, 3.0 Hz), 3.82 (dd, 1H, J = 11.0, 3.0 
Hz), 3.74 (dd, 1H, J = 11.0, 3.0 Hz), 2.37 (ddd, 1H, J = 13.0, 6.0, 3.0 Hz), 2.20 (t, 2H, J = 
7.5 Hz), 1.91 (m, 1H), 1.51 (qt, 2H, J = 7.5, 7.5 Hz), 0.92 (t, 3H, J = 7.5 Hz), 0.90 (s, 9H), 
0.86 (s, 9H), 0.08 (d, 6H, J = 2.0 Hz), 0.04 (d, 6H, J = 2.5 Hz). 13C NMR (CDCl3, 125 
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MHz): δ 165.3, 155.8, 137.9, 105.9, 87.7, 85.9, 72.0, 63.0, 42.2, 30.0, 26.1, 25.9, 21.8, 
18.5, 18.1, 13.8, -4.5, -4.8, -5.3. 
 
4-N-Benzoyl-5-propyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (12) (Scheme 2.4) 
 Compound 11 (0.2 g, 0.4 mmol) was co-evaporated three times with anhydrous 
pyridine (5 mL), and the flask was flushed with Ar gas. To this was added 6 mL of 
anhydrous pyridine, followed by purging of the solution with argon by for 5 min.  To the 
flask, 56 µL of benzoyl chloride (0.48 mmol, 1.2 equiv) was added by syringe over 5 min. 
This mixture was stirred at room temperature under an argon atmosphere for 4 h. The 
course of the reaction was monitored by TLC (30:1 DCM:MeOH). Analysis of the crude 
mixture by mass spectrometry indicated the dibenzoylated product to be present. The crude 
product mixture was dissolved in 2.5 mL of 65:30:5 pyridine:MeOH:H2O, and this mixture 
was cooled on ice. To this was added 2.5 mL of cold 2N NaOH solution, in 65:30:5 
pyridine:MeOH:H2O. The reaction mixture was stirred on ice for 10 min. Ammonium 
chloride (0.1 g, 1.2 equiv) was added to quench the reaction. The crude sample was dried 
and re-dissolved in DCM, washed three times with 30 mL water, and dried with Na2SO4, 
and the organic layer was removed to result in crude solid 12. Compound 12 was further 
purified by silica column using 15:1 DCM:MeOH to give colorless solid (0.217 g) in 90% 
yield. ESI+-MS/MS: Exact mass calc: 602.3440 [M + H]+, Exact mass obs: 602.3421 [M + 
H]+ (error 3.2 ppm);  1H NMR (CDCl3, 500 MHz): δ 8.29 (dd, 2H, J = 7.0, 1.5 Hz), 7.62 
(s, 1H), 7.52 (t, 1H, J = 7.5 Hz), 7.44 (t, 2H, J = 7.5 Hz), 6.35 (dd, 1H, J = 7.5, 5.5 Hz), 
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4.41 (m, 1H), 3.97 (ddd, 1H, J = 3.0, 3.0, 3.0 Hz), 3.88 (dd, 1H, J = 11.3, 2.8 Hz), 3.78 (dd, 
1H, J = 11.3, 2.8 Hz), 2.51 (m, 2H), 2.33 (ddd, 1H, J = 13.0, 6.0, 2.5 Hz), 2.02 (ddd, 1H, J 
= 13.5, 7.5, 6.0 Hz), 1.68 (qt, 2H, J = 6.5, 6.5 Hz), 1.00 (t, 3H, J = 7.5 Hz), 0.94 (s, 9H), 
0.90 (s, 9H), 0.13 (d, 6H, J = 2.5 Hz), 0.09 (d, 6H, J = 3.5 Hz). 13C NMR (CDCl3, 125 
MHz): δ 179.7, 159.7, 148.0, 137.5, 136.9, 132.5, 130.0, 128.2, 116.0, 88.2, 85.6, 72.4, 
63.2, 41.8, 30.2, 26.1, 25.9, 22.5, 18.6, 18.1, 14.1, -4.5, -4.7, -5.3.   
 
4-N-Benzoyl-5-propyl-2′-deoxycytidine (13) (Scheme 2.4) 
Compound 12 (0.25 g, 0.502 mmol) was dried under vacuum and co-evaporated 
with of anhydrous pyridine (3 x 5 mL), and the flask was purged with Ar. To this was 
added 7 mL of anhydrous DCM to dissolve the solid, followed by purging of the solution 
mixture with Ar for 5 min. To the flask, was injected 327 µL of Et3N:H3F (2.01 mmol) by 
syringe over 30 minutes. The reaction was stirred, away from light, for 16 h at room 
temperature. The course of the reaction was monitored by TLC (30:1, DCM:MeOH). The 
resulting crude product was purified using column chromatography with a mobile phase of 
15:1 DCM:MeOH to afford compound 13 (0.131 g) as a white solid in 92% yield. ESI+-
MS/MS: m/z 374.0 [M + H]+ → m/z 258.0 [M + H – deoxyribose]+, Exact mass calc: 
374.1710 [M + H]+, Exact mass obs: 374.1704 [M + H]+ (error 1.6 ppm); 1H NMR 
(MeOD/DMSO-d6, 500 MHz): δ 8.49 (d, 2H, J = 6.0 Hz), 7.38 (s, 1H), 6.82 (t, 1H, J = 7.3 
Hz), 6.73 (t, 2H, J = 7.5 Hz), 5.53 (dd, 1H, J = 6.5, 6.5 Hz), 3.64 (m, 1H), 3.19 (ddd, 1H, 
J = 3.0, 3.0, 3.0 Hz), 3.03 (dd, 1H, J = 11.7, 3.3 Hz), 2.96 (dd, 1H, J = 12.0, 3.5 Hz), 1.77 
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(m, 2H), 1.55 (m, 1H), 1.49 (m, 1H), 0.92 (m, 2H), 0.24 (t, 3H, J = 7.5 Hz). 13C NMR 
(CDCl3, 125 MHz): δ 180.3, 160.8, 149.3, 140.2, 138.6, 133.7, 130.8, 129.5, 116.0, 89.3, 
86.9, 71.8, 62.5, 41.7, 30.5, 22.8, 14.4. 
 
4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-propyl-2′-deoxycytidine (14) (Scheme 2.4) 
Compound 13 (50 mg, 0.13 mmol) was dried under vacuum overnight and co-
evaporated with anhydrous pyridine (3 x 5 mL) and this flask was kept under vacuum 
overnight. The flask was immediately capped and purged with Ar and transferred to a glove 
bag filled with Ar. Anhydrous pyridine (kept over activated 4Å molecular sieves) was 
degassed with Ar for 20 min.  To the solution in the glove bag, 3 mL of anhydrous, 
degassed pyridine solution and dimethoxytrityl chloride (DMTrCl) (0.091 g, 0.27 mmol) 
were added sequentially. Upon addition of all reagents, the flask was taken out of the glove 
bag and the reaction was stirred for 16 h at room temperature away from light. The progress 
of the reaction was monitored by TLC. After completion of the reaction, the crude sample 
was quickly dried under high vacuum and 30 mL of DCM was added. The organic layer 
was washed three times with 25 mL each of ice cold H2O, dried using anhydrous Na2SO4, 
and the solvent removed under reduced pressure. The resulting solid was purified on a short 
silica-flash column packed in 95:5 Hexane:TEA using the solvent gradient: 95:5 
Hexane:TEA, 5:25:70 TEA:EtOAc:Hexane, 5:47.5:47.5 TEA:EtOAc:Hexane, 95:5 
EtOAc:TEA. Upon evaporation of solvent, the resulting oily product was dissolved in 1 
mL of anhydrous DCM and allowed to dry under high vacuum overnight, to get compound 
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14 as a white foam (0.075 g, 77% yield). ESI+-MS/MS: m/z 676.1 [M + H]+ → m/z 303.1 
[dimethoxytrityl cation]+, 258.1 [M + H – deoxyribose]+, Exact mass calc: 698.2837 [M + 
Na]+, Exact mass obs: 698.2833 [M + Na]+ (error 0.5 ppm); 1H NMR (ACN-d4, 400 MHz): 
δ 8.27 (dd, 2H, J = 6.8, 1.6 Hz), 7.69 (s, 1H), 7.59 (m, 1H), 7.49 (m, 4H), 7.34 (m, 7H), 
6.90 (m, 4H), 6.27 (dd, 1H, J = 6.6, 6.6 Hz), 4.50 (ddd, 1H, J = 5.2, 5.2, 5.2 Hz), 4.00 (ddd, 
1H, J = 3.6, 3.6, 3.6 Hz), 3.79 (s, 6H), 3.33 (d, 2H, J = 3.6 Hz), 2.35 (t, 2H, J = 6.4 Hz), 
2.16 (m, 2H), 1.47 (m, 2H), 0.80 (t, 3H, J = 7.4 Hz). 
 
4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-propyl-2′-deoxycytidine-3′-[(2-cyanoethyl)- 
(N,N-diisopropyl)]-phosphoramidite (15) (Scheme 2.4) 
Into a flame dried round bottom flask was added 4-N-Benzoyl-5-O′-
(dimethoxytrityl)-5-propyl-2′-deoxycytidine (14, 0.050 g, 0.074 mmol) that was dried 
under high vacuum overnight, in an Ar filled glove bag.  Anhydrous DCM (kept over 
activated 4 Å molecular sieves) was degassed with Ar for 20 min.  All additions were 
performed in an Ar glove bag in the following order: anhydrous diisopropylethylamine 
(129 µL, 0.074 mmol), anhydrous DCM (2.5 mL) and 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite (33 µL, 0.148 mmol). The flask was capped, and the 
reaction mixture stirred for 15 h under an argon atmosphere at room temperature away 
from light. After 15 h, 250 µL of anhydrous MeOH was added to prevent the oxidation of 
phosphoramidite and 200 µL of Et3N was added to prevent hydrolysis during work-up.  To 
this solution was added 30 mL of EtOAc and the organic layer extracted three times with 
85 
 
ice-cold brine, dried over anhydrous Na2SO4 and dried under reduced pressure. The 
resulting solid was dissolved in a 5 mL of 5:95 TEA:EtOAc and purified on a short silica-
flash column using the gradient elution described below: 95:5 hexane:TEA, 5:25:70 
TEA:EtOAc:hexane, 5:47.5:47.5 TEA:EtOAc:hexane, 95:5 EtOAc:TEA. Evaporation of 
solvent resulted in a white foam (0.049 g, 76% yield). 1H NMR (Acetone-d6, 400 MHz): δ 
8.26 (d, 2H, J = 7.2 Hz), 7.82 (s, 1H), 7.57-7.44  (m, 5H), 7.39-7.23 (m, 7H), 6.91 (m, 4H), 
6.35 (m, 1H), 4.77 (m, 1H), 4.21 (m, 1H), 3.90-3.80 (m, 1H), 3.77 (s, 6H), 3.75-3.58 (m, 
3H), 3.47 (m, 2H), 2.76 (m, 2H), 2.62 (t, 2H, J = 6.0 Hz), 2.56 (m, 1H), 2.26 (m, 1H), 1.48 
(m, 2H), 1.19-1.07 (m, 12H), 0.76 (t, 3H, J = 7.2 Hz). 31P NMR (ACN-d4, 162 MHz): δ 
148.37, 148.21. 
 
3′,5′-O-t-butyldimethylsilyl-5-vinyl-2′-deoxycytidine (16) (Scheme 2.5) 
Compound 2 (2.5 g, 4.3 mmol) was dried under high vacuum for 2 days and then 
coevaporated three times with 30 mL each anhydrous pyridine, and then dried under high 
vacuum for another two days.  The flask was taken into an Ar-glove bag and to the 
nucleoside was added 75 mL of anhydrous deoxygenated 1-methyl-2-pyrolidinone. The 
resulting solution was again degassed by bubbling Ar for 2 h.  The remaining additions 
were done inside an Ar-glove bag.  To the nucleoside was added tri(2-furanyl)phosphine 
(0.55 g, 2.35 mmol), Pd2(dba)3 (0.504 g, 0.55 mmol) and tributylvinyltin (1.9 mL, 6.5 
mmol) sequentially. The flask was sealed, and the reaction mixture was stirred, away from 
light for 1 day at 60 °C.  The reaction was monitored by TLC with 16:1 DCM:IPA and 9:1 
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EtOAC:hexane. Since a little starting material remained, another portion of tributylvinyltin 
(0.8 mL, 3.25 mmol) was added, and the reaction mixture was stirred for another 12 h. The 
crude reaction containing the product was divided to five portions and each portion diluted 
with 100 mL of EtOAC and washed four times with 25 mL each H2O.  The combined 
organic layers were dried with Na2SO4 and concentrated under reduced pressure. The 
resulting crude product was dissolved in 200 mL acetonitrile and washed five times with 
25 mL each of hexane.  The ACN layer was partitioned over hexane and the ACN was 
dried to afford crude compound 16. The product was purified on a silica column using a 
gradient of DCM to 15:85 IPA:DCM to obtain compound 16 (1.2 g) in 58% yield. ESI+-
MS: Exact mass calc: 482.2865 [M + H]+, Exact mass obs: 482.2850 [M + H]+ (error 3.1 
ppm);  1H NMR (CDCl3, 500 MHz): δ 7.72 (s, 1H), 6.32 (dd, 1H, J = 17.0, 11.0 Hz), 6.26 
(dd, 1H, J = 6.3, 6.3 Hz), 5.40 (d, 1H, J = 17.5 Hz), 5.24 (d, 1H, J = 11.0 Hz), 4.33 (d, 1H, 
J = 2.5 Hz), 3.94 (s, 1H), 3.83 (d, 1H, J = 11.0 Hz), 3.73 (d, 1H, J = 11.5 Hz), 2.42 (m, 
1H), 1.94 (m, 1H), 0.86 (s, 18H), 0.04 (d, 6H, J = 4.5 Hz), 0.03 (s, 6H). 13C NMR (CDCl3, 
125 MHz): δ 164.1, 155.3, 138.2, 128.4, 117.2, 105.8, 88.0, 86.4, 72.1, 63.0, 42.4 26.0, 
25.8, 18.5, 18.1, -4.5, -4.8, -5.3, -5.4. 
 
4-N-Benzoyl-3ʹ,5ʹ-O-(t-butyldimethylsilyl)- 5-vinyl-2ʹ-deoxycytidine (17) (Scheme 
2.5) 
Compound 16 (0.81 g, 1.68 mmol) was dried on high vacuum overnight, co-
evaporated with anhydrous pyridine (3 x 5 mL) and dissolved in 20 mL of anhydrous 
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pyridine. The flask was capped with a rubber septum under Ar atmosphere. To the stirred 
solution was added benzoyl chloride (234 µL, 2.01 mmol) and stirred for overnight at room 
temperature. The reaction was checked by TLC (30:1 DCM:MeOH). The next morning,  
another 234 µL (2.01 mmol) of benzoyl chloride was added, and the reaction was stirred 
for 24 h. Solvents were evaporated under reduced pressure, and the residue was taken up 
in 30 mL of DCM, which was washed with water (3 x 30 mL) and dried over sodium sulfate 
for 30 minutes. The solution was filtered, evaporated under reduced pressure, and subjected 
to flash column. Purification was achieved using a gradient of DCM:MeOH to give 
compound 17 as a colorless solid (0.807 g, 82% yield). ESI+-MS: Exact mass calc: 
586.3127 [M + H]+, Exact mass obs: 586.3137 [M + H]+ (error 1.7 ppm);  1H NMR (CDCl3, 
500 MHz): δ 13.13 (s, 1H), 8.16-8.17 (d, 2H, J = 7.5 Hz), 7.99 (S, 1H), 7.58-7.61 (m, 1H), 
7.49-7.52 (m, 2H), 6.77-6.80 (m, 1H), 6.13 (t, 1H), 5.93-5.96 (d, 1H, J = 6.5 Hz), 5.32-
5.34 (d, 1H, J = 17.5 Hz), 4.39-4.40 (m, 1H), 3.80-3.90 (m, 1H), 3.81-3.84 (m, 1H), 3.74-
3.77 (m, 1H), 2.36-2.42 (m, 1H), 2.21-2.27 (m, 1H), 0.87-0.88 (2s, 20H), -0.12--0.10 (2s, 
12H). 13C NMR (CDCl3, 125 MHz): δ 141.32, 139.24, 135.35, 132.04, 131.10, 130.88, 
118.07, 114.08, 90.21, 88.65, 74.57, 65.26, 28.49, 28.35, 20.75, 20.48, 20.39, -0.50, -2.07, 
-2.24, -2.74. 
  
4-N-Benzoyl-5-vinyl-2ʹ-deoxycytidine (18) (Scheme 2.5) 
Compound 17 (0.81 g, 1.38 mmol) was dried on high vacuum overnight then co-
evaporated three times with 5 mL of anhydrous pyridine. To this was added 15 mL 
88 
 
anhydrous DCM. The solution and flask were purged with argon for 5 min. To the flask, 
900 µL (5.5 mmol) triethylamine trihydrofluoride was added over 30 minutes. The reaction 
was stirred in the dark for 16 h at room temperature. The completion of the reaction was 
monitored by TLC. The reaction mixture was evaporated under reduced pressure and the 
residue was extracted with DCM and dried over anhydrous Na2SO4 and purified on a silica 
gel column run washed with 15:1 DCM:MeOH and eluted with a mixture of 9:1 
DCM:MeOH. Yield (0.64 g, 80%).  ESI+-MS: Exact mass calc: 358.1397 [M + H]+, Exact 
mass obs: 358.1398 [M + H]+ (error 0.3 ppm);  1H NMR (CDCl3, 500 MHz): δ 8.64 (s, 
1H), 8.16-8.18 (d, 2H, J = 7.0 Hz), 7.59 (t, 1H), 7.52 (t, 2H), 6.77-6.82 (m, 1H), 6.17 (t, 
1H), 5.84-5.88 (d, 1H, J = 18 Hz), 5.26-5.31 (m, 3H), 4.30-4.32 (m, 1H), 3.87-3.88 (m, 
1H), 3.71-3.75 (m, 1H), 3.62-3.66 (m, 1H), 2.27 (t, 2H). 13C NMR (CDCl3, 125 MHz): δ 
141.32, 139.24, 135.35, 132.04, 131.10, 130.88, 118.07, 114.08, 90.21, 88.65, 74.57, 
65.26, 28.49, 28.35.  
 
4-N-Benzoyl-5ʹ-O-(dimethoxytrityl)-5-vinyl-2ʹdeoxycytidine (19) (Scheme 2.5) 
Compound 18 (155 mg, 0.43 mmol) was dried by repeated co-evaporation with dry 
pyridine (3 × 5 mL). The residue was dissolved in dry pyridine (6 mL) and 4,4′-
dimethoxytrityl chloride (220 mg, 0.64 mmol) was added in portions and stirred at rt for 
7h. After completion of the reaction (monitored by TLC), methanol (1 mL) was added to 
the reaction mixture, and stirring was continued for another 30 min. The reaction mixture 
was evaporated to dryness under reduced pressure, and the remaining residue was dissolved 
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in dichloromethane (25 mL) and washed with 5% aq. NaHCO3 solution (50 mL) and water 
(50 mL). The organic layer was dried over Na2SO4, the solvent was evaporated under 
reduced pressure, and the residue was subjected to flash chromatography (silica gel, 
column 10 × 4 cm, eluted with CH2Cl2/acetone 95:5 to 85:15). Evaporation of the fractions 
corresponding to the product on TLC afforded 19 (0.167 g, 60%) as a pale-yellow foam. 
TLC (silica gel, CH2Cl2/MeOH 9:1). Rf 0.8.  Exact mass calc: 660.2704 [M + H]+, Exact 
mass obs: 660.2688 [M + H]+ (error 2.4 ppm). 1H- NMR [DMSO (d6), 500 MHz]: δ 2.26-
2.29 (m, 1H), 2.37-2.40 (m, 2H), 3.25-2.52 (d, 1H), 3.72 (s, 3H), 3.73 (s, 3H), 3.98-3.99 
(d, 1H), 4.28 (s, 1H), 5.08-5.10 (d, 1H), 5.37-5.38 (d, 1H), 5.70-5.74 (d, 1H), 6.19 (t, 1H), 
6.44-6.50 (m, 1H), 6.87-6.90 (m, 4H), 7.21-7.27 (m, 5H), 7.31 (t, 2H), 7.38-7.40 (d, 2H), 
7.51 (t, 2H), 7.60 (t, 1H), 7.96 (brs, 1H), 8.16-8.17 (d, 2H). 13C- NMR [DMSO (d6), 500 
MHz]: δ 173.75, 158.61, 158. 60, 157.70, 147.25, 145.13, 139.24, 137.03, 135.86, 135.83, 
133.11, 130.20, 130.17, 129.81, 128.87, 128.37, 128.16, 127.24, 115.84, 113.70, 111.90, 
86.26, 70.61, 64.07, 55.49, 55.48, 31.15.  
 
4-N-Benzoyl-5ʹ-O-(dimethoxytrityl)-5-vinyl-2ʹdeoxycytidine 3ʹ-(2-cyanoethyl)-N, Nʹ-
diisopropyl phosphoramidite (20) (Scheme 2.5) 
A solution of 19 (100 mg, 0.15 mmol) in dry CH2Cl2 (10 mL) was stirred with (i-
Pr)2NEt (52 μL, 39 mg, 0.30 mmol) at room temperature. Then, 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite (67 μL, 72 mg, 0.30 mmol) was added and the reaction 
mixture was stirred for 30 min. Upon completion of the reaction (monitored by TLC), the 
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reaction mixture was diluted with CH2Cl2 (30 mL) and was poured into 5% NaHCO3 
solution (30 mL) and extracted with CH2Cl2 (3 × 20 mL). The combined organic phases 
were dried over Na2SO4, and the solvent was evaporated. The residual foam was applied 
to a flash chromatography column (silica gel, 8 × 3 cm, eluted with CH2Cl2/acetone 100:0 
→ 95:5). Evaporation of the fractions corresponding to the product on TLC afforded 20 
(90 mg, 70%) as a colorless viscous oil. TLC (silica gel, CH2Cl2/acetone 9:1). Rf 0.7. ESI+-
MS/MS: Exact mass calc: 860.3783 [M + H]+, Exact mass obs: 860.3771 [M + H]+ (error 
1.4 ppm). 31P NMR (CDCl3, 500 MHz): 149.24, 148.64.  
 
13C1015N2-5-Methyl-2′-deoxycytidine (21)  
13C1015N2-thymidine (3.5 mg, 0.014 mmol, Cambridge Isotope Labs, Tewksbury 
MA) was dissolved in 0.7 mL DCM. To the stirred solution, 360 µL triethylamine (TEA) 
(2.6 mmol) and 270 µL chlorotrimethyl-silane (2.2 mmol) were added. The solution was 
stirred for 30 min at 23 °C and then quenched with 2 mL cold 1 M sodium bicarbonate 
(NaHCO3). Phases were separated, the organic layer dried with anhydrous magnesium 
sulfate (MgSO4), filtered, and evaporated under reduced pressure. The resulting brown 
residue was co-evaporated with anhydrous toluene (3 x 1 mL). At the same time, a 
suspension of 1,2,4-triazole (120 mg, 1.7 mmol), TEA (370 µL, 2.7 mmol), and 
phosphorous oxychloride (POCl3) (37 µL, 0.40 mmol) in 2 mL acetonitrile (ACN) was 
stirred on ice for 30 min. The residue was then dissolved in 3 mL ACN, added to the 
suspension of triazole, TEA, and POCl3, and stirred for 2 h at room temperature. The 
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reaction mixture was concentrated under reduced pressure and re-dissolved in 2 mL of 
DCM. The DCM solution was washed with 1 M cold NaHCO3, separated, dried with 
MgSO4, filtered, and the solvent was removed under vacuum. The residue was dissolved 
in 5.5 mL of 7 N methanolic ammonia and placed with a magnetic stir bar in a Teflon tube, 
which had been chilled on ice for 30 min. The Teflon tube was capped and placed in a 
stainless-steel bomb that was then sealed. The bomb was placed in an oil bath preheated to 
75 °C and allowed to react for 3 days. After cooling the stainless-steel bomb to below room 
temperature, the bomb was opened, and the remaining ammonia was allowed to evaporate 
overnight. The residue was dissolved in 50:50 MeOH:DCM and dried prior to HPLC 
purification on an Agilent 1100 system. Purification was done using a Synergi 4u Hydro-
RP 80A column [250 mm x 4.6 mm] from Phenomenex (Torrance, CA). The starting 
material and product were eluted isocratically using 6% MeOH in 10 mM ammonium 
formate at pH 4.2 for 32 min followed by an increase to 50% ACN and subsequent 
equilibration to initial conditions. The product 21 eluted at 12.5 min and starting material 
at 20.9 min. Carbograph SPE cartridges (Grace Analytical, Deerfield, IL) were conditioned 
in MeOH and then water, the product was loaded onto the cartridge, followed by a water 
wash and 3 successive methanol elutions. Product identity was confirmed by matching the 
UV spectra to a commercial unlabeled standard and HPLC-ESI+-MS/MS. ESI+-MS/MS: 
m/z 253.9 [M + H]+→ m/z 133.2 [M + H - deoxyribose]+ Exact mass calc: 254.1412 [M + 
H]+, Exact mass obs: 254.1408 [M + H]+ (error 1.6 ppm). 
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Solid Phase Synthesis and Purification of DNA Oligodeoxynucleotides 
DNA sequences used in this study were derived from codons 153-158 of the human 
p53 tumor suppressor gene (5-CCCGGCACC CGC[15N3,13C1-G]TCCGCG-3) (Table 
2.1). Oligodeoxynucleotides containing a structurally modified C:G base pair at the first 
position of p53 codon 157 were synthesized using an ABI 394 DNA Synthesizer (Applied 
Biosystems, California) in accordance to standard solid phase oligodeoxynucleotide 
synthesis protocols.234  
The oligodeoxynucleotides were purified by reversed phase HPLC using an Agilent 
1100 system interfaced with a UV-VWD detector.235-236 The oligodeoxynucleotides 
containing modified cytosine base were purified on a Supelcosil LC-18-DB column (10 
mm × 250 mm, 5 m, Supelco, Bellefonte, PA) eluted at 40C and a flow rate of 3 mL/min. 
HPLC buffers were 100 mM triethylammonium acetate, pH 7.0 (A), and acetonitrile (B). 
A linear gradient of 16.8-26% B in 21 minutes followed by a gradient increase to 34% B 
in the next 19 minutes was used. Following HPLC purification, the oligodeoxynucleotides 
were desalted by NAP-5-illustra™ size exclusion columns (GE Healthcare, Piscataway, 
NJ) according to the manufacturer’s protocols. The presence of C5-alkyl-dC in the 
oligodeoxynucleotides was confirmed by capillary HPLC-ESI--MS (Table 2.1),236-238 and 
their concentrations were determined from the extent of 2'-deoxyguanosine in enzymatic 
digests using previously published protocols.239-241  
Double stranded DNA was obtained by combining equal amounts of the 
complementary strands (200 pmol) in 10 mM Tris-HCl (pH 8.0), 50 mM sodium chloride 
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buffer to achieve a concentration of 200 M. The DNA mixtures were heated at 90°C for 
5 mins and then allowed to cool slowly to room temperature. Each duplex contained a 
15N3,13C1-labeled guanine at the first position of codon 157, base paired to cytosine or a 
C5-alkylcytosine analog (Table 2.2).242 
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Table 2.1. Nucleobase sequences and molecular weights of oligodeoxynucleotides 
employed in this study. 
 
Oligodeoxynucleotide 
ID 
Sequence (5  3) MW  
Calc. Obs.# 
(+)p53 exon 5 
(-)p53 exon 5 
(-)p53 exon 5-MeC 
(-)p53 exon 5-Et-C 
(-)p53 exon 5-prop-C 
(-)p53 exon 5-vinyl-C 
CCCGGCACCCGCG*TCCGCG 
CGCGGACGCGGGTGCCGGG 
CGCGGA[Methyl-C]GCGGGTGCCGGG 
CGCGGA[Ethyl-C]GCGGGTGCCGGG 
CGCGGA[Propyl-C]GCGGGTGCCGGG 
CGCGGA[Vinyl-C]GCGGGTGCCGGG 
5715.7 
5911.9 
5925.9 
5939.9 
5953.9 
5937.9 
5714.9 
5910.7 
5925.4 
5939.5 
5954.2 
5939.0 
# from HPLC-ESI-MS, G* = [15N3,13C1-G]  
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Table 2.2. Thermal melting points of structurally modified DNA duplexes employed in 
this work. Double-stranded DNA were obtained by dissolving equimolar amounts of the 
complimentary strands in 10 mM sodium phosphate buffer, pH 7.0 containing 50 mM 
NaCl to give a 9.7 μM final DNA concentration. DNA melting temperatures were 
obtained using a Varian Cary 100 Bio UV-visible spectrophotometer by linearly 
increasing the temperature by 0.5 °C/min from 30 to 90 °C. The melting points (Tm) was 
determined using Cary WinUV Thermal software (Varian, Palo Alto, CA) by averaging 
N = 3 runs. Data for native, methyl, ethyl, and propyl strands are reproduced from 
reference 9.242 
Double stranded DNA  Sequence Tm (ºC) a 
ds native 5-CCCGGCACCCGC  G*TCCGCG-3 
3-GGGCCGTGGGCG  CAGGCGC-5 
80.7 ± 0.5 
ds methyl 5-CCCGGCACCCGC     G*TCCGCG-3 
3-GGGCCGTGGGCG MeCAGGCGC-5 
81.5 ± 0.2 
ds ethyl 5-CCCGGCACCCGC        G*TCCGCG-3 
3-GGGCCGTGGGCG EthylCAGGCGC-5 
82.1 ± 0.2 
ds propyl 5-CCCGGCACCCGC         G*TCCGCG-3 
3-GGGCCGTGGGCG PropylCAGGCGC-5 
80.2 ± 1.1 
ds vinyl 5-CCCGGCACCCGC        G*TCCGCG-3 
3-GGGCCGTGGGCG VinylCAGGCGC-5 
83.0 ± 0.8 
   a 9.7 μM dsDNA in 50 mM NaCl, 10 mM NaH2PO4, pH 7.0 (pH with NaOH). G* = 
[15N3,13C1-G]  
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DNA Methyltransferase Experiments  
Synthetic DNA duplexes (250 -1500 fmol) were incubated with recombinant 
human DNMT1 enzyme (0.75U, New England Biolabs, Ipswich MA), 100 mg/ml BSA, 
and 160 µM S-adenosylmethionine (SAM) in 1X DNMT buffer for 15 min at 37 °C. The 
reactions were quenched by freezing on dry ice. The enzyme was inactivated by heating at 
65 °C for 50 min. DNA was digested to 2′-deoxynucleosides in the presence of 
phosphodiesterase I (PDE I, 86 mU), phosphodiesterase II (PDE II, 77 mU), alkaline 
phosphatase (29 U), and DNase I (34 U) in 10 mM Tris-HCl/15 mM MgCl2 buffer, pH 7 
(35 µL total volume, 18 h at 37 °C). Samples were spiked with 2 pmol of 13C1015N2-MeC 
(internal standard for mass spectrometry) and purified by SPE using Thermo Fisher 
Scientific Hypersep Hypercarb (50 mg/mL) cartridges. Briefly, the cartridges were 
equilibrated with 2 mL MeOH and 2 mL deionized water. The volume of samples was 
adjusted to 500 µL prior to loading onto pre-equilibrated columns. The samples were 
washed with 2 mL each of deionized water and eluted in 1.6 mL of MeOH.  
 
HPLC-ESI+-MS/MS of 5-methyl-dC 
The amounts of MeC present in DNA before and after incubation with DNMT1 were 
determined by HPLC-ESI+-MS/MS utilizing a Thermo TSQ Vantage mass spectrometer 
interfaced with a Thermo Dionex Ultimate 3000. The mass spectrometer settings were 
optimized by direct infusion of standards at the same flow rate and composition of the 
eluting peaks. The mass source was typically operated at 2700 V, sheath gas 27, 
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declustering voltage 22 V, capillary temperature 270 ℃, S-lens 93, collision gas 1.0 mTorr, 
and the collision energy at 8 V. The following MS/MS transitions were utilized: m/z 242.1 
[M + H]+  m/z 126.1 [M – deoxyribose + H]+ for MeC and m/z 254.1 [M + H]+  m/z 
133.2 [M – deoxyribose + H]+ for the corresponding internal standard13C1015N2-MeC. 
Chromatographic separation was achieved using a Thermo Fisher Hypercarb column (0.3 
mm x 100 mm, 3 m) eluted at a flow rate of 14 L/min at ambient temperature.  HPLC 
solvents were 15 mM NH4OAc (A) and ACN (B).  A linear gradient of 15% to 60% B in 
10 min was used, followed by an increase to 95% in 2 min and held at 95% B for 3 min. 
The column was returned to initial conditions over 2 min followed by equilibration at 15% 
B for 7 min. Under these conditions, both the MeC and 13C1015N2-MeC internal standard eluted 
at 6.1 min.   
 MeC amounts introduced during DNMT1 reaction was calculated by comparing the 
HPLC-ESI-MS/MS peak areas corresponding to MeC and 13C1015N2-MeC internal standard. 
Values were adjusted by subtracting MeC amount generated spontaneously in the absence 
of the enzyme. The amount of DNMT1 mediated formation of MeC was used to calculate 
the velocity of methyl transfer. Plots of methylation velocities vs. DNA concentrations 
were generated for each DNA sequence (substrate) and fitted to a Michaelis-Menten 
equation below: 
Y = Vmax*X/ (Km + X), 
where the Vmax is the maximal methylation rate of DNA by DNMT1, and Km is the 
concentration of substrate required to reach the half-maximal rate. Statistical differences 
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in Vmax were calculated in GraphPad Prism using ANOVA using Tukey correction for 
multiple testing.  
 
Homology Modeling 
All molecular modeling was performed using the Schrödinger modeling suite 
package.243 Since both the mouse and human DNMT1 shared an 85% sequence 
similarity244, homology modeling of the human DNMT1 (hDNMT1) was carried out using 
the published crystal structure of the mouse DNMT1 in complex with hemi-methylated 
DNA (PDB: 4DA4)10 based on its reference sequence (NP_001124295.1). This method245-
246 takes advantage of the observation that protein structure is more highly conserved than 
its amino acid sequence, and that small or medium changes in sequence normally result in 
little variation in the 3D structure.247 The DNA sequence was modified accordingly to 
match the sequence used experimentally to determine DNA methylation rates. Schrödinger 
Maestro (Schrödinger, LLC, NY) was used to model the extended forms of 5-
methylcytosine (5-ethyl-dC, 5-propyl-dC, 5-vinyl-dC) within the modeled DNA template. 
Each of the modeled hDNMT1 – DNA complexes was subjected to standard protein 
preparation protocols at physiological pH, followed by energy minimization of the 
hydrogen atoms using OPLS3 force field with Generalized Born implicit solvent model to 
optimize all hydrogen-bonding networks.248-249 To understand local structural effects 
induced by extension of 5-methylcytosine to ethylC, propylC, and vinylC, energy minimization 
of the modified base was carried out with a 15Å spherical radius restraint.  
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2.3 Results 
2.3.1 Synthetic Strategy 
In order to incorporate 5-ethyl-dC, 5-propyl-dC, and 5-vinyl-dC into DNA strands, 
the corresponding nucleoside phosphoramidites were synthesized. The key starting 
material for the synthesis of these phosphoramidites was TBS-protected-5-iodo-dC (5-I-
dC, 2 in Scheme 2.2).250-251 5-I-dC was subjected to Sonogashira and Stille cross- coupling 
reactions to introduce ethyl (Scheme 2.3), propyl (Scheme 2.4), or vinyl (Scheme 2.5) 
groups at the C-5 of dC.  
 C5-ethyl and propyl groups on cytidine were introduced by Sonogashira cross-
coupling of compound 2 with TMS-protected acetylene (Scheme 2.3) or propyne gas 
(Scheme 2.4), respectively. The reactions were conducted in the presence of 
tetrakis(triphenyl-phosphine)palladium(0) at room temperature.252-253 5-(Trimethylsilyl)-
ethynyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (3) and 5-propyn-1-yl-3ʹ,5ʹ-O-t-
butyldimethylsilyl-2ʹ-deoxycytidine (10) were obtained in 35% and 85% yield, 
respectively. The C-5 vinyl group was introduced via Stille coupling between 2 and 
tributylvinyltin in presence of palladium catalyst (Scheme 2.5). Compound 2 was reacted 
with tributylvinyltin in presence of palladium to get TBS-protected-5-vinyl-dC in 58% 
yield. The deprotection of the TMS group of compound 3 was achieved in the presence of 
potassium hydroxide in methanol to obtain compound 4 in 90% yield. The resulting 5-
ethynyl-3′,5′-t-butyldimethylsilyl-2′-deoxycytidine 4 and compound 10 were subjected to 
hydrogenation to obtain the corresponding saturated compounds 5 and 11 in good yields.  
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Scheme 2.2. Synthesis of common precursor 5-iodo-3′,5′-O-t-butyldimethylsilyl-2′-
deoxycytidine (2): (i) Iodine, iodic acid, water, glacial acetic acid, CCl4 (ii) TBSCl, 
imidazole, DMF. 
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Scheme 2.3. Synthesis of 4-N-benzoyl-5′-DMT-5-ethyl-2′-dC-3′-phosphoramidite (9): (i) 
TMS acetylene, Pd(PPh3)4, CuI, anhydrous DMF, 48 h room temperature. (ii) 1 N KOH, 
anhydrous MeOH, 3 h room temperature. (iii) 10% Pd-C, H2 (1atm), 24 h at room 
temperature. (iv) PhCOCl, anhydrous pyridine, overnight, room temperature. (v) 
Et3N•3HF, anhydrous DCM, 16 h. (vi) DMTrCl, anhydrous pyridine, 16 h. (vii) 2-
Cyanoethyl-N,N-diisopropylchlorophosphoramidite, DIPEA, anhydrous DCM, 16 h, room 
temperature. 
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Scheme 2.4. Synthesis of 4-N-Benzoyl-5′-DMT-5-propyl-2′-dC-3′-phosphoramidite (15): 
(i) propyne (5 psi), Pd(PPh3)4, CuI, anhydrous DMF, 24 h at room temperature. (ii) 10% 
Pd-C, anhydrous MeOH, H2 (1atm), 24 h at room temperature. (iii) a. PhCOCl, anhydrous 
pyridine, overnight, room temperature. (iv) Et3N•3HF, anhydrous DCM, 16 h. (v) DMTrCl, 
anhydrous pyridine, 16 h. (vi) 2-Cyanoethyl-N,N-diisopropylchlorophosphoramidite, 
DIPEA, anhydrous DCM, 16h, room temperature. 
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Scheme 2.5. Synthesis of 4-N-benzoyl-5′-DMT-5-vinyl-2′-dC-3′-phosphoramidite (20): (i) 
tributylvinyl tin, Pd2(dba)3, tri(2-furanyl)phosphine, anhydrous 1-methyl-2-pyrolidinone, 
24 h 60 °C (ii) PhCOCl, anhydrous pyridine, overnight, room temperature. (iii) Et3N•3HF, 
anhydrous DCM, 16 h. (iv) DMTrCl, anhydrous pyridine, 16 h. (v) 2-Cyanoethyl-N,N-
diisopropylchloro phosphoramidite, DIPEA, anhydrous DCM, 16 h, room temperature.  
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TBS-protected 5-ethyl-dC, 5-propyl-dC, and 5-vinyl-dC nucleosides were 
converted to the corresponding phosphoramidites to enable their incorporation into DNA 
strands (Schemes 2.3, 2.4, and 2.5). In this process, nucleosides 5, 11 and 16 were 
protected at exocyclic amine with benzoyl chloride to give the protected derivatives 6, 12 
and 17 in good yields (6, 80-90%; 12, 90% and 17, 82%). During the amine protection of 
the propyl-derivative (13) we observed a mixture of the expected mono-benzoylated (12) 
and the unexpected dibenzoylated product. This issue was resolved by stirring the crude 
product mixture in a mixture of 65:30:5 pyridine:MeOH:water containing 1N NaOH at 0 
℃ for 10 minutes and quenching the reaction with solid ammonium chloride.234 Following 
benzoylation of the exocyclic amine, the TBS protecting groups were removed by treating 
the nucleosides 6, 12 and 17 with triethylamine trihydrofluoride over 16 h in dry DCM to 
give nucleosides 7, 13 and 18 in comparable yields (Scheme 2.3, Scheme 2.4, and Scheme 
2.5). Further, the 5ʹ-OH group of synthetic nucleosides was protected with DMT-Cl in 
anhydrous pyridine to give the corresponding DMT derivatives 8, 14 and 19 in good to 
excellent yields.  Phosphitylation of the DMT-ethers 8, 14 and 19 in the presence of DIPEA 
with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite resulted in the 
phosphoramidites 4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-ethyl-2′-deoxycytidine-3′-[(2-
cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (9) in Scheme 2.3 and 4-N-Benzoyl-5′-
O-(dimethoxytrityl)-5-propyl-2′-deoxycytidine-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-
phosphoramidite (15) in Scheme 2.4 and 4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-vinyl-2′-
deoxycytidine-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite 20 in Scheme 2.5 
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[9 (62%), 15 (76%), 20 (70%)]. All intermediates and final compounds were structurally 
characterized by a combination of 1H-,13C-,31P-NMR, HRMS, and MS/MS (Appendix 
A.1-A.19). 
 The novel C5-functionalized dC phosphoramidites 9, 15, and 20 were used in solid 
phase synthesis to generate oligodeoxynucleotide 19-mers 5-CGCGGA[alkyl-
C]GCGGGT GCCGGG-3 representing codons 155-160 of the p53 tumor suppressor gene 
(Table 2.1). In the resulting DNA duplexes (Table 2.2), structurally modified cytosine is 
base paired with guanine at the first position of p53 codon 157, a prominent mutational 
“hotspot” in cancer.254 All DNA strands were purified by reverse phase HPLC and 
characterized by ESI--MS (Table 2.1 and Figures 2.1-2.3).235-236 To obtain double stranded 
DNA, synthetic strands containing dC analogues were annealed to their compliments 
(Table 2.2). The duplexes were characterized by circular dichroism spectroscopy and 
thermal melting curves (Figure 2.4 and Table 2.2).236-238 These data indicated that the 
presence of the C5-alkylated cytidine analogs did not alter the overall secondary structure 
of the DNA duplexes, although small changes in Tm values were observed.  
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Figure 2.1. Deconvoluted ESI- mass spectrum of DNA oligomers: 5-CGCGGA[Et-
C]GCGGGTGCCGGG-3 (M = 5939.9). 
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Figure 2.2. Deconvoluted ESI- mass spectrum of DNA oligomer: 5-CGCGGA[Pr-
C]GCGGGTGCCGGG-3 (M = 5953.9). 
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Figure 2.3. Deconvoluted ESI- mass spectrum of DNA oligomer: 5ʹ-CGCGGA[V-
C]GCGGGTGCCGGG-3 (M = 5937.9). 
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Figure 2.4. Circular Dichroism (CD) spectra of DNA oligonucleotides used in this work. 
Double-stranded DNA were obtained by dissolving equimolar amounts of the 
complimentary strands in 10 mM sodium phosphate buffer, pH 7.0 containing 50 mM NaCl 
to give a 9.7 μM final DNA concentration. The CD spectra were obtained with on a Jasco 
J-815 spectropolarimeter scanning the wavelengths from 350 to 200 nm in a 1 mm quartz 
cuvette, using a wavelength gradient of 0.5 nm. Spectra below are the average of N = 3 
scans. 
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2.3.2 Influence of C-5 substituent on DNMT1-catalyzed cytosine methylation 
 To determine whether C-5 alkylcytosines with extended alkyl chain length are able 
to direct DNMT1 mediated cytosine methylation, DNA methylation assays were conducted 
with recombinant human DNMT1 and structurally modified duplexes containing 5-ethyl-
dC, 5-propyl-dC, and 5-vinyl-dC in a CpG sequence opposite unsubstituted dC (Scheme 
2.6). 5-methyl-dC was employed as a positive control, while unsubstituted dC served as a 
negative control for methylation reactions. Following incubation of DNMT1 and DNA 
duplexes in the presence of SAM and DNMT buffer, isotope dilution HPLC-ESI-MS/MS 
assay developed in our laboratory (Scheme 2.6) was employed to quantify the extent of 
DNMT1-mediated methyl transfer.  
 To quantify DNA methylation amounts, DNA was enzymatically digested to their 
corresponding 2ʹ-deoxynucleosides and spiked with 13C1015N2-MeC internal standard, 
followed by solid phase extraction (SPE) (Scheme 2.6). MeC was quantified by capillary 
HPLC ESI+-MS/MS using selected reaction monitoring of m/z 242.1 [M + H+]  m/z 126.1 
[M – deoxyribose + H+] for MeC and m/z 254.1 [M + H+]  m/z 133.2 [M – deoxyribose 
+ H+] for 13C1015N2-MeC internal standard (Figure 2.5). The amount of MeC formed was 
calculated by multiplying the amount of internal standard by the ratio of the areas for 
analyte and internal standard and subtracting the corresponding controls as shown in 
equation 1.  
Equation 1: 𝑀𝑒𝐶𝐷𝑁𝑀𝑇1 =  
𝐴𝑟𝑒𝑎𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝐴𝑟𝑒𝑎𝐼𝑆𝑇𝐷
∗ (𝐼𝑆𝑇𝐷) −  𝑀𝑒𝐶𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
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Scheme 2.6. Mass spectrometry based assay to quantify the rates of DNMT1-mediated 
methyl transfer in the presence of MeC and its analogues with extended C-5 side chain. 
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Figure 2.5. Capillary HPLC+-ESI-MS/MS detection of 5-methyl-dC in methylation 
reactions. 
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 Data were fitted into Michaelis-Menten curves to allow for kinetic analyses (Figure 
2.6). The Vmax and Km values were determined via nonlinear regression using data from 
three or more individual points.255 As anticipated, no DNMT1 mediated methylation was 
observed for DNA duplexes containing unmodified C:G base pair, while 5-methyl-dC 
containing DNA was efficiently methylated (Figure 2.6, Table 2.3). 5-ethyl-dC containing 
DNA was recognized as a DNMT1 substrate, although the Vmax value was significantly 
reduced as compared to the native substrate (2.4 x 10-2 nM/min vs 9.6 x 10-2 nM/min, 
respectively, p = 0.017) (Figure 2.6, Table 2.3). The corresponding Km values were 21.8 
± 13.7 and 3.90 ± 6.42 nM, for 5-methyl-dC and 5-ethyl-dC, respectively. In contrast, 
neither PropylC nor vinylC were able to direct DNA methylation under the conditions tested 
(Figure 2.6). 
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Figure 2.6. Michaelis-Menten plots showing activity of human DNMT1 toward DNA 
containing 5-alkyl-dC analogs (Sequence: 5-CGCGGA[alkyl-C]GCGGGTGCCGGG-3). 
The error bars represent the standard deviation of at least N = 3 repeats. 
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Table 2.3. Kinetic parameters of DNMT1 mediated methylation of DNA duplexes 
containing 5-alkyl-dC.a  
DNA Duplex Vmax (x10-2 nM/min) Km (nM) Vmax/Km (x10-2 min-1) 
ds native 
0.72 ± 0.22 0.450 ± 5.99 1.6 ± 21 
ds methyl 
9.6 ± 2.9 21.8 ± 13.7 0.44 ± 0.31 
ds ethyl 
2.4 ± 0.59 3.90 ± 6.42 0.62 ± 1.7 
a The Vmax and Km values were determined via nonlinear regression using data from three or more individual points. 
The ranges in Vmax and Km are the standard error for regression analysis. Error was propagated for Vmax/Km using the 
equation: 
𝐷𝑐
𝑐
= √(
𝐷𝑎
𝑎
)
2
+ (
𝐷𝑏
𝑏
)
2
; where a, b, and c are Vmax, Km, and Vmax/Km respectively.  
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2.3.3 DNMT1 homology modeling 
To determine whether the observed decrease in DNMT1 activity is associated with 
altered protein binding to structurally modified DNA, molecular modeling studies were 
conducted. Published crystal structures reveal two distinctive modes of binding between 
the unmethylated (PDB: 3PTA) and the hemi-methylated (PDB: 4DA4) DNA to DNMT1 
(Figure 2.7A).10, 244 In the catalytically productive complex, a large helical distortion 
around the central hemi-MeCpG site in the hemi-methylated DNA is observed (Figure 
2.7B). To understand the effects of increasing C5-alkyl chain length on the activity of 
DNMT1, we generated a homology model of a productive hDNMT1 complex with hemi-
methylated DNA.245-246 A localized energy minimization encompassing all amino acid 
residues within 15 Å of the modified cytosine bases was performed to determine how the 
increased length of the alkyl chain influences the recognition of hemi-methylated CpG sites 
in DNA.  
Within the productive hDNMT1-DNA complex, the target recognition domain 
(TRD) of the protein consists of a hydrophobic concave surface consisting of C1505, 
L1502, L1515, and M1535.10 This pocket harbors the 5-methyl group of MeC and is 
involved in the recognition of the hemi-methylated MeCpG. We found that extension of the 
C5-alkyl chain disrupts DNA binding within the shallow hydrophobic pocket of the TRD 
due to the excessive steric bulk (Figure 2.7C). This distortion leads to a 2.1 Å displacement 
of L1502 in the case of 5-propyl-dC (Figure 2.7D) and 1.4 Å for 5-ethyl-dC. For the vinyl 
substitution, we also see a displacement of L1502 with the same magnitude of 1.4 Å as to 
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EthylC. Thus, the difference of DNMT1 activity between 5-ethyl-dC and 5-vinyl-dC is likely 
due to the additional loss of rotational freedom by the co-planar geometry of the 
substitution. 
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Figure 2.7. A. Crystal structures of human DNMT1 protein bound to methylated DNA 
(magenta)10 or unmethylated DNA (blue)244 reveal two distinctive binding orientations. B. 
Hemi-methylated DNA in the productive DNMT1 complex undergoes a large helical 
distortion. C. Excessive steric bulk from growing C5 alkyl chain distorts the MeC 
recognition pocket. D. PropylC causes a 2.1 Å shift in the position of L1502. 
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2.4 Discussion 
In cells, 5-methyl-dC at a hemimethylated CpG sites directs DNMT1 mediated 
DNA methylation of cytosine in the opposite strand. DNMT1 binds to hemimethylated 
DNA via the target recognition domain (TRD) of the protein, which is a hydrophobic 
pocket composed of M1535, C1501, L1502, L1515, and W1512.10 Following recognition 
of MeC by the TRD, the cytidine to be methylated is flipped out of the duplex to enter the 
protein active site. The thiolate of the active site cysteine (C1226) forms a covalent bond 
with C-6, thereby activating the C5 position for methyl transfer from S-
adenosylmethionine (SAM). Base catalyzed removal of the C5 proton allows for re-
aromatization and release of the newly formed MeC (Scheme 2.7).10, 256  
  
120 
 
Scheme 2.7. Reaction mechanism of DNMT1 mediated methylation of cytosine. 
  
121 
 
 In this work, we probed whether the TRD of DNMT1 could recognize C-5 
alkylcytosine with an extended alkyl chain length and direct maintenance cytosine 
methylation using kinetic assays with human DNMT1. Using an isotope dilution, HPLC-
ESI-MS/MS assay, we evaluated DNMT1 activity on synthetic DNA duplexes containing 
5-ethyl-dC, 5-propyl-dC, and 5-vinyl-dC at a central CpG site opposite an unmodified dC. 
We found that DNMT1 was able to methylate 5-ethyl-dC containing DNA at a rate 
significantly less than the native substrate MeC (Vmax = 2.4 x 10-2 nM/min vs. 9.6 x 10-2 
nM/min, respectively), but there was no methyl transfer activity for DNA containing 5-
vinyl-dC or 5-propyl-dC (Figure 2.6 and Table 2.3).  
Our data suggests that the increase in steric bulk at C-5 by extending the alkyl chain 
length hinders DNMT1 enzyme activity. Although DNMT1 is able to recognize and 
methylate the DNA sequence containing 5-ethyl-dC, duplexes containing 5-propyl-dC are 
poor DNMT1 substrates (Figure 2.6). Valinluck et al. previously reported that DNMT1 
was capable of accommodating DNA duplexes containing 5-chloro-dC, 5-bromo-dC, and 
iodo-dC, but not the more rigid 5-propynyl-dC.231 In contrast, oxidation of MeC to 5-
hydroxymethyl-dC, 5-formyl-dC, and 5-carboxyl-dC hindered DNMT1 activity.233 In 
addition, 5-vinyl-dC containing duplex was not a substrate for DNMT1 (Figure 2.6). 
 Upon observing the reduced activity of DNMT1 toward DNA containing 5-ethyl-
dC and inactivity on DNA containing 5-vinyl-dC or 5-propyl-dC, we explored the potential 
for structural changes in the MeC recognition site when DNA contained PropylC, EthylC, and 
VinylC using molecular modeling. A homology model for hDNMT1 was created by 
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replacing the sequence of mouse DNMT1 in the published crystal structure of the 
catalytically productive complex (PDB: 4DA4) with the sequence human DNMT1.10 Using 
localized energy minimization around the modified cytosine, we found that modification 
of C5-alkyl substituent displaces the residues within the TRD, especially L1502 (Figures 
2.7C and 2.7D). The magnitude of displacement of the nearby L1502 residue is largest for 
the bulkiest alkyl group propyl at 2.1 Å and less significant for ethyl and vinyl 1.4 Å 
(Figure 2.7D and Table 2.3). The large disruptions needed in the TRD to accommodate 
extended alkyl side chains reduce the recognition of C5-alkyl cytosines by DNMT1 and 
prevent the formation of a productive DNA-DNMT1 complex.   
Our model supports the kinetic data shown in Figure 2.6 and Table 2.3, with the 
Km values reflecting either a productive or unproductive mode of binding. For 
unmethylated DNA, we observe the lowest Km value (0.450 nM, Table 2.3), demonstrating 
that in the unproductive DNMT1-DNA complex, DNA is more tightly bound. The 
productive DNMT1-DNA complex is hallmarked by a large distortion in the DNA duplex 
and a change in the mode of binding, resulting in a lower Km value.10, 244 As the length of 
the C5-alkyl chain increases, it causes a disruption in the TRD pocket. This hinders the 
recognition of the hemi-methylated MeCpG, causing the enzyme to adopt an unproductive 
mode of tighter binding with a lower Km value. 
 In summary, we have synthesized DNA duplexes containing a range of 5-alkyl-dC 
analogues with extended side chain. These unnatural DNA substrates were used to explore 
the ability of DNMT1 protein to recognize and methylate CpG sequences containing C5-
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alkylcytosine modifications with extended alkyl chain. The enzyme was capable of 
recognizing and methylating DNA containing MeC and EthylC with similar efficiencies, 
indicating that the ethyl group can be tolerated. In contrast, DNMT1 showed no enzymatic 
activity towards VinylC and PropylC, containing duplexes under the conditions tested (Figure 
2.6 and Table 2.3). We hypothesize that DNMT1 can bind to DNA to form two distinct 
complexes: a tighter binding inactive conformation and a lower affinity active 
conformation. Moreover, molecular models of DNMT1-DNA interactions indicate that the 
presence of larger C-5 alkyl chains at dC disrupt the integrity of the DNA recognition 
pocket, with PropylC pushing DNMT1 conformation toward the inactive complex. Although 
EthylC and VinylC cause a smaller disruption of the DNA recognition pocket, only EthylC 
duplex is a substrate for DNMT1, suggesting that the presence of a C-5 vinyl group affects 
other steps within the catalytic cycle.  
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III. MAINTENANCE DNA METHYLTRANSFERASE ACTIVITY IN THE 
PRESENCE OF OXIDIZED FORMS OF 5-METHYLCYTOSINE: 
STRUCTURAL BASIS FOR TET-MEDIATED DNA DEMETHYLATION 
Adapted from: 
Seiler, C.L.; Fernandez, J.; Koerperich, Z.; Andersen, M.P.; Kotandeniya, D.; Nguyen, 
M.E.; Sham, Y.Y.; and Tretyakova N.Y.; Maintenance DNA methyltransferase activity in 
the presence of oxidized forms of 5-methylcytosine: Structural basis for TET-mediated, 
DNA demethylation, Biochemistry, Accepted with revision August 2018. 
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3.1 Introduction 
5-Methylcytosine (MeC) is a stable epigenetic mark most commonly found at CpG 
dinucleotides of DNA, where cytosine bases in both strands are methylated.257 Cytosine 
methylation typically has a repressive effect, leading to reduced levels of gene expression.9-
10 Methylated CpG sites within gene promoter regions interfere with transcription factor 
binding and instead are recognized by methyl-CpG binding proteins, promoting the 
recruitment of histone deacetylases and the formation of closed chromatin.9-10  
In human cells, DNA methylation marks are introduced by de novo 
methyltransferases DNMT3a/b and are subsequently preserved by maintenance DNA 
methyltransferase 1 (DNMT1).12 The activity of DNMT1 as a maintenance 
methyltransferase during replication is necessary to ensure accurate transmission of 
epigenetic methylation marks to progeny cells. DNMT1 is recruited to the replication fork 
by UHRF1 and acts at hemimethylated CpG sites generated during DNA replication 
through recognition of the methylated CG sites on the template strand of the DNA.258-259 
DNMT1 specifically recognizes and methylates hemi-methylated CG sites.10, 244 Formation 
of an enzymatically active complex requires MeC binding to a concave hydrophobic pocket 
within the target recognition domain (TRD) of DNMT1.10, 260 This induces local melting 
of the DNA duplex, allowing unmethylated cytosine in the opposite strand of DNA to be 
actively “flipped” out of the DNA duplex stack to enter the protein active site.10, 258, 260-261 
The reversible addition of a thiolate from an active site cysteine residue of DNMT1 to the 
C-6 position of cytosine activates the C-5 position of the nucleobase, allowing it to accept 
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a methyl group from the S-adenosylmethionine (SAM) cofactor.10, 262 The covalent DNA-
protein complex is reversed via base catalyzed removal of the H-5 proton of the nucleobase 
and re-aromatization via elimination of the covalently attached cysteine (Scheme 2.7 in 
Chapter II).10     
Crystal structures reveal two distinctive modes of DNMT1-DNA binding.10, 244 In 
productive DNMT1-DNA complex containing a hemi-methylated CG dinucleotide 
(PDB:4DA4), hydrophobic amino acid side chains of M1535, C1501, L1502 and L1515 
form a target recognition domain (TRD) involved in interactions with hemimethylated 
MeCpG.10 As a hemimethylated CpG site emerges from the replication complex, the TRD 
of DNMT1 specifically recognizes MeC and facilitates maintenance methylation. A 
different binding mode is revealed in the crystal structure of DNMT1 interacting with 
unmethylated DNA (PDB:3PTA).244 In the unproductive DNMT1-DNA complex, the zinc 
finger-containing CXXC domain of the protein prevents de novo methylation by 
positioning the CXXC-BAH1 linker region of the protein between the DNA and the 
catalytic active site.244 Furthermore, the TRD of the protein assumes a retracted position 
that prevents it from direct interaction with the DNA.244 This autoinhibitory mechanism 
protects DNA from unintended de novo methylation by DNMT1.244   
 Ten Eleven Translocation (TET) dioxygenases sequentially oxidize the methyl 
group of MeC in DNA to give 5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC), 
and 5-carboxylcytosine (caC) (Scheme 3.1).13, 15-16 Both fC and caC can be excised by 
thymine DNA glycosylase (TDG) and replaced with cytosine via TDG-mediated base 
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excision repair pathway, leading to active demethylation.263 Additionally, oxidized forms 
of MeC promote passive DNA demethylation by interfering with DNMT1 activity at 
hemimethylated CpG sites.19 The relative contributions of passive and active DNA 
demethylation are dependent on the cell type, developmental factors, and the stage of the 
cell cycle.264-265 However, to our knowledge, the kinetics of DNMT1-mediated methyl 
transfer in the presence of oxidized forms of MeC (oxo-MeC) has not been elucidated, and 
the structural origins of reduced activity of DNMT1 protein in the presence of oxo-MeC 
are not well understood.  
 In the present study, a mass spectrometry based quantitative assay developed in our 
laboratory was used to examine the kinetics of DNMT1-mediated maintenance methylation 
in the presence of MeCG, hmCG, fCG, and caCG, while molecular dynamics simulations 
were conducted to examine the structural origins of the reduced DNMT1 activity in the 
presence of oxidized forms of 5-methylcytosine.20 Our results support a model in which 
MeC oxidation to hmC, fC, and caC prevents the formation of a productive DNMT1- DNA 
complex by weakening hydrophobic interactions between the modified cytosine and the 
TRD of the DNMT1 protein, leading to reduced maintenance methylation rates and 
allowing for passive DNA demethylation.   
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Scheme 3.1: Epigenetic modifications of cytosine in DNA.  
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3.2 Materials and Methods 
Materials 
All nucleoside phosphoramidites including 5-methyl-dC, 5-hydroxymethyl-dC, 5-
formyl-dC-III, 5-carboxy-dC, Ac-dC, dT, dA, dG, and dmf-dG, reagents, and controlled 
pore glass solid support for oligodeoxynucleotide synthesis were acquired from Glen 
Research Corporation (Sterling, VA). Human recombinant DNA methyltransferase 1 
(DNMT1) and Δ580-DNMT1266 (missing the PCNA,267 DNMT3A/B interaction 
domains267-268) were purchased from New England BioLabs (Ipswich, MA). 
Phosphodiesterase I, phosphodiesterase II, and DNase I were acquired from Worthington 
Biochemical Corporation (Lakewood, NJ). Bovine intestinal alkaline phosphatase was 
procured from Sigma Aldrich Chemical Company (Milwaukee, WI). All remaining 
laboratory chemicals and solvents were purchased from ThermoFisher Scientific 
(Waltham, MA) and Sigma-Aldrich (Milwaukee, WI). The synthesis of 13C10
15N2-5-
Methyl-2ʹ-deoxycytidine was described previously.20 
 
Synthesis of MeC, hmC, fC and caC Containing Oligodeoxynucleotides 
Synthetic DNA oligodeoxynucleotides (Table 3.1) were assembled by solid phase 
synthesis on an ABI 394 DNA synthesizer (Applied Biosystems, Grand Island, NY). MeC 
and its oxidized forms (MeC, hmC, fC, and caC) were added via manual coupling.242 MeC 
containing strands were cleaved from solid support and deprotected using 30% ammonium 
hydroxide for 16 h at room temperature. hmC containing DNA was cleaved from support 
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and deprotected using 30% ammonium hydroxide at 75 °C for 16 h. fC containing DNA 
was cleaved from solid support by incubation in 30% ammonium hydroxide for 16 h, 
followed by desalting using Illustra® Nap-5 cartridges (GE Healthcare, Buckinghamshire, 
UK). The 5-(1,3-dioxane-2-yl) protecting group on fC was cleaved using glacial acetic acid 
for 6 h at room temperature to reveal the unprotected oligodeoxynucleotide. Synthetic 
DNA strands containing caC were cleaved and deprotected using 0.4 M methanolic sodium 
hydroxide (80% methanol:20% 2 M sodium hydroxide) overnight. Following the removal 
of the supernatant and neutralization of the base with 2 M triethyl ammonium acetate, silica 
solid support was sonicated with water 3 times to maximize DNA yields.   
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Table 3.1: Nucleotide sequences and mass spectrometry characterization (HPLC-ESI--
MS/MS) of DNA oligomers used in methylation experiments. Measurements were taken 
on Agilent MSD Ion Trap operating in the negative ion mode.  
Sequence (5′-3′) Calculated MW Observed MW 
TCAGATTCGCGCCGGCTGCGATAAGCT 8276.4 8275.9 
AGCTTATCGCAGCCGGCGCGAATCTGA 8285.4 8285.1 
AGCTTATCGCAGCMeCGGCGCGAATCTGA 8299.5 8299.4 
AGCTTATCGCAGChmCGGCGCGAATCTGA 8315.5 8315.0 
AGCTTATCGCAGCfCGGCGCGAATCTGA 8313.4 8313.5 
AGCTTATCGCAGCcaCGGCGCGAATCTGA 8329.4 8329.0 
AGCTTATCGCAGCMeCGTCGCGAATCTGA 8274.5 8274.4 
AGCTTATCGCAGCMeCGACGCGAATCTGA 8283.5 8283.4 
AGCTTATCGCAGCMeCGCCGCGAATCTGA 8259.4 8259.4 
TCAGATTCGCGACGGCTGCGATAAGCT 8300.5 8300.4 
TCAGATTCGCGTCGGCTGCGATAAGCT 8291.4 8291.4 
TCAGATTCGCGGCGGCTGCGATAAGCT 8316.5 8316.5 
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Synthetic DNA strands were purified by reverse phase HPLC using an Agilent 1100 
HPLC system interfaced with a UV variable wavelength detector set at 260 nm. A Varian 
Pursuit C-18 HPLC column (5 µm, 250 x 10.0 mm) was eluted at flow rate of 3 mL/min 
with a gradient of 100 mM triethylammonium acetate pH 7.0 (A) and acetonitrile (B). In 
method A, solvent composition was linearly changed from 8.4% to 12% B over 30 min, 
increased to 17.5% over 10 min and further to 32.5% over 5 min. Solvent composition 
returned to initial conditions over 2 min, followed by re-equilibration for 15 min. In method 
B, solvent composition was changed from 9% to 16.3% B over 30 min, increased to 20% 
over 10 min, further to 32.5% over 5 min, and returned to initial conditions over 2 min, 
followed by equilibration over 15 min. Method A was used to purify C, MeC, hmC, and 
caC containing strands while method B was used to purify fC containing DNA.  
Following HPLC purification, synthetic DNA strands were desalted using Illustra 
Nap-5 cartridges (GE Healthcare) according to the manufacturer’s instructions. The 
presence of MeC, hmC, fC, or caC in synthetic DNA strands was confirmed by HPLC-
ESI--MS analyses on an Agilent MSD Ion Trap interfaced with an Agilent 1100 HPLC 
system (Table 3.1). A Zorbax 300-SB C-18 column (5 µm, 150 x 0.5 mm) was eluted with 
a gradient of 15 mM ammonium acetate (A) and acetonitrile (B). Solvent composition was 
held at 2% B for 3 min, then linearly increased to 40% over 16 min, further to 55% over 1 
min, followed by a return to initial conditions over 1 min and equilibration for 13 min. 
DNA concentrations were determined by quantitation of the 2′-deoxyguanosine in 
enzymatic digests.239-241 
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DNA Methyltransferase experiments 
Human DNMT1 (0.75U, New England BioLabs, Ipswich, MA) was incubated with 
synthetic DNA duplexes (250 – 1500 fmol) containing a single, centrally located CpG site 
with MeC, hmC, fC, or caC opposite the target C (Table 3.2). Methylation reactions were 
conducted in commercial DNMT buffer in the presence of 0.1 mg/mL bovine serum 
albumin (BSA) and 160 µM S-adenosylmethionine (SAM) for 15 min at 37 °C. The 
reactions were quenched by placing samples on dry ice, followed by enzyme inactivation 
by heating at 65 °C for 40 min. DNA was digested to 2′-deoxynucleotides in the presence 
of PDE I (55 mU), PDE II (63 mU), DNase I (28 U), and alkaline phosphatase (48 U) in a 
solution containing 10 mM Tris-HCl pH 7.0 and 15 mM magnesium chloride. Samples 
were spiked with 13C1015N2-5-methyl-2′-deoxycytidine (internal standard for mass 
spectrometry, 1.33 pmol) and purified by offline HPLC. A Waters Atlantis T3 column (3 
µm, 4.6 mm x 150 mm) was eluted with a gradient of 5 mM ammonium formate pH 4.0 
(A) and methanol (B). Solvent composition was linearly changed from 3% B to 20% B in 
15 min, further to 40% B over 5 min, increased to 80% over 5 min, held at 80% for 2 min, 
and returned to initial conditions over 2 min, followed by column reequilibration for 8 min. 
HPLC fractions containing MeC and its internal standard (8.9 – 10.2 min) were collected, 
concentrated under reduced pressure, and reconstituted in 12 µL of 15 mM ammonium 
acetate buffer prior to HPLC-ESI+-MS/MS analysis. 
  
134 
 
Table 3.2: DNA duplexes used to investigate the effects of TET oxidation and local 
sequence on the rate of cytosine methylation mediated by DNMT1. 
Duplex 
Name 
Duplex sequence  Melting 
temperature  
Tm ± SD (°C) 
(-)C 5′-TCAGATTCGCGCCGGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCGGCCGACGCTATTCGA-5′ 
77.4 ± 0.2 
(-)MeC 5′-TCAGATTCGCGCC     GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCGGMeCCGACGCTATTCGA-5′ 
77.0 ± 0.6 
(-)hmC 5′-TCAGATTCGCGCC     GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCGGhmCCGACGCTATTCGA-5′ 
76.6 ± 0.9 
(-)fC 5′-TCAGATTCGCGCC   GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCGGfCCGACGCTATTCGA-5′ 
77.5 ± 0.6 
(-)caC 5′-TCAGATTCGCGCC     GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCGGcaCCGACGCTATTCGA-5′ 
78.0 ± 0.4 
MeCGT 5′-TCAGATTCGCGAC     GGCTGCGATAAGCT-3′  
3′-AGTCTAAGCGCTGMeCCGACGCTATTCGA-5′ 
75.7 ± 0.3 
MeCGA 5′-TCAGATTCGCGTC     GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCAGMeCCGACGCTATTCGA-5′ 
75.5 ± 0.7 
MeCGC 5′-TCAGATTCGCGGC    GGCTGCGATAAGCT-3′ 
3′-AGTCTAAGCGCCGMeCCGACGCTATTCGA-5′ 
77.3 ± 0.4 
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HPLC-ESI+-MS/MS analysis 
Quantification of MeC was carried out by isotope dilution HPLC-ESI+-MS/MS 
with 13C1015N2-MeC as an internal standard. A Thermo Dionex Ultimate3000 HPLC 
system was coupled to a Thermo TSQ Vantage mass spectrometer (ThermoFisher 
Scientific, Waltham, MA). A Thermo Hypercarb column (3 µm, 100 x 0.5 mm) was 
maintained at 60 °C and eluted with a gradient of 15 mM ammonium acetate (A) and 
acetonitrile (B). Solvent composition was changed from 15 to 60% B over 10 min, further 
to 95% over 2 min, held at 95% B for 3 min, and returned to initial conditions over 2 min, 
followed by re-equilibration for 7 min. HPLC eluent was directed into the mass 
spectrometer during 2-12 min of the chromatographic run. Typical MS parameters were as 
follows: spray voltage, 3200 V; sheath gas pressure, 20 psi; capillary temperature 350 °C; 
collision energy, 8; declustering voltage, 22 V; collision gas pressure, 1.5 mTorr; tuned S-
Lens, 93; Q1 (full width at half maximum), 0.4; Q3 (full width at half maximum), 0.7; scan 
width, 0.4; scan time, 0.1 s. The mass spectrometer parameters were optimized upon direct 
infusion of authentic standards of MeC. The instrument was operated in the selected 
reaction monitoring mode by following the transitions m/z 254.1 [M + H]+ →126.1 [M + 
H - dR]+ for MeC and m/z 254.1[M + H]+ →133.1 [M + H - dR]+ for 13C1015N2-MeC 
(Figure 3.1). MeC amounts in each sample were determined from HPLC-ESI+-MS/MS 
peak areas corresponding to the analyte and its internal standard using calibration curves 
constructed with authentic standards.  
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Figure 3.1: HPLC-ESI+-MS/MS analysis of MeC and 13C1015N2-MeC in hydrolysates of 
DNA following DNMT1 treatment and offline-HPLC fractionation.  
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Methylation velocity (VMeC, M/min) was calculated from the HPLC-ESI
+-MS/MS 
areas corresponding to the analyte and internal standard according to the following 
equation: 
VMeC = (AAN / AIS) * CIS / [(V * t) * 1 x 10-6], 
where AAN and AIS are the areas under the HPLC-ESI
+-MS/MS peaks corresponding to 
MeC (analyte, AN) and its 13C, 15N-labeled internal standard (IS), respectively, CIS
 is the 
amount of internal standard used in pmol, V is the volume in microliters, and t is the 
reaction time in min. Steady-state kinetic parameters (Km and Vmax) for methyl transfer 
reaction were determined by plotting the calculated velocities vs. substrate concentration. 
 
Kinetic Analyses  
The MeC amounts determined by HPLC-ESI+-MS/MS were plotted against DNA 
concentrations using Prism 6 software from GraphPad Software, Inc. (La Jolla, CA). The 
kinetic curves were fitted to the Michaelis-Menton equation using non-linear regression to 
give the values of Km and Vmax. 
 
Electrophoretic Mobility Shift Assay (EMSA) to study DNMT1-DNA binding  
DNA strands (Table 3.1) (50 pmol) were radiolabeled by incubation with T4 
polynucleotide kinase (20 U, New England BioLabs, Beverly, MA) and γ32P-ATP (5 µCi, 
PerkinElmer Life Sciences, Boston, MA) in 1X polynucleotide kinase reaction buffer for 
1 hour at 37 °C. The enzyme was inactivated by heating at 65 °C for 10 min, and the free 
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γ32P-ATP was removed by Illustra MicroSpin G-25 Column (GE Healthcare, Pittsburgh, 
PA). After radiolabeling the forward and reverse strands, the complementary DNA strands 
were annealed by heating to 90 °C for 5 min followed by slowly cooling to room 
temperature to obtain double stranded DNA substrates (Table 3.2).  
32P-end-labeled DNA duplexes (Table 3.2) containing MeC, hmC, fC, or caC (2 
nM) were incubated with purified human Δ580-Dmnt1 (0-128 nM, New England BioLabs, 
Beverly, MA), and 1X gel shift assay buffer (10 mM HEPES, 50 mM KCl, 0.1 mM EDTA, 
1 mM DTT 2.5 mM MgCl2, 0.2% Triton X-100, and 10% glycerol) at 37 °C for 30 min. 
The mixture was then loaded onto 4 % polyacrylamide gel (37.5:1 
acrylamide:bisacrylamide ratio, prepared with 0.5X TBE) while running at 300 V for 10 
minutes. The gels were electrophoresed at 140 V for an additional 40 minutes at 4 °C. Gels 
were imaged with a Typhoon FLA 7000 instrument (GE Healthcare). 
 
Homology Modeling  
All molecular modeling simulations were performed using the Schrödinger 
modeling suite package (Schrödinger, LLC, NY).243 Homology modeling was carried out 
using Schrodinger’s Prime as described previously.20 In brief, homology modeling of the 
human DNMT1 (hDNMT1) utilized the crystal structure of mouse DNMT1 (mDNMT1) 
in complex with hemi-methylated DNA (PDB: 4DA4) based on its reference sequence 
(NP_001124295.1).10 mDNMT1 shares an 85% sequence similarity with the hDNMT1 
reference sequence (Figure A2.1 in Appendix A2). The DNA sequence was then modified 
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to match the sequence used experimentally in determining DNA methylation rates. Each 
oxidized form of 5-methylcytosine (hmC, fC, caC) was subsequently modeled within the 
DNA template.  
 
Molecular Dynamics 
Desmond269 was used to simulate each oxidized forms of 5-methylcytosine (hmC, 
fC, caC) within the modeled DNA template. As reported previously, each of the modeled 
hDNMT1 – DNA complexes was subjected to standard protein preparation protocols.20 
DNMT1-DNA complexes containing MeC or caC at a central CpG site were solvated with 
a 15 Å buffer region from its outer edge inside a rectangular box of TIP3P explicit solvent 
model.270 150 mM Na+ and Cl- counter ions were added to electroneutralize the final 
system. Each MD simulation was carried out using Desmond with default protocol for 
initialization, followed by 100 ns of unrestrained production simulation run under 
isothermal isobaric (NPT) conditions at 310 K and 1 atm with the OPLS3 force field. The 
long-range electrostatic interactions were evaluated by the Particle-Mesh Ewald method 
under periodic boundary conditions with a dielectric constant of 1. The stability of the 
protein-DNA complex was assessed by evaluating the protein CαRMSD and DNA 
backbone phosphorus RMSD (P_RMSD)271 with respect to the minimized starting 
structure. 
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3.3 Results 
3.3.1 Kinetics of DNMT1 mediated cytosine methylation in the presence of MeC and 
its oxidized forms   
To examine the kinetics of DNMT1 mediated cytosine methylation in the presence 
of MeC and its oxidized variants, synthetic DNA duplexes (5ʹ-AGCTTATCGCAGC XG 
GCGCGAATCTGA-3ʹ) containing a single MeC, hmC, fC, or caC residue (X) at the 
central CpG site were prepared (Table 1). In the resulting double stranded DNA substrates 
(Table 3.1).  In the resulting double stranded DNA substrates (Table 3.2), a single centrally 
located CpG site contains C (negative control), MeC (positive control), hmC, fC, or caC 
opposite unsubstituted cytosine. The ability of these 27-mer duplexes to serve as DNMT1 
substrates was established by electrophoretic gel mobility shift (EMSA) assays, in which 
radiolabeled DNA duplexes were incubated with increasing amounts of human Δ580-
DNMT1 protein (0-128 nM), followed by separation on 4% non-denaturing 
polyacrylamide gel to detect DNA-protein complexes266 (Figure 3.2). An electrophoretic 
mobility shift characteristic of the formation of DNA-protein complexes was observed, 
consistent with DNMT1 binding to synthetic DNA duplexes. 
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Figure 3.2: Gel shift assays to detect Δ580-DNMT1 interaction with DNA duplexes 
containing MeC (A), hmC (B), and fC (C). No shift was observed for DNA containing C 
or caC. DNA sequence is provided in Table 3.2. 
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To establish the kinetics of DNMT1-mediated methyl transfer in the presence of 
MeC and its oxidized forms, a mass spectrometry based assay developed in our laboratory 
was employed (Scheme 3.2).20 Following in vitro methylation reactions in the presence of 
human recombinant DNMT1 and S-adenosylmethionine cofactor, the amounts of newly 
formed MeC were determined by capillary HPLC-ESI+-MS/MS using 13C10
15N2-mC 
internal standard.20 In brief, DNA was spiked with known amounts of 13C10
15N2-mC and 
enzymatically digested to 2ʹ-deoxynucleosides, which were analyzed by HPLC-ESI+-
MS/MS as reported previously.20 Steady-state kinetic parameters (Km and Vmax) for methyl 
transfer reaction were determined by plotting the methylation velocity at a particular 
substrate concentration and using non-linear regression to fit the data to the Michaelis 
Menten equation.20 The methylation velocity was calculated using Equation 1 as shown in 
the supplementary Scheme 3.3.  
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Scheme 3.2: Experimental scheme for the HPLC-ESI+-MS/MS analysis of MeC. 
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Scheme 3.3: Example calculation for methylation velocity from LC-MS/MS peak areas 
using equation 1. Where AAN is the measured area of the analyte, AIS is the measured area 
of the internal standard, CIS is the concentration of internal standard spiked, v is the final 
reaction volume in microliters, and t is the time of the reaction in minutes. 
𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
(𝐴𝐴𝑁 𝐴𝐼𝑆⁄ ) ∗ 𝐶𝐼𝑆
[𝑣 ∗ 𝑡 ∗ 1𝑥10−6]
=  
(𝐴𝐴𝑁 𝐴𝐼𝑆⁄ ) ∗ 1.33 𝑝𝑚𝑜𝑙
25 𝑢𝐿 ∗ 15 min∗ 1𝑥10−6
𝐿
𝑢𝐿
= (𝐴𝐴𝑁 𝐴𝐼𝑆⁄ )[3.55 
𝑛𝑀
𝑚𝑖𝑛
] 
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We found that DNMT1 methylation kinetics at CpG sites was strongly affected by 
the oxidation status of MeC in the opposite strand. The highest value of Vmax (190 x 10
-11 
M/min) was observed for DNA duplexes containing MeCG dinucleotide (Figure 3.3A), 
which is similar to previous reports (27.2 – 163 x 10-11 M/min) that also observed a large 
effect of sequence context on methyl transfer rates.272 Much lower rates of methyl transfer 
were observed for CpG sites containing hmC (41 x 10-11 M/min), fC (11.0 x 10-11 M/min), 
and caC (0.77 x 10-11 M/min) (Table 3.3). In general, DNMT1-mediated methylation rates 
decreased upon oxidation of MeC in the opposite strand (Figure 3.3A, Table 3.3). Indeed, 
the Vmax values for methylation of cytosines placed opposite hmC, fC, and caC were 4-, 
17-, and 240-fold lower than for MeC containing DNA, respectively (Table 3.3). The Km 
values for MeC, hmC, fC, and caC were 28, 20, 13, and 1.1 nM respectively (Table 3.3). 
Catalytic efficiencies (Vmax/Km) for methyl transfer to cytosine residues opposite C, MeC, 
hmC, fC, and caC in CpG dinucleotides were calculated as 0.56, 6.7, 2.1, 0.85, and 0.71 
(x10-2 min-1M-1) respectively (Table 3.3). Overall, our results indicate that the ability of 
MeC to direct DNMT1-mediated maintenance methylation of CpG sites is reduced upon 
its oxidation to hmC, fC, and caC. This reduced maintenance methylation activity is likely 
to lead to passive DNA demethylation.273 In contrast, DNMT1 efficiency was only weakly 
affected by local sequence context, with Vmax/Km values of 8.1, 12, 6.2, and 8.4 (x10
-2 min-
1M-1) for MeCGG, MeCGC, MeCGA, and MeCGT, respectively (Figure 3.3B, Table 3.4). 
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Figure 3.3: Michaelis-Menton plots for full-length DNMT1 mediated methylation for 
DNA duplexes containing central CG, MeCG, hmCG, fCG, and caCG dinucleotides DNA 
duplexes were incubated with hDNMT1 and SAM for 15 min at 37 °C. After quenching, 
DNA was digested to nucleosides, spiked with 13C1015N2-mC and analyzed for MeC by 
LC-MS/MS. The methylation velocity was plotted against DNA concentrations. (A) 
Influence of oxidation state of the methyl group on the rates of maintenance methylation 
in DNA duplexes 5ʹ-AGCTTATCGCAGC XG GCGCGAATCTGA-3ʹ (X =C, MeC, hmC, 
fC, or caC). (B) Influence of 3'-neighboring nucleobase on methyl transfer rates for DNA 
duplexes of the sequence (5ʹ-AGCTTATCGCAGC MeCGX CGCGAATCTGA-3ʹ where X 
= C, G, T, or A). 
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Table 3.3: Kinetic parameters of the DNMT1 mediated methylation of 27-mer duplexes 
containing modified cytosines.a   
DNA Duplex Vmax (x10-11min-1) Km (nM) Vmax/Km (x10-2 min-1M-1) 
(-)C 1.8 ± 0.61 3.2 ± 8.6 0.56 ± 1.5 
(-)MeC 190 ± 18 28 ± 5.7 6.7 ± 1.5 
(-)hmC 41 ± 5.1 20 ± 6.2 2.1 ± 0.69 
(-)fC 11 ± 1.1 13 ± 4.0 0.85 ± 0.33 
(-)caC 0.77 ± 0.19 1.1 ± 1.0 0.71 ± 0.67 
a The Vmax and Km values were determined via nonlinear regression using data from three 
or more individual points. The ranges in Vmax and Km are the standard error for regression 
analysis. Error was propagated for Vmax/Km using the equation: 
𝐷𝑐
𝑐
= √(
𝐷𝑎
𝑎
)
2
+ (
𝐷𝑏
𝑏
)
2
; 
where a, b, and c are Vmax, Km, and Vmax/Km respectively.   
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Table 3.4: Kinetic parameters for DNMT1 mediated methylation of DNA sequences with 
varied sequence context.a 
DNA Duplex Vmax (x10-11min-1) Km (nM) Vmax/Km (x10-2 min-1M-1) 
MeCGT 200 ± 20 24 ± 5.4 8.4 ± 2.0 
MeCGA 230 ± 40 36 ± 12 6.2 ± 2.4 
MeCGC 170 ± 24 14 ± 5.8 12 ± 5.3 
MeCGG 170 ± 10 21 ± 2.9 8.1 ± 1.2 
a The Vmax and Km values were determined via nonlinear regression using data from three 
or more individual points. The ranges in Vmax and Km are the standard error for regression 
analysis. Error was propagated for Vmax/Km using the equation: 
𝐷𝑐
𝑐
= √(
𝐷𝑎
𝑎
)
2
+ (
𝐷𝑏
𝑏
)
2
; 
where a, b, and c are Vmax, Km, and Vmax/Km respectively.  
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3.3.2 Molecular modeling of DNMT1-DNA complexes containing oxidized forms of 
MeC 
To establish the structural origins of reduced DNMT1 activity in the presence of 
oxidized forms of MeC, molecular models of DNMT1-DNA complexes were considered. 
For this purpose, homology models of the productive hDNMT1 complex with DNA 
duplexes containing MeC, hmC, fC, and caC were created (Figure 3.4). Molecular 
modeling of hDNMT1 protein was carried out using the published crystal structure of 
mDNMT1 in complex with hemi-methylated DNA.10 The associated DNA duplex was 
modeled to reflect the sequence employed in our experimental studies (Table 3.2). The 
homology model was based upon the sequence alignment of hDNMT1 with the published 
crystal structure of mDNMT1 (PDB: 4DA4, Appendix A2: Figure A2.1). Alignment of 
the hDNMT1 reference sequence with the sequence of mDNMT1 reveals an 85% identity. 
Importantly, the residues making up the hydrophobic binding pocket of the TRD (C1501, 
L1502, W1512, and M1535) are conserved between mDNMT1 and hDNMT1 (Figure 3.5). 
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Figure 3.4. Homology model of the productive human DNMT1 – DNA complex. 
Homology modeling was performed using the Schrödinger modeling suite package and the 
crystal structure of mouse DNMT1 in complex with hemi-methylated DNA (PDB: 
4DA4)10 coupled with the reference sequence of hDNMT1. 
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Figure 3.5. Sequence alignment of the target recognition domain. Alignment of the 
published crystal structure of mDNMT1 (PDB: 4DA4)10 with the hDNMT1 reference 
sequence (NP_001124295.1) demonstrates that the residues making up the hydrophobic 
binding pocket of the TRD (C1501, L1502, W1512, and M1535) are conserved in both 
mDNMT1 and hDNMT1. These conserved residues are starred below.  
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In order to examine the structural effects of TET-mediated oxidation of MeC on 
DNA-protein binding, MeC was sequentially replaced with hmC, fC, and caC. Molecular 
dynamics (MD) simulations of hDNMT1 in complex with DNA containing either MeC, 
hmC, fC, or caC were performed to determine how oxidized forms of MeC influence the 
recognition of hemi-methylated CpG sites in DNA by the TRD of DNMT1. The TRD of 
human DNMT1 contains a hydrophobic binding pocket consisting of M1535, C1501, 
L1502 and W1512.10 This pocket harbors the 5-methyl group of MeC and is involved in 
the recognition of the hemi-methylated MeCpG in productive hDNMT1-DNA 
complexes.10 
MD simulations were carried out using the previously developed homology model 
of hDNMT1 in complex with hemi-methylated DNA.20 The root-mean-square deviation 
(RMSD) was used to determine the stability of the protein and DNA structures over the 
MD simulation. The RMSD is a similarity measure widely used in the analysis of 
macromolecular structures and dynamics as it measures the total structural deviation from 
the starting position. The stability of the enzyme-DNA complex for each modification is 
demonstrated by the RMSD of the protein backbone (C RMSD) and the RMSD of the 
DNA phosphorous backbone (Figure 3.6A and 3.6B). The rise of the RMSD represents 
the equilibration from the coordinates of the initial model then the RMSD of MeC and its 
oxidized forms remains stable over the 100 ns of simulation. Monitoring the interactions 
of MeC and its oxidized forms with amino acid residues within the hydrophobic pocket of 
the TRD, we observed an iterative increase in distance between the oxidized forms of MeC 
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and DNMT1 residues including Cys1501, Leu1502, and Met1535 (Table 3.5, Figure 3.7, 
Figure 3.8). This suggests that oxidation to caC may lead to a conformational change to 
the unproductive mode of binding. Our results demonstrate that as MeC is oxidized to hmC, 
fC, and caC, the increased size and hydrophilicity of the C-5 substituent induces a spatial 
displacement of the oxidized MeC from the TRD binding pocket, disrupting the 
hydrophobic interactions between DNMT1 and DNA and leading to a loss of enzymatic 
activity. Our model supports the experimentally observed trend for hDNMT1 enzymatic 
activity that caC leads to the largest perturbation of the TRD, causing a significant loss in 
activity. (Figure 3.3A, Table 3.2). 
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Table 3.5: Average distance (Å) between MeC, hmC, fC or caC and residues in the TRD 
as calculated by the molecular dynamics simulation. Distances are averaged from 50-100 
ns.  
Residue MeC distance 
(Å) 
hmC distance 
(Å) 
fC distance 
(Å) 
caC distance 
(Å) 
Cys1501 4.44 ± 0.49 6.47 ± 0.47 5.42 ± 0.46 10.12 ± 0.39 
Leu1502 4.01 ± 0.36 5.47 ± 0.51 4.39 ± 0.35 8.85 ± 0.47 
Met1535 4.39 ± 0.34 4.39 ± 0.30 5.88 ± 0.49 9.34 ± 0.75 
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Figure 3.6. Stability of the DNA-Protein complex. A. C RMSD demonstrates stability of 
the protein backbone during the MD simulation. B. The RMSD of the DNA phosphorus 
backbone shows the stability of the DNA duplex with respect to the starting minimized 
structure.  
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Figure 3.7. Molecular dynamics (MD) simulations demonstrate an incremental spatial 
displacement of oxo-mC from the TRD hydrophobic binding pocket. A. Residues 
Cys1501, Leu1502, and Met1535 make up the target recognition domain (TRD) and harbor 
the methyl group of MeC, providing the specificity of DNMT1 for hemi-methylated DNA. 
The MD simulations quantify the displacement of the oxidized forms of MeC from these 
residues in the TRD: B. Cys1501 C. Leu1502 D. Met1535 
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Figure 3.8. Overlay of MeC and caC structures after 100 ns MD simulation. The MeC 
structure is shown in cyan and the caC structure is shown in magenta. Distances between 
key residues which make up the TRD (Cys1501, Leu1502, Met1535) and the C5 position 
of each base are shown in dashed lines (mC: cyan, caC: magenta). The increased distances 
between caC and the residues in the TRD suggest a structural change in the DNMT1-DNA 
mode of binding. 
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3.4 Discussion 
Epigenetic DNA methylation marks (mC) must be removed as part of normal 
development,274 neuronal plasticity,275 and memory formation, resulting in chromatin 
remodeling and gene reactivation.275 DNA demethylation can be accomplished via passive 
or active DNA demethylation processes.276 Active demethylation is mediated by the 
iterative oxidation of MeC to hmC, fC, and caC by Ten Eleven Translocation (TET) 
proteins, followed by excision of fC and caC by TDG and their replacement with C via 
base excision repair mechanism.13, 15-16, 263 Passive demethylation occurs when DNMT1 
fails to methylate hemi-methylated DNA sequences generated during DNA replication.5 
Recent studies have shown that oxidized forms of MeC may participate in passive DNA 
demethylation by reducing the activity of maintenance methyltransferase (DNMT1).19, 233 
However, the structural origins and the mechanistic details for reduced DNMT1 activity in 
the presence of oxidized MeC variant remained unknown. 
Two distinct modes of DNMT1-DNA binding are known. The protein adopts an 
unproductive mode of binding in complex with unmethylated DNA (PDB: 3PTA) and a 
productive mode of binding when bound to hemi-methylated (PDB:4DA4) DNA (Figure 
3.9).10, 20, 244 In the unproductive DNMT1-DNA complex, the double stranded DNA retains 
its base pairing, and the auto inhibitory mechanism described earlier prevents DNMT1 
from performing de novo DNA methylation and directs its activity to hemimethylated 
sites.244 In the productive DNMT1-DNA complex formed with CpG sites containing a 
single MeC, both the enzyme and its DNA substrate undergo a large conformational 
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change, which is initiated by MeC binding in a hydrophobic segment within the TRD 
(Figure 3.9).10 This recognition of MeC by the TRD results in the insertion of amino acid 
sidechains from the catalytic and recognition domains of DNMT1 into both grooves of the 
DNA.10 This productive mode of binding undergoes a local melting of the DNA duplex, 
rotating the target cytosine out of the DNA helix into the catalytic pocket and allowing for 
methyl transfer to take place.10 The side chain of Met1235 inserts into the DNA from the 
minor groove and occupies the space vacated by the target cytosine.10 
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Figure 3.9. Crystal structures of DNMT1 bound to methylated DNA (teal, PDB: 4DA4)10 
or unmethylated DNA (pink, PDB: 3PTA)244 reveal a productive and unproductive mode 
of binding, respectively. A shift in angle of binding highlighted by a black arrow. Cofactor, 
SAH, is shown as spheres. 
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The enzymatic mechanism of DNMT1 enzyme is well understood and involves 
nucleophilic addition of a cysteine in the active site to the C6 position of cytosine, followed 
by methyl transfer from the SAM cofactor to the C5 position.10 Following methyl transfer, 
an excess proton from the C5 position is abstracted, and the covalent bond between the 
enzyme and cytosine base is cleaved to liberate the methylated DNA (Scheme 2.7 in 
Chapter II of this Thesis).261-262 Nucleophilic addition of the cysteine residue of DNMT1 
to DNA is fast and reversible, while the following methyl transfer is the rate-limiting step 
during the formation of MeC.277 
The purpose of the present work was to establish kinetic parameters for DNMT1 
mediated methylation in the presence of MeC, hmC, fC, and caC and to elucidate the 
structural mechanisms of their effects on methyl transfer kinetics. A novel mass 
spectrometry based assay developed in our laboratory was used to follow the kinetics of 
methyl transfer.20 We found that the rates of methyl transfer drastically decreased as the 
oxidation state of the methyl group on MeC increased from MeC to hmC, fC, and caC 
(Vmax, 190, 41, 11, and 0.77 x10-11min-1, for MeC, hmC, fC, and caC respectively – see 
Figure 3.3, Table 3.3). Taken together with previous reports by Ji et al.233 and Valinluck 
et al.,19 our results show that unlike MeC, its oxidized forms fail to effectively direct 
DNMT1 enzyme to methylate the cytosine in the opposite strand. The Vmax/Km values also 
decreased according to the oxidation status hmC > fC > caC, indicating that the overall 
efficiency of enzymatic methylation was reduced. The catalytic efficiency for methyl 
transfer in the presence of for hmC, fC, and caC decreased 3.3-, 7.9-, and 9.5-fold relative 
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to MeC (Table 3.3). In addition, MeC oxidation to hmC, fC, and caC leads to lower Km 
values for DNMT1-DNA binding (Table 3.3), indicative of the formation of tightly bound 
unproductive complexes. Indeed, previous reports by Pradhan et al. demonstrated that 
DNMT1 binds unmethylated DNA with higher affinity than hemi-methylated DNA.266 
In contrast, local nucleotide sequence context had a minimal effect on methylation 
transfer kinetics (Figure 3.3B, Table 3.4) When the 3ʹ neighboring base was altered 
(MeCGX), this did not change the kinetic parameters for methyl transfer. The efficiency 
of methyl transfer was slightly higher in MeCGC context (Figure 3.3B, Table 3.4). This 
of interest because MeC is commonly found in promoter CpG islands of inactive genes.278-
279 
In our earlier study, extending the aliphatic side chain on C-5 of cytosine beyond 
methyl (5-ethyl-dC, 5-propyl-dC) resulted in a loss of DNMT1 maintenance methylation.20 
In that study, Vmax and Km values for MeC-containing DNA were determined as 9.6 x 10-2 
nM/min and 21.8 nM using the sequence 5ʹ-CGCGGA[mC]GCGGGTGCCGGG-3ʹ.20 As 
the length of the C5-alkyl chain increased, DNMT1-DNA binding via the TRD was 
disrupted, causing the enzyme to adopt an unproductive mode of binding to DNA.20 
Specifically, when the C5 alkyl chain on cytosine was extended from methyl to ethyl, we 
observed a 4-fold loss in Vmax, and a similar efficiency of DNMT1-mediated methyl 
transfer (Table 2.3 in Chapter II of this thesis).20 Further increase of the C-5 substituent 
size to propyl completely abolished methylation.20 Since 5-ethyl-dC and hmC are of 
comparable size, but DNMT1 activity is 2-3 fold less efficient for hmC-containing 
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duplexes, this suggests that in addition to steric effects, oxidation of the methyl group of 
MeC leads to a loss of hydrophobic interactions with the TRD of the protein (Table 3.3 
and Table 2.3 in Chapter II of this thesis).20 
 To examine the structural basis for reduced DNMT1 methylation activity in the 
presence of oxo-mC, a computational model of hDNMT1-DNA complex was developed. 
We found that as MeC was oxidized to hmC, fC, and caC, hydrophobic interactions 
responsible for DNMT1 recognition of hemimethylated CpG sites in DNA were disrupted. 
The increased distances between caC and the residues in the TRD (Figure 3.7) suggest a 
structural change in the DNMT1-DNA mode of binding. In the presence of oxo-mC, the 
loss of key hydrophobic interactions prevents the formation of a productive DNA-protein 
complex and instead DNMT1 forms tightly bound unproductive DNMT1-DNA complexes 
characterized by lower Km value (Figure 3.8, Figure 3.9, Table 3.3).10, 20, 266 Overall, our 
results confirm that oxidized forms of MeC participate in passive DNA demethylation and 
provide further kinetic and structural details for this important epigenetic process. 
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IV. EPIGENETIC EFFECTS OF INFLAMMATION AND EXPOSURE TO 
TOBACCO CARCINOGEN NNK IN THE A/J MOUSE MODEL OF SMOKING-
INDUCED LUNG CANCER 
Adapted from: 
Seiler, C. L.; Song, J.M.; Kotandeniya, D.; Chen, J.; Kono, T.; Sarver, A.; Colwell, M.; 
Upadhyaya, P.; Ren, Y.; Faulk, C.; De Flora, S.; Chen, Y.; Kassie, F.; and Tretyakova, N. 
Y.; Epigenetic Effects of Inflammation and Exposure to Tobacco Carcinogen NNK in the 
A/J Mouse Model of Smoking-Induced Lung Cancer,  
Manuscript in preparation  
 
This work was performed in collaboration with Dr. Jung Min Song, Dr. Delshanee 
Kotandeniya, Jianji Chen, Dr. Thomas Kono, Dr. Aaron Sarver, Mathia Colwell, Dr. 
Pramod Upadhyaya, Yanan Ren, Dr. Chris Faulk, Dr. Silvio De Flora (University of Genoa 
Italy), Dr. Yue Chen, Dr. Fekadu Kassie, under the direction of Dr. Natalia Tretyakova. 
Dr. Delshanee Kotendeniya performed initial method development and quantitation of 
MeC, hmC, and fC in 2 week treated mice. Dr. Jung Min Song carried out the qRT-PCR 
for 9, 22, and 44-week mouse treatments, methylation specific PCR, and animal treatments 
under the direction of Dr. Fekadu Kassie. Jianji Chen and Dr. Yue Chen measure histone 
acetylation levels. Christopher Seiler and Mathia Colwell performed the bisulfite 
pyrosequencing for DNA from the 6-week study. Dr. Pramod Upadhyaya provided NNK 
for animal treatment. Yanan Ren performed statistical calculations for the LC-MS/MS data. 
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Dr. Chris Faulk designed the pyrosequencing assays for mTet1 and mAhrr. Dr. Silvio De 
Flora provided DNA from mice exposed to cigarette smoke. Christopher Seiler finalized 
and validated the HPLC-MS/MS methodology for epigenetic DNA marks and applied it to 
6 weeks treated, and tumor samples. Christopher Seiler performed oxoBS-Seq and 
conducted data analysis with the guidance of Dr. Aaron Sarver. Dr. Tom Kono and Dr. 
Aaron Sarver performed bioinformatics support for oxBS-Seq data. Internal standards for 
fC and caC were synthesized by Christopher Seiler. Christopher Seiler and Natalia 
Tretyakova wrote the manuscript. 
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4.1 Introduction 
Lung cancer is responsible for 30% of all cancer deaths worldwide and is expected 
to kill 154,050 Americans this year, with over 80% of cases directly attributable to 
smoking.101 Cigarette smoke contains over 60 known carcinogens including tobacco 
specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which 
forms promutagenic DNA adducts and induces cancer driving mutations in the K-ras 
protooncogene.104 In addition to genetic alterations, epigenetic changes such as deregulated 
DNA methylation, altered histone acetylation, and aberrant micro RNA expression are 
common in smoking-induced lung tumors.3  
Aberrant DNA methylation patterns in malignant cells result in silencing of tumor 
suppressor genes, activation of protooncogenes, and decreased chromosomal stability.280 
Smoking-induced lung tumors exhibit elevated methylation of tumor suppressor genes 
such as MGMT, hMLH1, p16, RASSF1A, DAPK1, and RAR-β.107-108 These 
“epimutations” cooperate with genetic alterations to drive the malignant lung tumor 
phenotype.281 However, the mechanistic origins and the timing of epigenetic changes 
associated with smoking have remained largely unknown, limiting our understanding of 
lung cancer etiology and hindering the development of novel treatments.  
Chronic inflammation plays a central role in the pathogenesis of lung cancer.282 
Smoking induces neutrophilic inflammation and reduces mucociliary clearance via several 
mechanisms, including exposure to endotoxins present in tobacco smoke (e.g. 
lipopolysaccharide (LPS), 2,400 ng/pack).105 When administered intranasally to laboratory 
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mice, LPS induces inflammatory response mimicking chronic obstructive pulmonary 
disease (COPD), a major risk factor for lung cancer development in smokers.141 Sustained 
inflammation in the lung in humans can lead to COPD, increasing the risk of developing 
lung cancer in smokers.283-284 Indeed, chronic exposure of A/J mice to LPS increases lung 
tumor size and multiplicity following treatment with NNK, supporting a role for 
inflammation in lung cancer etiology.141 Due to the increased risk of lung cancer from 
chronic inflammation, the use of anti-inflammatory agents is a potential chemopreventative 
strategy.140 Common non-steroidal anti-inflammatory agents (NSAIDs) have been shown 
to reduce the prevalence of colorectal cancers,285 and may affect lung carcinogenesis.286-
288  
  In the present work, we examined the dynamic changes in cytosine methylation, 
hydroxymethylation, formylation (Figure 4.1), histone acetylation, and gene expression 
patterns in lung tissues of A/J mice chronically exposed to cigarette smoke, NNK and LPS 
alone, or in combination. Our results reveal that many of the epigenetic changes 
characteristic for lung tumors can be observed soon after an inflammatory stimulus. 
Because epigenetic alterations are expected to be reversible, the use of epigenetic 
modulators may open a possibility for novel strategies for lung cancer chemoprevention 
and treatment. 
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Figure 4.1. Epigenetic DNA marks and enzymatic pathways involved in their formation. 
Formation of MeC from cytosine is catalyzed by DNMT enzymes. Oxidation of MeC to 
hmC, fC, and caC is carried out by TET dioxygenases and can lead to DNA demethylation.  
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4.2 Materials and Methods  
Chemicals and Enzymes.  
PDE I, PDE II, and DNase I were purchased from Worthington Biochemical Corp. 
(Lakewood, NJ), while calf intestinal alkaline phosphatase was from Sigma-Aldrich, 
(Madison, WI).  Nanosep10K filters were acquired from Pall corp. (Port Washington, NY). 
O-(biotinylcarbazoylmethyl) hydroxylamine was obtained from Cayman Chemical (Ann 
Arbor, MI). Isotopically labeled D3-hmC was purchased from Cambridge Isotope Labs 
(Cambridge, MA). 13C10,15N2-5-methyl-2ʹ-deoxycytidine was synthesized as previously 
described.20 All other chemicals used were bought from Sigma-Aldrich (Milwaukee, WI) 
or Fisher Scientific (Fairlawn, NJ). 
 
Animal Treatments  
 Female A/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME) 
and housed in specific-pathogen-free animal quarters at Research Animal Resources, 
University of Minnesota Academic Health Center. All animal experiments were performed 
according to the U.S. National Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals and was approved by the Institutional Animal Care and Use 
Committee, University of Minnesota.  
 
Short Term Treatment of mice with NNK, LPS and NNK/LPS: Female A/J mice (6 weeks 
of age) were divided into 3 groups (3 animals per group). Mice in Group 1 were treated 
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intraperitoneally (IP) with NNK (25 mg/kg, in 0.3 ml physiological saline solution) every 
day for 3 – 9 days and 12.5 mg/kg NNK daily on days 10-15 days. For lipopolysaccharide 
(LPS) treatments, 8.3 µg of LPS was administered intranasally twice a week in the first 
week of the experiment, and 4.15 µg LPS was given once a week during the second week. 
Mice were euthanized in a CO2 chamber the day after NNK treatment. Tissues (lung, brain, 
kidney) were harvested and stored frozen at -80 °C until analysis.  
Chronic Treatment with NNK, LPS, and NNK/ LPS: Female A/J mice (6 weeks of age) 
were divided into four groups: control (N = 4), NNK (N = 5), LPS (N = 4), and NNK+LPS 
(N = 4). NNK was administered IP (50 mg/kg) twice a week during weeks 1 and 3, and 
once during week 5 for a total of 5 doses. LPS was given intranasally (4 µg/mouse) twice 
in week 1, and once a week during weeks 3, 4, and 5, for a total of 5 doses. Control mice 
were treated with physiological saline IP for the same duration of time. Mice were 
euthanized in a CO2 chamber during the sixth week of treatment. Tissues (lung and brain) 
were harvested and stored at -80 °C until analysis.  
Animal treatment for gene expression analyses: Six-week-old female A/J mice received 
a single dose of NNK (100 mg/kg, IP). Mice were intranasally treated with LPS once a 
week under isoflurane anesthesia for 9 or 22 weeks (5 µg LPS per dose in 50 μL of PBS) 
or for 44 weeks with reduced LPS (2 µg per dose in 50 µL of PBS). After 9, 22, or 44 
weeks of treatment, the mice were euthanized with an over dose of carbon dioxide. Whole 
lung tissues were collected from mice treated for 9 weeks and tumors from 22 and 44-week 
treatments and kept at -80 °C.  
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Lung Tumor induction with NNK/LPS: Female A/J mice (7 weeks of age) were divided 
into three groups (20 per group). Group 1 was treated intraperitoneally (IP) with NNK (100 
mg/kg, in 0.3 ml PBS) once a week for two weeks, group 2 was treated intranasally with 4 
µg of LPS (in 50 µL of 1 X PBS) a week after the 2nd dose of NNK administration and 
subsequently treated with the same dose of LPS once a week until week 27. Mice in control 
group 3 were given physiological saline (0.3 mL, IP). Mice were euthanized in a CO2 
chamber.  Tumors (≥ 100) were pooled from lung lobes of 4-5 mice in group 1 and 2 and 
stored frozen at -80 °C until analysis.  
 
Cigarette smoke exposure treatment: This study was conducted at the University 
of Genoa, Italy. Newborn, female A/J mice were divided into two groups (4 per 
group). Group 1 was exposed to filtered air for the duration of the study, and group 
2 was exposed to environmental cigarette smoke starting 12 hours after birth. Mice 
were euthanized in a CO2 chamber. The lungs were isolated, and DNA was 
extracted from the left lung and stored at -20 ℃ until analysis.140 
 
Synthesis of Stable Isotope Labeled Internal Standards 
 13C1015N2-5-formyl-2′-deoxycytidine: To the stirring solution of 13C1015N2-5-
methyl-2′-deoxycytidine (1 mg, synthesized previously in Chapter II of this thesis)20 in a 1 
M phosphate buffer at pH 7 was added sodium persulfate (16.4 mg). The mixture was 
placed in a preheated oil bath and stirred at 70 °C for 3 days. The reaction mixture was 
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purified by RP-HPLC using a Synergi Hydro-RP (250 mm x 4.6 mm x 4 µm, Phenomenex, 
Torrance CA) with a linear gradient of acetonitrile and water (3% to 5% over 25 min), with 
product eluting at 16.8 minutes.   
 13C1015N2-5-carboxyl-2′-deoxycytidine: 13C1015N2-5-formyl-2′-deoxycytidine (57 
µg, 210 nmol) was placed in an Eppendorf tube along with potassium monophosphate (16 
mg, Sigma-Aldrich), isoamylene (82 µL, Sigma-Aldrich), sodium chlorite (16 mg, Sigma-
Aldrich), water (180 µL), tetrahydrofuran (444 µL, Fisher Scientific), and t-butanol (800 
µL, Fisher Scientific). The reaction was stirred for 2.5 hours at room temperature and then 
acidified with 400 µL of 1 N HCl. The reaction mixture was separated by RP-HPLC using 
a gradient of 0.1% formic acid in water and 0.1% formic acid in acetonitrile on a Synergi 
Hydro-RP column (250 mm x 4.6 mm x 4 µm, Phenomenex) with a linear increase from 
3% to 5% acetonitrile and 13C1015N2-cadC eluted at 7 min. 
 
DNA Digestion and Enrichment of MeC, hmC, fC, and caC 
 Genomic DNA was extracted from lung, kidney, and brain tissues using IBI-Mini 
Genomic DNA Kit (IBI Scientific, Peosta IA) according to the manufacturer’s protocol. 
DNA concentrations were determined by UV spectroscopy.  
 Genomic DNA (2-10 µg) was subjected to hydrolysis with PDE I (3.6 U, 5 g), 
PDE II (3.2 U), DNase I (50U), and alkaline phosphatase (10 U) in 10 mM Tris HCl/15 
mM MgCl2 buffer (pH 7) at 37 °C overnight. The hydrolysates were spiked with 13C1015N2-
5-methyl-2′-deoxycytidine (1 pmol), 5-hydroxymethyl-d2-2′-deoxycytidine-6-d1 (900 
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fmol), 13C1015N2-5-formyl-2′-deoxycytidine (500 fmol), and 13C1015N2-5-carboxyl-2′-
deoxycytidine (300 fmol) (internal standards for mass spectrometry synthesized in our 
laboratory)20 and filtered through Nanosep 10K Omega filters (Pall Corporation, Port 
Washington, NY).  
 DNA hydrolysates were dissolved in 100 mM ammonium acetate buffer (pH 4.5) 
containing 100 mM aniline and 400 µM O-(biotinylcarbazoylmethyl) hydroxylamine 
(Cayman Chemical. Ann Arbor, MI) and allowed to react for 24 h to derivatize fC to 
biotinyl-fC.14 The resulting mixture was dried, followed by offline HPLC to enrich for 
MeC, hmC, biotinyl-fC, and caC using an Atlantis T3 column (Waters, 4.6 x 150 mm, 3 
µm) was eluted at a flow rate of 0.9 mL/min with a gradient of  5 mM ammonium formate 
buffer, pH 4.0 (A) and methanol (B). Solvent composition was changed linearly from 3 to 
30% B over 15 min, increased to 80% over the next 3 min, maintained at 80% B for the 
next 2 min, and brought back to 3 % B. The column was equilibrated for 7 min. dC was 
quantified by HPLC-UV using calibration curves obtained by analyzing authentic dC 
standards. HPLC fractions corresponding to MeC, hmC, caC, and biotinyl-fC (7-8.6 min 
for both hmC and caC, 9-10.5 min for MeC, and 18.7-20.2 min for biotinyl-fC) were 
combined, dried, and analyzed by isotope dilution HPLC-ESI-MS/MS. 
 
HPLC-ESI+-MS/MS quantitation of MeC, hmC, and fC 
  Quantitation of MeC, hmC, and biotinyl-fC was performed using a Dionex 
Ultimate 3000UHPLC (Thermo Fisher, Waltham MA) interfaced with a Thermo TSQ 
174 
 
Vantage mass spectrometer (Thermo Fisher). Chromatographic separation was achieved 
on a Zorbax SB-C18 column (0.5 x 150 mm, 3 µm, Agilent) eluted at a flow rate of 15 
L/min with a gradient of 2 mM ammonium formate (A) and methanol (B). Solvent 
composition was maintained at 5% B for the first 3 min and linearly changed from 5 to 
40% B for 7 min. Solvent composition was a returned to initial conditions (5% B), and the 
column was re-equilibrated for 4 min. Under these conditions, MeC and 13C1015N2-MeC 
eluted at 4.1 min, both hmC and the internal standard d3-hmC eluted at 3.5 min, while 
biotinyl-fC and its internal standard (13C1015N2-biotinyl-fC) eluted at 7.0 min. Quantitation 
was achieved by monitoring the transitions m/z 258.1 [M + H+]  m/z 141.1 [M – 
deoxyribose + H+] for hmC, m/z 261.2 [M + H+]  m/z 145.1 [M – deoxyribose + H+] for 
D3-hmC, m/z 242.1 [M + H+]  m/z 126.1 [M + H+] for MeC, m/z 254.2 [M + H+]  m/z 
133.1 [M + H+] for 13C1015N2-MeC, m/z 569.1 [M + H+]  m/z 453.3 [M – deoxyribose + 
H+] for Biotinyl-5fC, m/z 581.2 [M + H+]  m/z 460.4 [M – deoxyribose + H+] for 
Biotinyl-13C1015N2-5fC. Mass spectrometer were determined by infusion of authentic 
standards. Typical MS settings were: a spray voltage of 2700 V, a sheath gas of 15 units, 
the declustering voltage was 5 V, and the ion transfer tube was maintained at 350 ℃. The 
full-width at half-maximum (FWHM) was maintained at 0.7 for both Q1 and Q3. 
Fragmentation was induced using a collision gas of 1.0 mTorr and a collision energy of 
10.3 V.  
 
HPLC-ESI--MS/MS analyses of caC 
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 caC was quantified in the negative ion mode by monitoring the transitions m/z 
270.00 [M - H+]  109.97 [M – deoxyribose – CO2 - H+] for caC and m/z 282.00 [M - H+] 
 116.05 [M – deoxyribose – CO2 - H+] for 13C1015N2-caC internal standard. 
Chromatographic separation was achieved on a Thermo Hypercarb column (0.5 x 100 mm, 
3 µm, Thermo Fisher Scientific) eluted at a flow rate of 14 L/min with a gradient of 2.5 
mM ammonium bicarbonate (A) and acetonitrile (B). Solvent composition was increased 
from 10 to 15% B over the first 3 min and further to 60% B over 7 min. Solvent composition 
was returned to initial conditions over 1 min and re-equilibrated over 6 min. Under these 
conditions, caC and 13C1015N2-caC eluted at 5.5 minutes. MS parameters were optimized 
to achieve maximum sensitivity. The mass spectrometer was operated in negative mode 
with an S-lens voltage of 72 V, a spray voltage of -3.0 kV, capillary temperature at 270 °C, 
declustering voltage of 7 V, and nitrogen as a sheath gas at 20 arbitrary units. CID was 
achieved at with collision energy of 18 V. Argon was used as a collision gas with a pressure 
of 1.0 mTorr. MS/MS analyses were performed with a scan width of 0.1 m/z and a scan 
time of 0.1.  
 
HPLC-ESI+-MS/MS method validation  
Fixed amounts of isotopically labeled internal standards (1 pmol 13C1015N2-MeC, 
900 fmol d3-hmC, and 500 fmol 13C1015N2-fC) and increasing amounts of the corresponding 
unlabeled nucleosides (2 pmol – 200 pmol MeC, 100 fmol – 20 pmol hmC, and 1 fmol – 
500 fmol fC) were spiked into 1 µg of commercial calf thymus DNA (Sigma). Samples 
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were processed by enzymatic hydrolysis, ultrafiltration, and offline HPLC as described 
above and subjected to HPLC-ESI-MS/MS analysis. The observed amounts of MeC, hmC, 
and fC were plotted against theoretical values followed by linear regression analysis 
(Figure 4.2).  
 The LOD and LOQ values of the new method were determined by spiking synthetic 
dsDNA (5 µg, sequence: 5′-AGCTTATCGCAGCCGGCGCGAATCTGA-3′) with 
increasing amounts of synthetic oligodeoxynucleotides each containing a single MeC, 
hmC, or fC residue (5′-AGCTTATCGCAGCXGGCGCGAATCTGA-3′, where X = MeC, 
hmC, or fC) and fixed amounts of internal standards (1 pmol 13C1015N2-MeC, 900 fmol d3-
hmC, and 300 fmol 13C1015N2-fC), followed by sample processing and capillary HPLC-
ESI-MS/MS analysis as described as above. The LOD values were determined as the 
lowest analyte amounts that consistently produced signal-to-noise ratios above 3. The LOQ 
was defined as the minimum amount of analyte that produced a coefficient of variation less 
than 15% and a signal-to-noise ratio greater than 10.  
 To evaluate precision and inter-day and intra-day accuracy of the method, samples 
were processed as above and analyzed three times per day on three consecutive days. 
Accuracy was calculated for each analyte using the equation: Am/Aa x 100%, where Am is 
the measured amount of analyte and Aa is the amount of analyte added.  
 
Histone acetylation analysis:  
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 Lung tissues from control and treated mice were homogenized with a glass douncer 
on ice. Total histones were extracted from the lysates as previously described.289 Histone 
proteins were acetylated with (13C2,d3)-acetyl N-hydroxysuccinimide ester to block all 
unmodified lysines and then digested by trypsin.290 The peptides were desalted with C18 
Stage Tips (3M Corporation, St. Paul, MN) prior to analysis.  
Tryptic peptides were analyzed by nano-flow liquid chromatography electrospray 
tandem mass spectrometry (nanoLC-ESI-MS/MS) using a Thermo Scientific Orbitrap 
Fusion mass spectrometer (Thermo Scientific, San Jose, CA) coupled to a Proxeon Easy 
nLC 1000 UPLC system (Thermo Fisher Scientific, Odense, Denmark). Each sample was 
re-suspended in HPLC buffer A (0.1% formic acid in water) and loaded onto an in-house 
packed C18 column (25 cm x 75 m I.D.) packed with ReproSil-Pur Basic C18 beads (2.5 
μm, Dr. Maisch GmbH). Peptides were eluted with a gradient of 5% to 15% B (0.1% formic 
acid in acetonitrile) over 26 minutes, then 15% to 35% HPLC buffer B over 16 minutes at 
300 nL/min.  
Tryptic peptides from histone proteins were analyzed using a FT survey scan from 
300-1600 m/z at a resolution of FWHM 120,000 (at 200 m/z), followed by HCD MS/MS 
scans using the top speed mode (3 seconds per cycle) at a resolution of FWHM 15,000 (at 
200 m/z) and the normalized collision energy at 35%. The targeted MS/MS data acquisition 
was achieved with an inclusion list for fully labeled histone tryptic peptides that covered 
known lysine acetylation sites. For each peptide, modification isomers with all possible 
combinations of light/heavy lysine acetylation (delta mass of 42.010565 and 47.036094 
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Da, respectively) at detectable charge states were considered in the inclusion list for 
targeted fragmentations.  
 MS data was searched against the Uniprot Mus musculus proteome database 
(http://www.uniprot.org) using MaxQuant search engine (v1.4.1.2) as previously 
described.282-284 Heavy and light acetylation on lysine as well as methionine oxidation were 
included as variable modifications, with 6 ppm specified as the precursor mass error and 
0.025 Da as the fragment mass error. All peptide spectra matches were filtered at 1% False 
Discovery Rate with a minimum Andromeda score cutoff of 40. The HPLC elution profile 
were manually evaluated to ensure accurate quantifications. Only peptides that were 
confidently identified were selected for stoichiometry analysis. Acetylation stoichiometries 
of specific sites were calculated using in-house developed scripts based on the extracted 
peak areas of each modification isomer and quantification of modification-specific 
fragment ions.1 Statistical significance analysis of site-specific acetylation stoichiometry 
dynamics between control and treated samples was conducted using two-sided Student’s t-
test using SAS statistical software 9.3 (SAS Institute Inc., Cary, NC). 
 
Methylation specific PCR (MSP) assay 
Genomic DNA was isolated from mouse lung tissues or lung tumors using a 
QIAamp DNA mini kit (Qiagen, Valencia, CA). For bisulfite conversion, 0.5 μg of the 
isolated genomic DNA was treated with sodium bisulfite using an EpiTect Bisulfite kit 
(Qiagen, Valencia, CA).   
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Methylation specific nPCR of bisulfite treated DNA was performed using EpiTect 
MSP kit (Qiagen, Valencia, CA) using methylated and unmethylated primer sets listed in 
Table 4.1. PCR reaction conditions were performed as follows: 1 cycle at 95°C for 10 min; 
40 cycles at 94°C for 15 s, 48°C for 30 s, and 72°C for 30 s; 1 cycle at 72°C for 10 min. 
The resulting PCR products were analyzed on 2% agarose gels after staining ethidium 
bromide. Three human NSCLC cell lines (A549, H1299 and H2009) and a mouse cancer 
cell line (MCS) derived from mouse lung tumors induced were used as positive control 
samples to indicate the correct fragment by MSP. 
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Table 4.1. MSP primer sequences employed in this study.  
MSP primer Forward primer (5ʹ-3ʹ) Reverse primer (5ʹ-3ʹ) 
mDAPK1   
Methylated AGGAGTCGCGAGCGTAGC CAACTATCGCGTACGC 
Unmethylated TGGGAGGAGTTGTGAGTGT ACAACTATCACTTCATAC ACC 
mRAR-BETA   
Methylated TCGTGGTTTTTTTGTGCGGTTC CAACATACAAAAAAAAAAACTGCGG 
Unmethylated TTGTGGATTTTTTTGTGTGGTTTG CAACATACAAAAAAAAAAACTCACAA 
mGATA2   
Methylated ATTAGGTAGATAGGGCGTAGAGTTC CTAACTATCTCTCGATTCCCGAC 
Unmethylated GATTAGGTAGATAGGGTGTAGAGTTTG TTCTAACTATCTCTCAATTCCCAAC 
mCDH13   
Methylated TATTTGTTATGTAAAACGAGGGAGC CAAATAAATCAACGACAACATCG 
Unmethylated TTTGTTATGTAAAATGAGGGAGTGT CCAAATAAATCAACAACATCAC 
mRUNX3   
Methylated TGTAGTTATAAGATTTTTTAAGGGGTC CACAAAATACAAAAAACCAACTCG 
Unmethylated GTAGTTATAAGATTTTTTAAGGGGTTGT TCACAAAATACAAAAAACCAACTCA 
hDAPK1   
Methylated GGGATTTTAGTATATATTTCGGGAC GAACTACCCTACCAAACCGA 
Unmethylated TTGGGATTTTAGTATATATTTTGGGAT CAAACTACCCTACCAAACCA 
hRAR-BETA   
Methylated GGTTAGTAGTTCGGGTAGGTTTTATC CCGAATCCTACCCCGACG 
Unmethylated TTAGTAGTTTGGGTAGGGTTTATT CCAAATCCTACCCCAACA 
hGATA2   
Methylated CGGGTATTTTTTTGTTTTTTGC TAACCTCGCTACCTTCCTAACG 
Unmethylated TTTTGGGTATTTTTTTGTTTTTTGT CTAACCTCACTACCTTCCTAACACT 
hCDH13   
Methylated AAGAAGTAAATGGGATGTTATTTTC AAAACCAATAACTTTACAAAACGAA 
Unmethylated TTAAAGTAAATGGGATGTTATTTTT ACCAAAACCAATAACTTTACAAAACA 
hRUNX3   
Methylated GGTTTAGTTAATGAGTTAAGGTCGC TCTAATAAATACGAAAACGACCGA 
Unmethylated TTTAGTTAATGAGTTAAGGTTGTGA TCTAATAAATACAAAAACAACCAA A 
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Quantitative reverse transcription–PCR (qRT-PCR) analysis  
Total RNA was extracted from frozen mouse lung or lung tumor tissues using the 
miRNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instruction. 
The purity and the integrity of total RNA were confirmed by Nanodrop UV-
Spectrophotometer and the RNA was stored at -80 ℃ until later use. The first-strand 
complementary DNA was synthesized by using QuantiTect Reverse Transcription Kit 
(Qiagen, Valencia, CA) with one microgram of RNA in 20 µL reaction. The first-strand 
complementary DNA mixture was further diluted to 200 µL with RNase-free water and 
stored at -20 °C until use. 
qRT–PCR was performed by Light Cycler 96 (Roche, Indianapolis, IN) using 
QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA) and gene specific primers 
(Table 4.2). Twenty five nanograms of complementary DNA was added to a 20 µL 
reaction. The final concentration of each primer was 0.5 µM. For PCR amplification, a 
program of initial denaturation at 95 °C for 15 min, followed by 45 cycles consisting of 
denaturation at 94 °C for 15 s, annealing at 50 °C for 30 s and extension at 72 °C for 34 s 
was used. All samples were normalized to an internal control (β-actin). Comparative Ct 
method was used to assess the relative levels of gene expression. Values were expressed 
as relative units compared with vehicle control (mouse lung tissue) and the standard error.  
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Table 4.2. Primer sequences used for qRT-PCR.  
Gene 
name 
Forward primer (5ʹ-3ʹ) Reverse primer (5ʹ-3ʹ) 
mDAPK1 CCGCTGTCAACTACGACTTT GTCCTGGATTGTCATCCTCTTC 
mRAR-β CCTCTGACTGACCTTGTGTTC GGCGGTCTCCACAGATTAAA 
mGATA2 GACGACAACCACCACCTTAT TGCTGGACATCTTCCGATTC 
mCDH13 CCTGACAAGCCATCTCCTAAC GACATCCAATCCTGCCATATCT 
mPRDM2 TAGGTCCCGTGTGTGTATCT CTGCTTTCCCATCACTCTGT 
mRUNX3 GAGTTTCACGCTCACAATCAC GCCTTGGTCTGGTCTTCTATC 
mRASSF1 GAGACACCCGATCTTTCTCAAG CACTGAAACAGGACGCACTA 
mβ-actin ACTCTTCCAGCCTTCCTTCC GTACTTGCGCTCAGGAGGAG 
mTet1 AGATGGCTCCAGTTGCTTATC CTTCCGTTGTGCATGTTGTG 
mTet2 GTCCTGATGTGGCAGCTATT TCCTCACTCGATCTCCGATATAC 
mTet3 GAGTTCCCTACCTGCGATTG TCCATGAGTTCCCGGATAGA 
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Methylation Analysis by Pyrosequencing  
DNA isolated from mouse lung tissues (100 ng) was treated with bisulfite using 
EpiTect Bisulfite Kit (Qiagen, Frederick MD) according to the manufacturer’s instructions. 
Bisulfite treated DNA was amplified by PCR with primers for the following genes: Ahrr, 
DAPK1, CDH13, Tet1, and Rassf1. The thermocycler protocol for amplification reactions 
consisted of 95C for 30 sec, the optimal annealing temperature for 30 sec, and 72C for 
30 sec, each reaction completing 40 rounds of PCR.  PCR product amplicon sizes were 
checked on a QIAxcel (Qiagen) prior to pyrosequencing to ensure the correct gene was 
amplified. Bisulfite converted DNA was prepared for pyrosequencing according to the 
instructions in the PyroMark assay kit (Qiagen, Frederick, MD), including three controls: 
“no template control” (NTC), bisulfite converted 100% and 0% methylated mouse DNA. 
Methylated mouse DNA controls were created by methylation of genomic mouse DNA 
with M.SssI. Pyrosequencing was carried out according the design files from Qiagen and 
the Qiagen Assay Design Software on the PyroMark Q96 (Qiagen). CpG methylation 
values were used for statistical analysis, and values defined as “failed” were discarded. 
Statistical significance was calculated in GraphPad Prism 6 using 2-way ANOVA.  
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4.3 Results 
Development of quantitative HPLC-ESI-MS/MS methodology for MeC, hmC, 
fC, and caC 
 To allow for accurate quantitation of epigenetic DNA marks, we have developed 
an isotope dilution HPLC-ESI-MS/MS methodology for MeC, hmC, fC, and caC (Figure 
4.2). Our approach involves enzymatic digestion of genomic DNA (2-10 µg) to 2ʹ-
deoxynucleosides, followed by offline HPLC enrichment of MeC, hmC, fC, and caC and 
quantitation by capillary HPLC-ESI-MS/MS. Absolute quantitation is achieved by isotope 
dilution with the corresponding isotopically labeled internal standards (13C1015N2-MeC, D3-
hmC, 13C1015N2-fC, 13C1015N2-caC), which were synthesized in our laboratory as described 
in the methods section.20 To improve HPLC retention and HPLC-ESI+-MS/MS sensitivity 
for fC, it was derivatized with a biotin-containing aldehyde reactive probe.14 HPLC-ESI-
MS/MS detection of MeC, hmC, and fC was conducted by monitoring a neutral loss of 
deoxyribose (116 mass units) from each nucleoside (Figure 4.2), while a loss of 
deoxyribose and carbon dioxide was monitored for caC (Figure 4.2). Quantitative HPLC-
ESI+-MS/MS methodology was validated by analyzing synthetic DNA spiked with known 
concentrations of each analyte (Figure 4.3). The method’s LOD was 3.1 fmol for MeC, 
6.2 fmol for hmC, 1.2 fmol for fC, and 5 fmol for caC, while the corresponding LOQ values 
for MeC, hmC, fC, and caC were 6.2 fmol, 9.3 fmol, 4.9 fmol, and 8 fmol respectively, in 
1 µg of genomic DNA. Excellent accuracy and precision were achieved for analyzing 
known amounts of MeC, hmC, and fC spiked into blank DNA. The sensitivity of our 
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analytical methodology was sufficient to quantify global amounts of MeC, hmC and fC in 
1-2 µg of genomic DNA (Figures 4.2 and 4.4).   
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Figure 4.2. Representative capillary HPLC-ESI-MS/MS traces for accurate quantification 
of MeC, hmC, fC, and caC in mouse DNA. 
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Figure 4.3. HPLC-ESI-MS/MS validation curves for MeC, hmC, and fC. Fixed amounts 
of isotopically labeled internal standards (1 pmol 13C1015N2-MeC, 900 fmol d3-hmC, and 
500 fmol 13C1015N2-fC) were spiked into calf thymus DNA and along with increasing 
amounts of the corresponding unlabeled nucleosides. Samples were processed as 
described above and subjected to HPLC-ESI+-MS/MS analysis.  
 
 
  
188 
 
DNA methylation and hydroxymethylation changes in lung DNA of A/J mice exposed 
to cigarette smoke 
 Mass spectrometry based approach was used to quantify global cytosine 
methylation, hydroxymethylation, and formylation in lung DNA of A/J mice following 
whole-body exposure to environmental cigarette smoke (ECS) for 10 weeks, starting at 
birth, with or without oral co-administration of aspirin. These tissues were available form 
an earlier study by La Maestra et al.140 These authors previously showed that while no 
histopathological change were apparent in the lungs of these mice, ECS caused a 
considerable downregulation of pulmonary microRNAs affecting both adaptive 
mechanisms and disease-related pathways.291 Most notably, aspirin modulated the 
expression of microRNAs with a variety of functions including regulation of 
cyclooxygenases and inflammation.291 We found that global levels of cytosine methylation, 
hydroxymethylation, and formylation remained relatively stable upon exposure to ECS or 
aspirin treatment (Figure 4.4).  
To probe for site specific methylation and hydroxymethylation changes in DNA 
induced by ECS exposure, we conducted reduced representation bisulfite sequencing 
(RRBS) and oxidative-RRBS (oxoRRBS).205 DNA isolated form lung tissues of female 
A/J mice (ECS and control groups, N = 4 per group) was prepared for sequencing using 
NuGEN Ovation RRBS Methyl-Seq with TrueMethyl oxBS modules.205 The libraries were 
sequenced to a depth of 15-20 million reads. The amount of methylation at a covered 
cytosine could be inferred directly from the oxoRRBS data using MethPipe.195 To examine 
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the changes in site-specific levels of hydroxymethylation, we first calculated the amounts 
of hmC present at each site from the RRBS and oxoRRBS data (See Section 1.4.8 and 
Figure 1.8 of Chapter I of this thesis for more information).292 From these data, the sites 
with changes in methylation or hydroxymethylation greater than 5%, having more than 200 
reads, and showing statistically significant changes in methylation293 or 
hydroxymethylation were mapped to the nearest gene.  
Site-specific methylation changes in ECS exposed mice ranged from increases of 
30% to decreases of 36%. For each of the differentially methylated site (1537 sites), a 
methylation ratio was calculated in both the ECS treated and control samples. Methylation 
ratios are calculated by dividing the number of methylated reads by the coverage of the 
site. The methylation ratios are shown in a methylation heat map (Figure 4.4) normalized 
by z-score with hierarchal clustering. Hydroxymethylation changes calculated from the 
RRBS and oxoRRBS data ranged from increases of 56% to decreases of 47%. For each 
site with differential hydroxymethylation (N = 5524) a hydroxymethylation ratio was 
calculated. The ratios are shown in a heat map (Figure 4.5) normalized by z-score. 
CpG sites showing increases and decreases in methylation were analyzed separately 
using Ingenuity Pathway Analysis (IPA) to identify any enrichments of associated 
functions and diseases. From this analyses, we found that genes with increased methylation 
(N = 193) were enriched for the formation of tumors, carcinomas, and development (p < 1 
x 10-6, Table 4.3). The genes having a corresponding decrease in methylation (N = 357) 
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were analyzed in a similar fashion and found to also be associated with cancer and tumor 
development (Table 4.4).  
Genes showing more than a 5% increase in hydroxymethylation (N = 1762) were 
also analyzed by IPA in the same manner to identify enrichment of the associated diseases 
and functions. The diseases and functions show a very high enrichment for genes 
associated with cancer, in particular, particularly adenocarcinoma (Table 4.5). Decreased 
levels of hmC was also observed in numerous genes (1350 genes), for which the enriched 
diseases and functions were determined. From this analysis, genes showing a decrease in 
hmC are also enriched in cancer associated genes (Table 4.6). 
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Figure 4.4. Global amounts of MeC, hmC, and fC in lung DNA of mice exposed to 
cigarette smoke for 10 weeks with or without aspirin co-treatment. 
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Figure 4.5. Site-specific cytosine methylation and hydroxymethylation levels in lung DNA 
of female A/J mice exposed to ETC for 10 weeks. Sites exhibiting > 5% change are 
included. A. A heatmap of the methylation ratio at specific sites in control and ECS 
exposed mice (>1500 sites). Data is expressed as methylation ratios (0-1). B. A heatmap 
of the hydroxymethylation ratio at specific sites in control and ECS exposed mice (>5500 
sites). Data is expressed as normalized z-scores. 
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Table 4.3. Biological functions and diseases association of genes exhibiting increased 
cytosine methylation in the lungs of female A/J mice exposed to cigarette smoke for 10 
weeks. Top 100 genes were analyzed using IPA.  
Function Annotation p-value 
Liver tumor 1.35E-06 
Development of adenocarcinoma 2.68E-06 
Abnormality of endometrium 3.14E-06 
Organismal death 3.25E-06 
Endometrial carcinoma 4.97E-06 
Uterine carcinoma 5.26E-06 
Development of genital tumor 5.94E-06 
Female genital tract adenocarcinoma 6.12E-06 
Development of head 6.29E-06 
Endometrioid carcinoma 6.57E-06 
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Table 4.4. Disease and functional enrichment of genes  hypomethylated  in mouse lung 
DNA following cigarette smoke exposure for 10 weeks. Top 100 genes by magnitude of 
MeC decrease were analyzed using IPA. 
Function Annotation p-value 
Pelvic cancer 6.77E-09 
Pelvic tumor 1.25E-08 
Cancer of secretory structure 2.44E-08 
Genital tract cancer 2.8E-08 
Genital tumor 4.89E-08 
Male genital neoplasm 6E-08 
Prostatic tumor 6.46E-08 
Malignant genitourinary solid tumor 8.56E-08 
Malignant neoplasm of male genital organ 9.03E-08 
Prostatic carcinoma 1.54E-07 
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Table 4.5. Disease and functional enrichment of genes exhibiting increased cytosine 
hydroxymethylation (hmC) in the lung following exposure of A/J mice to cigarette smoke 
for 10 weeks. The top 100 genes by magnitude of hmC increase were analyzed using 
IPA. 
Function Annotation p-value 
Large intestine carcinoma 6.14E-36 
Gastrointestinal adenocarcinoma 9E-36 
Large intestine adenocarcinoma 1.38E-35 
Gastrointestinal carcinoma 1.6E-35 
Abdominal adenocarcinoma 2.52E-35 
Liver lesion 1.55E-33 
Non-melanoma solid tumor 2.72E-33 
Non-hematological solid tumor 8.99E-33 
Liver tumor 1.35E-32 
Gastrointestinal tumor 1.42E-32 
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Table 4.6. Disease and functional enrichment for genes with decreased hmC following 
exposure of A/J mice to cigarette smoke for 10 weeks. The top 100 genes by magnitude 
of hmC decrease were analyzed using IPA. 
Function Annotation p-value 
Gastrointestinal adenocarcinoma 7.23E-36 
Large intestine adenocarcinoma 4.93E-35 
Large intestine carcinoma 5.15E-35 
Gastrointestinal carcinoma 1.17E-33 
Intestinal tumor 1.02E-32 
Large intestine neoplasm 1.45E-32 
Gastrointestinal tumor 1.69E-32 
Adenocarcinoma 2.47E-32 
Malignant neoplasm of large intestine 4.75E-32 
Abdominal adenocarcinoma 9.45E-32 
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Early epigenetic changes in the lung of A/J mice treated with tobacco carcinogen NNK 
and inflammatory agent LPS  
 While our RRBS data presented above provided evidence of epigenetic changes in 
lung DNA of mice exposed to cigarette smoke (Figure 4.5), it not clear which components 
of tobacco smoke are responsible.  Cigarette smoke contains a complex mixture of 
chemicals (over 7,000), including tobacco specific nitrosamine NNK (118 ng/cigarette)294 
and bacterial endotoxin lipopolysaccharide (LPS) (2,400 ng/pack).105 LPS is a major 
component of the outer membrane of Gram-negative bacteria.  Upon inhalation, LPS 
induces immune response and inflammation by binding the CD14/TLR4/MD2 receptor 
complex in monocytes, dendritic cells, macrophages and B cells, promoting the secretion 
of pro-inflammatory cytokines, nitric oxide, and eicosanoids.295   
 In order to identify cigarette smoke components responsible for epigenetic effects 
of ECS (Figure 4.5), A/J mice were treated with NNK, LPS, or both NNK and LPS for 1-
15 days. HPLC-ESI-MS/MS was used to quantify global MeC, hmC, fC, and caC in target 
(lung) and non-target tissues (kidney, brain). The amounts of MeC and hmC observed in 
lung tissue of A/J mice (3-3.5% of total cytosines being methylated and 0.1-0.12% total 
cytosine being hydroxymethylated) were comparable to the levels of MeC and hmC 
previously reported in lung tissue of C57BL/6N mice (4.2% of total cytosines for MeC and 
0.15% for hmC).30 We found that the global genomic levels of MeC and hmC in mouse 
lung were essentially unchanged over the two week treatment with NNK (Figure 4.6). 
However, global hmC concentrations were significantly lower in lung tissues of mice 
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treated with LPS (8.3 µg twice in week 1 and 4.15 µg once in week 2, p < 0.05, see Figure 
4.6) or LPS/NNK in combination (0.13 ± 0.012 % vs 0.071 ± 0.008 %, p = 0.025). No 
significant changes were observed in mouse brain and kidney DNA (Figure 4.7). Overall, 
these results provide initial evidence that NNK alone has little effect on epigenetic marks 
of DNA, while LPS treatment may reduce the global levels of hmC in the target tissue 
(lung) but not in non-target tissues such as brain and kidney. 
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Figure 4.6. NNK and LPS alter the global levels of epigenetic modifications, MeC and 
hmC, in the lung tissue of treated A/J mice. Female A/J mice (6 weeks of age) were treated 
with NNK, with LPS, or both for a length of 2 weeks. Data are expressed as percent of dC 
and represents mean values ± SD of at least three animals. Global levels of MeC and hmC 
in the lung tissue of mice treated for 2 weeks with NNK or in combination with LPS 
showed little change for the levels of MeC, however a significant decrease was observed 
in hmC in the combination of NNK and LPS and in the mice sacrificed a week after the 
final treatment.  
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Figure 4.7. Early changes in global MeC and hmC levels in kidney and brain DNA of A/J 
mice treated with NNK and/or LPS. Female A/J mice (6 weeks of age) were treated 
intraperitoneally with NNK (25 mg/kg) every day on days 3 -9 and 12.5 mg/kg of NNK on 
days 10-14. For LPS treatments, 8.3 µg LPS was administered intranasally twice a week 
in the first week and 4.15 µg once during the second week. The error bars represent the 
average of N = 4 repeats for LPS-control and N = 3 for the rest of the groups. 
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 Since epigenetic changes from the two week long treatment with tobacco 
carcinogens were relatively minor, a longer study was initiated. A/J mice were treated with 
NNK, LPS or NNK+LPS for six weeks, and the global amounts of epigenetic marks in 
lung DNA were determined by HPLC-ESI+-MS/MS. As was the case in the short-term 
study (Figure 4.7), no significant changes in global MeC or hmC levels was observed for 
animals treated with NNK alone (p = 0.66 and 0.48, respectively, Figure 4.8).  In contrast, 
HPLC-ESI+-MS/MS analyses have revealed a small but significant increase in global 
amounts of MeC in lung DNA of mice treated with LPS alone (3.32 ± 0.12 % vs 3.52 ± 
0.09 %, p < 0.05) or NNK/LPS in combination (3.32 ± 0.12 % vs 3.56 ± 0.05 %, p < 0.05) 
(Figure 4.8). Furthermore, global hmC levels were significantly decreased in lung DNA 
of animals treated with LPS or with NNK/LPS (0.12 ± 0.006 % and 0.13 ± 0.009 % C, 
respectively as compared to 0.19 ± 0.007 % in control animals, p < 0.01) (Figure 4.8). An 
opposite trend was observed for fC, which was elevated in LPS and NNK/LPS treatment 
groups 0.0058 ± 0.0015% p = 0.05 and 0.0058 ± 0.0003% C p < 0.01 respectively as 
compared to 0.0026 ± 0.0007% in control, Figure 4.8). Overall, our quantitative HPLC-
ESI+-MS/MS results for epigenetic DNA marks indicate that LPS-induced inflammation 
causes significant global hydroxymethylation changes in the lung.  
 A different trend was observed in brain tissues of the same animals. In this case, 
global cytosine methylation was increased in groups treated with NNK, LPS, or NNK/LPS, 
while hmC remained unchanged (Figure 4.9). Global fC levels in the brain showed an 
increase for groups treated with NNK, LPS, but not NNK/LPS (Figure 4.9). Due to the 
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relatively high abundance of oxidized forms of MeC in the brain, we were able to detect 
and quantify caC in this tissue (0.0012% ± 0.0003%), with amounts showing no change 
across treatment groups (Figure 4.9). These results indicate that treatment with LPS and 
NNK induces tissue dependent epigenetic changes, with most pronounced effects detected 
in the lung. 
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Figure 4.8. NNK and LPS alter the global levels of epigenetic modifications, MeC, hmC, 
and fC in the lung tissue of treated A/J mice. Female A/J mice (6 weeks of age) were treated 
intraperitoneally with NNK, intranasally with LPS, or both in combination for a length of 
6 weeks. Data are expressed as percent of dC and represents mean values ± SD of at least 
three animals. LPS induced lung tissue inflammation drives changes in the global levels of 
MeC, hmC, and fC whether alone, or in co-exposure with NNK. 
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Figure 4.9. Global changes in genomic MeC, hmC, fC, and caC levels in the brain of A/J 
mice chronically treated with NNK, LPS, or both NNK and LPS for 5 weeks. NNK (50 
mg/kg) was given IP twice during weeks 1 and 3, and once during week 5. LPS (4 
µg/mouse) was administered intranasally twice during week 1, and once a week in weeks 
3, 4, and 5. The error bars represent the average of N = 4 repeats.   
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DNA methylation levels at specific genes in DNA from 6-week chronic mouse 
treatment 
 To detected site-specific methylation changes following chronic exposure to NNK 
and LPS, pyrosequencing study of five genes (Ahrr, DAPK1, CDH13, Tet1, and Rassf1) 
was conducted. These genes were selected for further study due to their association with 
cigarette smoke studies in humans.296 These experiments revealed a range of methylation 
at specific CpGs in each gene, CDH13 2-23%, Ahrr 5-24%, DAPK1 5-23%, Tet1 5-46%, 
and Rassf1 9-14% (Figure 4.10). The methylation level of the Ahrr gene was measured at 
9 CpG sites. In the Ahrr gene, small increases (0.3-2.5%) were observed for NNK and LPS 
treatment alone. In the combined treatment of NNK and LPS an increase in methylation 
was observed for CpGs 3 (+3%, p < 0.05), 4 (+2.8%), 6 (+2.1%), and 9 (+3.3%). 
Pyrosequencing of the DAPK1 gene provided methylation levels for 5 CpG sites. DAPK1 
methylation was increased at each CpG and for each condition except in the NNK treatment 
at CpG 4 which showed a slightly decreased methylation level. In the combination 
treatment of NNK and LPS, the methylation level of each CpG site in DAPK1 increased 
0.8%, 1.6%, 1.5%, and 5.3% (p < 0.01) for sites 1, 2, 3, and 4 respectively and decreased 
0.1% at site 5. In the CDH13 gene, site specific methylation was increased at CpGs 1, 3, 
and 4 in both the LPS alone and in the combination of NNK and LPS. The increases at 
these CpG sites for LPS treatment were 3.2% (p < 0.05), 1.5%, and 4.8% (p < 0.01) and 
for treatment with NNK and LPS were 5.2% (p < 0.01), 2.5%, and 5.5% (p < 0.01) 
respectively. Pyrosequencing detected site specific methylation changes in the Tet1 
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promoter with NNK treatment causing a +0.3%, 0%, +0.1%, +1.3%, and -1.2% for CpGs 
1, 2, 3, 4, and 5 respectively while LPS treatment caused +0.6%, +0.2%, -0.1%, +0.5%, 
and -4.2% (p = 0.01) for those same sites. Combined NNK + LPS treatment caused 
increased methylation at all CpGs measured (except CpG 5), with methylation changes of 
+1.6%, +1.2%, +1.0%, +1.5%, -1.6%, +1.1%, and +3.5% (p < 0.05) at each of those sites. 
Site-specific methylation of the Rassf1 gene was measured at 4 CpG sites by 
pyrosequencing. Cytosine methylation of Rassf1 was decreased at CpGs 1 and 2 in all 
conditions. At CpG 3 in Rassf1, methylation levels were increased 3.9% (p < 0.05), 3.7% 
(p < 0.05), and 4.5% (p = 0.01) and at CpG 4 the methylation level increased 0.9% and 
0.5% in NNK and the combination of NNK and LPS treatment. 
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Figure 4.10. Methylation status of specific CpG sites within promoter regions of Ahrr, 
DAPK1, CDH13, Tet1, and Rassf1 genes in lung DNA of mice treated for 6 weeks with 
vehicle, NNK, LPS, and NNK/LPS determined by bisulfite pyrosequencing. * indicates p 
< 0.05 vs. control. 
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Histone acetylation changes 
Histone acetylation is a key regulatory mechanism that maintains epigenetic 
memory in eukaryotic cells.297 Site-specific acetylation of histones H3 and H4 strongly 
correlates with the global gene expression profiles and transcriptional activation 
activities.298-299 On the other hand, dysregulation of histone acetylation contributes to 
tumorigenesis and disease progression in lung cancer and other types of carcinomas.298, 300 
To determine whether NNK and LPS treatments induce global changes in histone 
acetylation, we employed a recently developed chemical proteomics strategy that enables 
site-specific identification of the absolute lysine acetylation stoichiometries.290  
Histone proteins were extracted from lung tissues from A/J mice treated for 6 
weeks, labeled, and analyzed by nano HPLC-ESI+-MS/MS as described previously.289 The 
data were analyzed by in-house developed scripts to calculate site-specific acetylation 
stoichiometries.290 Our data shown in Figure 4.11 demonstrate that NNK and LPS 
treatments led to the overall down-regulation of lysine acetylation abundance on histone 
H3 and H4. More specifically, acetylation on histone H3K14 and H3K23 significantly 
decreased upon the treatment with NNK, LPS alone, or NNK/LPS, while the treatments 
did not significantly affect H3K18 acetylation (Figure 4.11). Histone H4 acetylation was 
also down-regulated by NNK and LPS treatment, but to a lesser extent than H3. NNK 
treatment alone and the combination of NNK/LPS treatment significantly downregulated 
histone H4K16 acetylation, while the treatments did not strongly decrease other histone H4 
N-terminal acetylation (Figure 4.11). It is worth noting that acetylation of H3K14, H3K23 
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and H4K16 are transcriptional activation marks that are strongly associated with active 
gene expression.299, 301-304 
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Figure 4.11. Histone lysine acetylation stoichiometry changes upon treatment of A/J mice 
with NNK, LPS, and coexposure to NNK and LPS for 6 weeks. Data is expressed as percent 
acetylated and represents mean values ± SD of at least 3 animals. Statistical significance 
was evaluated between treated and control samples using a two-sided Student’s t-test (* p< 
0.05, ** p<0.01). Histone acetylation stoichiometries were assessed to determine global 
gene activation by deacetylation due to exposure. Measured acetylation sites include 
lysines 5, 8, 12, and 16 on histone H4 and lysines 9, 14, 18, and 23 on Histone H3. 
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Gene expression levels in lung tissues of NNK/LPS treated mice  
 To determine whether LPS- and NNK-mediated changes in DNA and histone 
epigenetic marks lead to altered gene expression levels, we examined the expression levels 
of genes including Tet1, Tet2, Tet3, Dapk1, Gata2, Cdh13, Prdm2, and Rassf1, and 
transcription factor Runx3 using qRT-PCR (Figure 4.12).  We found that Tet1 expression 
was decreased in all treatment groups, while Tet isoforms 2 and 3 were unaffected. 
NNK/LPS treated animals showed more pronounced changes in Tet1 mRNA as compared 
to NNK only group (p < 0.05, see Figure 4.12). These results suggest that LPS-induced 
inflammation is associated with reduced levels of expression for the Tet1 gene, which is 
consistent with our observation of decreased levels of hmC in genomic DNA (Figures 4.4 
and 4.6). In addition, gene expression levels of tumor suppressor genes Dapk1, Gata2, 
Cdh13, Prdm2, and Rassf1 showed significant changes in the lungs of treated mice. The 
mRNA level of death-associate protein kinase 1 (Dapk1) showed a 2-fold decrease in both 
LPS and treated groups but was unchanged in NNK only group (Figure 4.12). Similarly, 
the expression levels of cellular adhesion protein cadherin 13 gene (Cdh13) decreased 3-
fold in both groups treated with LPS, but not in NNK only group (Figure 4.12). Expression 
levels of the retinoic acid receptor, beta (Rar-β) increased upon treatment with NNK but 
decreased in LPS alone and NNK/LPS groups (Figure 4.12). For the zinc-finger 
transcription factor Gata2, mRNA levels were reduced in each treatment group (Figure 
4.12) and was most significant in the NNK/LPS group, p < 0.05. The mRNA levels for PR 
Domain containing protein 2 (Prdm2) decreased slightly with treatment relative to control 
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(Figure 4.12). A small decrease in Ras association domain family member 1 (Rassf1) was 
observed in all treatment groups (p < 0.05) (Figure 4.12). In contrast, the expression of 
Runt related transcription factor 3 (Runx3) was elevated in both LPS treated groups but 
was unchanged in NNK only group. Overall, significant changes in expression levels of 
many critical genes were observed in the lung of mice treated with LPS to induce 
inflammation, but the effects of NNK alone on gene expression were relatively small.  
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Figure 4.12. Gene expression changes in the lung tissues of A/J mice treated with treated 
with a single dose of NNK (100 mg/kg, IP) in week 1, weekly LPS (5 µg/mouse in 50 µL 
PBS, intranasally under isoflurane anesthesia) starting week 2, both NNK and LPS or 
physiological saline only (control) for a total of 9 weeks. Data are calculated using the 
ΔΔCt method ± SD with three biological and three technical replicates. Genes were 
selected based on association with lung cancer.  
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Epigenetic changes in NNK/LPS induced pulmonary adenocarcinoma 
 To determine whether tobacco carcinogen-induced epigenetic changes persist 
throughout lung cancer development, MeC, hmC, and fC were quantified in mouse 
pulmonary adenocarcinomas induced by NNK/LPS treatment. Tumors (≥ 100) isolated 
from the lungs of 4-5 A/J mice that had been treated with NNK alone or NNK/LPS for 27 
weeks were excised and pooled.141 Genomic DNA was extracted from pooled tumor 
samples and analyzed for global levels of MeC, hmC, and fC by isotope dilution HPLC-
ESI+-MS/MS. The values were compared to non-tumor DNA from lung tissue of mice of 
the same age. We found that while global levels of MeC remained relatively stable across 
treatment groups (3.5 ± 0.2 - 3.6 ± 0.2 % of total Cs, p = 0.15, Figure 4.13), both hmC and 
fC levels were altered in tumors. Cytosine hydroxymethylation decreased significantly in 
DNA extracted from NNK- and NNK/LPS-induced tumors (0.07 and 0.08 %, respectively, 
as compared to 0.25 ± 0.015% of total Cs in normal lung tissue (p < 0.0001 and 0.0001, 
respectively, see Figure 4.13). Global amounts of fC showed a small decrease in NNK-
induced tumors (0.0026 ± 0.0007 vs 0.0017 ± 0.0008 % of total Cs, p = 0.027) and were 
increased in tumors induced by NNK/LPS treatment (0.0026 vs 0.0032 ± 0.001) although 
this difference was not statistically significant (Figure 4.13). Overall, global amounts of 
MeC, hmC, and fC in lung tumors exhibited the same overall trend as lung tissues prior to 
tumor formation (compare Figures 4.6 and 4.13). 
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Figure 4.13. NNK and LPS alter the global levels of epigenetic modifications, MeC, hmC, 
and fC in the lung tumors and normal control tissue of A/J mice. Female A/J mice (6 weeks 
of age) were treated intraperitoneally with NNK, intranasally with LPS, or in combination 
for a length of 27 weeks. Data are expressed as percent of dC and represents mean values 
± SD of at least three animals. 27-week exposure to NNK or the combination of NNK and 
LPS to generate lung tumors show global levels of MeC, hmC, and fC are deregulated.  
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Promoter methylation of tumor suppressor proteins in tumors of A/J mice 
 Methylation specific PCR analysis was conducted to determine whether global 
methylation and hydroxymethylation changes in tumors are accompanied by altered 
promoter methylation and hydroxymethylation of tumor suppressor genes. We found that 
the Dapk1 promoter was unmethylated in all samples, while the methylation of Cdh13, 
Runx3, and Gata2 promoters was unchanged between tumors and controls. However, Rar-
β promoter was methylated only in treated group but not in control lung (Figure 4.14).  
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Figure 4.14. Methylation specific PCR results from DNA isolated from lung tumors of A/J 
mice treated for 44 weeks with a single dose of NNK (100 mg/kg, IP) in week 1 and 
biweekly dosing of LPS (2 µg/mouse in 50 µL PBS, intranasally under isoflurane 
anesthesia) beginning in week 2.   
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Gene expression levels in lung tumors of NNK/LPS treated mice  
 To understand whether initial inflammation-induced changes in gene expression in 
the lung persist upon tumor formation, mRNA expression analyses were repeated in lung 
tumors of A/J mice formed 22 and 44 weeks post treatment with NNK, LPS, or with 
NNK/LPS. We observed pronounced gene expression changes in tumors (22-week tumors 
– Figure 4.15, and 44-week tumors - Figure 4.16). These results support the notion that 
inflammation mediated changes in gene expression contribute to carcinogenesis in the A/J 
mouse model of lung cancer.  
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Figure 4.15. Gene levels of TET proteins and tumor suppressor genes changes in lung 
tumors of A/J mice. Mice were treated with treated with a single dose of NNK (100 mg/kg, 
IP) in week 1, weekly LPS (5 µg/mouse in 50 µL PBS, intranasally under isoflurane 
anesthesia) starting week 2, both NNK and LPS or physiological saline only (control). 
Under these conditions, lung tumors were formed for both the NNK and NNK with LPS 
treatment groups for 22 weeks. Data were calculated from qRT-PCR using the ΔΔCt 
method ± SD with three biological and three technical replicates.  
  
220 
 
Figure 4.16. Gene expression changes in the lung tumors of A/J mice treated with a single 
dose of NNK (100 mg/kg, IP) in week 1, biweekly LPS (2 µg/dose in 50 µL PBS, 
intranasally under isoflurane anesthesia) starting week 2, or both NNK/LPS for a duration 
of 44 weeks as compared to normal lung tissue control. Data are calculated using the ΔΔCt 
method ± SD with three biological and three technical replicates. 
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4.4 Discussion  
 Lung cancer kills over one million people each year worldwide and is the leading 
cause of cancer death in the United States.305  With a 5 year survival rate of 5-54% 
depending on stage of disease, new prevention and treatment strategies for lung cancer are 
urgently needed.305 The primary risk factor for lung cancer development is smoking. 
Although the prevalence of smoking among adults in the United States has been 
decreasing, 16.8% of Americans continue to smoke.306 Cigarette smoke contains over 60 
known carcinogens including tobacco specific nitrosamine NNK.307 Following metabolic 
activation to reactive metabolites, NNK induces a range of promutagenic DNA adducts 
including O6-methylguanine.307-308 Error-prone polymerase bypass of DNA adducts leads 
to heritable mutations, which in turn contribute to lung cancer development.307 
Tumor promotion and inflammatory stimuli, in combination with genotoxic 
stimuli, are increasingly recognized as important factors in smoking-induced 
carcinogenesis.309 Tobacco smoke contains pro-inflammatory compounds such as 
lipopolysaccharide (LPS, 2,400 ng/pack).105 When administered to laboratory mice, LPS 
induces inflammatory response mimicking chronic obstructive pulmonary disease 
(COPD), a major risk factor for lung cancer development in smokers.283 While the exact 
mechanism of inflammation-driven lung tumor initiation and promotion is unknown, 
epigenetic changes are likely to play a critical role as other inflammation-driven cancers 
such as H. pylori-related gastric cancer,310 dextran sulfate-induced colon cancer,311 and 
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hepatitis C virus-induced hepatocellular carcinoma312 are characterized by 
hypermethylation of tumor suppressor genes. 
NSAIDs are commonly prescribed anti-inflammatory agents that have been shown 
to reduce the incidence of inflammation driven colorectal cancer.285 Although the efficacy 
of NSAIDs in preventing lung cancer chemoprevention remains to be established,286-288, 313 
aspirin has been shown to reduce the number of NNK induced lung tumors in A/J mouse 
model of smoking-induced lung cancer.314  
Irregular DNA methylation events, e.g. “epimutations”, have been shown to 
collaborate with genetic changes to drive the cancer phenotype.315-318 Epigenetic alterations 
such as aberrant cytosine methylation, abnormal histone acetylation, changes in micro 
RNA levels, and deregulated patterns of gene expression are increasingly recognized as 
key events in cancer etiology.319-324 Tumor DNA sequencing as part of The Cancer Genome 
Atlas (TCGA) has revealed that components of epigenetic machinery are among the genes 
most frequently mutated in human cancers.325 Many tumors are characterized by aberrant 
DNA methylation, decreased TET protein expression, and reduced levels of DNA 
hydroxymethylation.326  
It is crucial that we learn more about the epigenetic pathways of tumorigenesis. 
Unlike somatic mutations, which are difficult to correct with current treatments, epigenetic 
changes can be reversed with appropriate therapeutic agents.327 Epigenetic changes take 
place relatively soon following exposure and could be used as biomarkers of lung cancer 
susceptibility and to aid in early detection of lung tumors.323, 328 Finally, by providing 
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individualized “fingerprints” of smoking-mediated gene expression changes, epigenetic 
markers can facilitate the development of personalized therapies for lung cancer,329 
Because MeC typically acts as a repressive mark, its oxidation to hmC may trigger gene 
reactivation. Therefore, diminished oxidation of MeC to hmC in tumors is likely contribute 
to inactivation of tumor suppressor genes, triggering malignant transformation.330 
However, the dynamics, mechanisms, and contributions of epigenetic changes to cancer 
etiology remain poorly understood.     
Multiple studies have been conducted to determine the role of cytosine methylation 
in cancer. However, many of the earlier studies have been limited to investigating MeC at 
a single endpoint following tumor formation and did not examine early epigenetic changes. 
Furthermore, traditional sequencing methods did not distinguish between MeC and hmC, 
since both of them resist bisulfite conversion.167, 204 Although gene-specific 
hypermethylation of Dapk1, Rassf1a, Mgmt, Mlh1 and p16 have been identified as 
epigenetic changes associated with lung tumor development, the timing of cell epigenetic 
transformations has not been identified.108, 331-333 Cytosine hydroxymethylation, 
formylation, and carboxylation has been studied to a lesser extent than methylation, 
although global hmC has been consistently found to be depleted in tumors, correlating with 
a decrease in Tet gene expression.334  
 The main goal of the present study was to characterize epigenetic changes in the 
lung following cigarette smoke exposure or inflammatory stimuli/tobacco carcinogen 
treatment in an established A/J mouse model of smoking induced lung cancer.141 A/J mice, 
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which were exposed to cigarette smoke starting 12 h after birth and continuing for 10 
weeks,140 were investigated for global and loci-specific changes in MeC and hmC using 
RRBS and oxoRRBS. The sites with changes in methylation and hydroxymethylation were 
assigned with the nearest gene and analyzed using IPA to identify any enrichment in 
diseases and functions associated with those genes. For each group of genes input into IPA, 
increased MeC, decreased MeC, increased hmC, and decreased hmC, the overwhelming 
enrichment focused on various cancers (Tables 4.3-4.6). This indicates that exposure to 
cigarette smoke induces epigenetic changes in site-specific levels of MeC and hmC at 
genes that are associated with carcinogenesis.  
 Changes in site specific methylation and hydroxymethylation observed by RRBS 
and oxoRRBS in mice exposed to cigarette smoke (Figure 4.4) prompted us to investigate 
the epigenetic effects of tobacco carcinogen NNK and inflammatory agent LPS. From these 
analyses, we report a measurable change in global DNA methylation and 
hydroxymethylation that triggers gene expression changes in the A/J mouse model of 
smoking induced lung cancer. We found that global levels of MeC, hmC, and fC were 
unchanged in NNK-treated animals, but were affected in animals treated with LPS only or 
a combination of NNK and LPS. A 33% change in global hmC levels was observed in mice 
treated with LPS for 15 days. However, changes in global MeC were not observable until 
chronic treatment with LPS, at which point LPS and NNK/LPS treatments increased the 
amount of MeC by 6% and 5% respectively. Similarly, fC was increased by 2-fold after 
the same chronic treatment with LPS and NNK/LPS. This suggests that measurable 
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changes in global hmC occurred after 15 days of exposure to inflammation, while 
measurable changes in MeC and fC occur between two and six weeks of exposure to LPS, 
which indicates that hmC may be an early indicator of epigenetic shift in our model. 
 Based on the site-specific changes in cytosine methylation and hydroxymethylation 
in cigarette smoke exposed mice and the changes observed in global levels of MeC and 
hmC following 6 week exposure to LPS, we investigated whether NNK, LPS, or both in 
combination altered site specific methylation by pyrosequencing. DAPK1, CDH13, and 
Rassf1 were selected based on changes observed in lung cancer patients,110, 335-340 TET1 
was selected based on the decreases observed in hmC at 6 weeks, and the AHRR gene was 
selected based on its association with cigarette smoking.296, 341-342 In these genes, we 
observed an overall increase in CpG methylation due to the exposure to NNK, LPS, or 
NNK and LPS with both LPS and NNK plus LPS having the most pronounced changes. 
The increases were significant for LPS treatment in CDH13 (CpGs 1 and 4) and Rassf1 
(CpG 3), and in NNK plus LPS treatment in Rassf1 (CpG 3), DAPK1 (CpG 4), CDH13 
(CpGs 1 and 4), TET1 (CpG 7), and Rassf1 (CpG 3). These increases of methylation for 
tumor suppressor genes DAPK1, CDH13, Rassf1, and TET1 correspond to decreased 
expression observed in qRT-PCR of mice treated for 9 weeks. Our results showing 
increased methylation of key genes agree with previous work which showed that the 
expression of Rassf1a, CDH13 and DAPK1 is decreased in lung cancer due to increased 
gene methylation,338, 343-344 In addition, DAPK1 and CDH13 have increased methylation 
after 6 weeks of exposure.   
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 Histone lysine acetylation is generally associated with open chromatin and 
transcriptional activation.297 Our data revealed globally decreased acetylation abundance 
on histone H3 and H4 N-terminal sites upon NNK and LPS treatment, suggesting a 
potential transcriptional repression effect under these chemical treatments. 
Hypoacetylation of histone H4K16 has been reported in lung cancer.345 The phenomenon 
is strongly associated with the overexpression of histone deacetylases and the activity 
loss/mutations in histone acetyltransferases in lung cancer cells.346  In addition, LPS 
treatment has been previously shown to induce histone deacetylase expression and reduce 
histone acetylation abundance.347 Loss of histone acetylation, together with altered DNA 
methylation patterns, contribute to the accumulation of suppressive epigenetic marks and 
the decrease in expression of important tumor suppressor genes. 
 Gene expression analyses by qRT-PCR have revealed that the observed changes in 
global MeC, hmC, fC amounts coincide with a decrease in expression of Tet1 and Tet3 in 
NNK and LPS treated mice. These changes in gene expression support previous reports 
showing reduced Tet expression in tumors.334 Although gene expression of Tet1 and Tet3 
is decreased in lung tissue after 9 weeks of treatment with both NNK and NNK/LPS, global 
MeC and hmC in lung tissue were unchanged after 6 weeks in NNK treatment relative to 
control (Figure 4.8). In addition, Tet1 gene expression levels in lung tissue after 9 weeks 
of treatment shows a 10% decrease from vehicle to NNK and an even greater (35%) 
decrease for combined NNK/LPS treatment group. These results suggest that NNK 
exposure and inflammation work synergistically at early stages of exposure to cigarette 
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smoke to reduce Tet expression in the lung. Significant changes in gene expression were 
observed after 9 weeks of treatment and persisted through 22 and 44 weeks and tumor 
development. Specifically, the genes for which expression is decreased by 20% or more at 
9 weeks, such as Cdh13, Prdm2, Gata2, and Rassf1 show significant decreases after tumor 
formation by both 22 and 44 weeks. Gata2 is decreased 75% in NNK induced tumors 
relative to control compared to 20% in mouse lung tissue from mice treated for 9 weeks 
with NNK.  
 To investigate the mechanisms by which gene expression levels were affected, we 
explored promoter methylation for a subset of those genes. For Rar-β, we observed 
methylation of the promoter which corresponded to a decrease in gene expression. Cdh13 
promoter was methylated in both vehicle and NNK/LPS treated mice, making its role in 
regulation of gene expression unclear. These results suggest that gene promoter 
methylation is not the only mechanism responsible for controlling gene expression. It is 
possible that gene expression could be controlled by other regulating factors such as histone 
modifications, RNA processing, changes in N6-methyladenosine increasing RNA 
lifetimes348 or miRNA.349 
Our results indicate global epigenetic changes in the lung precede the formation of 
tumors, and that epigenetic changes are mediated by inflammation. We also observe that 
accompanying the epigenetic changes were altered gene expression levels generally 
resulting in decreased expression. We propose that inflammation-mediated early epigenetic 
changes in the lung lead to profound changes in gene expression of tumor suppressor 
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proteins, contributing to lung cancer etiology. Future studies should focus on defining the 
timing and contributions of changes in hmC in lung carcinogenesis, and the mediators 
responsible.  
Overall, our study using a well-established A/J mouse model for smoking induced 
lung cancer demonstrate that NNK and LPS treatments are sufficient to alter the global 
epigenetic landscape of cytosine methylation, cytosine hydroxymethylation, and histone 
acetylation, potentially predisposing pulmonary cells to the onset of tumorigenesis. In our 
future studies, oxoRRBS will be employed to characterize methylation changes with single 
nucleotide resolution in type II alveolar cells of laboratory mice exposed to cigarette 
smoke. Identification of aberrantly regulated histone acetylation sites upon NNK and LPS 
treatments will allow us to further investigate the mechanisms of chemical-induced 
alterations in the enzymatic activities of histone deacetylases and acetyltransferases that 
regulate these epigenetic marks during lung cancer progression. In addition, genome-wide 
ChIP-seq analysis targeting these histone acetylation sites will provide further details on 
the locus-specific dynamics of the epigenetic reprogramming induced by the chemical 
treatments. These data, oxoRRBS and ChIP-Seq, when combined with RNA-Seq analysis 
will allow us to determine specific cellular pathways that are transcriptionally suppressed 
and therefore contribute to the smoking mediated development of lung cancer. 
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V. EPIGENETIC EFFECTS OF INFLAMMATION IN TYPE II ALVEOLAR 
CELLS OF A/J MICE TREATED WITH LIPOPOLYSACCHARIDE  
Adapted from: 
Seiler, C. L.; Song, J.M.; Fernandez, J.; Abrahante, J.E.; Chen, Y.; Ren, Y.; Kassie, F.; 
and Tretyakova, N. Y.; Epigenetic Effects of Inflammation in Type II Alveolar Cells  
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5.1 Introduction 
Lung cancer is a leading cause of cancer deaths world-wide and is expected to kill 
154,050 Americans this year, with over 80% of cases directly attributable to smoking.101 
Cigarette smoke contains 60+ known carcinogens104 and co-carcinogens, including 
bacterial endotoxin lipopolysaccharide (LPS) (2,400 ng/pack).105 LPS induces an immune 
response in mammalian cells by interacting with the toll-like receptor 4 (TLR4).295 This 
interaction is mediated by MD-2 and CD14, which are necessary for TLR4 recognition and 
shuttling LPS toward TLR4, respectively.295 Through downstream signaling pathways, 
TLR4 activates NF-κB, which controls the expression of proinflammatory cytokines and 
immune related genes.295  
Inflammation of the lung, which is observed in chronic obstructive pulmonary 
disease (COPD), increases the risk of developing lung cancer.131, 350  The majority of 
smoking-induced lung cancers are defined as adenocarcinomas,121 which can arise from 
the alveolar type II cells in the lung.225 Type II cells have the ability to rapidly proliferate 
and differentiate following lung injury.225, 351 In addition, type II cells can increase in 
number following exposure to LPS.352 The proliferative ability and stem-like nature of type 
II cells makes them a key target for investigating the effects of LPS mediated inflammation 
in connection with lung carcinogenesis.  
 Lung cancer is characterized by both genetic and epigenetic changes, or so called 
“epimutations”.315 Changes in the patterns of  DNA methylation can lead to aberrant gene 
expression, which in turn play a role in carcinogenesis by upregulating protooncogenes and 
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downregulating tumor suppressor genes.11 DNA methylation is catalyzed by DNA 
methyltransferases (DNMT), which methylate the C5 position of cytosine to form 5-
methylcytosine (MeC).11 Methylation of gene promoter sequences typically leads to 
reduced levels of gene expression.319 Methylation marks can be removed via active or 
passive DNA demethylation.353 Ten Eleven Translocation (TET) family of proteins 
iteratively oxidize MeC to form 5-hydroxymethylcytosine, 5-formylcytosine, and 5-
carboxycytosine.13-15 Oxidized forms of MeC are also hypothesized to have their own 
epigenetic functions.203  
In our previous work, we investigated epigenetic alterations in mouse lung 
following inhalation exposure to cigarette smoke and LPS (Chapter 4 of this Thesis). We 
found that methylation and hydroxymethylation status of many genes was affected, 
including many genes involved in carcinogenesis (Figure 4.12 in Chapter 4 of this Thesis). 
However, the earlier study employed whole lung tissue, which is composed of many cell 
types including Type I and Type II alveolar epithelial cells, lung capillary endothelial cells, 
and fibroblasts, each with distinct epigenomes. Exposure to cigarette smoke and 
inflammatory agents may disproportionally affect different cell types. Furthermore, 
inflammation is associated with significant changes in cellular composition of the lungs, 
specifically macrophage infiltration and neutrophil accumulation.354 Therefore, studies 
utilizing whole tissue are unable to detect cell type-specific epigenetic changes. In the 
present study, we aimed to investigate the epigenetic responses of alveolar type II cells in 
the lung towards LPS induced inflammation in the A/J mouse model.   
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5.2 Materials and Methods 
Chemicals and Enzymes  
PDE I, PDE II, and DNase I were purchased from Worthington Biochemical Corp. 
(Lakewood, NJ), while calf intestinal alkaline phosphatase was from Sigma-Aldrich, 
(Madison, WI).  Nanosep10K filters were acquired from Pall corp. (Port Washington, NY). 
O-(Biotinylcarbazoylmethyl) hydroxylamine was obtained from Cayman Chemical (Ann 
Arbor, MI). Isotopically labeled D3-hmC was purchased from Cambridge Isotope Labs 
(Cambridge, MA). 13C10,15N2-5-methyl-2ʹ-deoxycytidine and 13C1015N2-5-formyl-2ʹ-
deoxycytidine were synthesized as previously described in Chapters II and IV.20 All other 
chemicals used were bought from Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific 
(Fairlawn, NJ). 
 
Animal Treatments  
 Female A/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and 
housed in specific-pathogen-free animal quarters at Research Animal Resources, 
University of Minnesota Academic Health Center. All animal experiments were performed 
according to the U.S. National Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee, University of Minnesota. 
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LPS treatment:  Female A/J mice (8 weeks of age) were divided into 2 groups (7 per group) 
and treated intranasally under isoflurane anesthesia. Mice in Group 1 were treated with 
physiological saline (50 µL) every day for 4 days and mice in group 2 were treated with 
lipopolysaccharide (LPS), 2 µg in 50 µL of physiological saline on day 1 and 5 µg in 50 
µL saline on days 2-4. Mice were euthanized in a CO2 chamber after 4 days of treatment. 
 
Isolation of Type II alveolar cells from lung tissue: 
 Type II alveolar cells were isolated from whole lung tissues according to published 
procedures.352, 355 Lung tissues were perfused with 30 mL of PBS. The whole lung tissue 
was then injected with 3 mL dispase (5 U/mL, Stem Cell Technology, Vancouver Canada) 
and placed on ice. Tissues were finely minced, and additional 60 µL dispase (5 U/mL) and 
7.5 µL DNase I (2 U/µL, Thermofisher Scientific, Fairlawn, NJ) was added prior to 
incubation at 37 °C for 45 min, with inverting every 5 min. Dissociated cells were pushed 
through a 100 micron cell strainer, followed by a 40 micron cell strainer (Corning, Corning, 
NY) to remove connective tissue. To the resulting cells, RBC lysis buffer (e-Biosciences, 
San Diego, CA) was added and mixed every 5 min for 30 min at room temperature. The 
suspension was centrifuged, the supernatant was removed, and the cells were resuspended 
in 50:50 DMEM/F-12 media. The cells were plated on dual antibody coated plates prepared 
24 h in advance with anti-mouse CD16/CD32 and anti-mouse CD45.1 (e-Biosciences). 
After incubation for 2 hours at 37 °C to facilitate negative selection for type II alveolar 
cells, the media containing the suspended type II alveolar cells was removed and pelleted 
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by centrifugation. Cells were lysed and stored at -80 ℃ in 750 µL of Trizol Reagent 
(Thermo Fisher, Fairlawn, NJ) until DNA/RNA isolation. 
 
HPLC-ESI+-MS/MS quantitation of MeC, hmC, and fC:  
 Genomic DNA was extracted from type II cells using Trizol extraction protocol 
according to the manufacturer’s protocol. DNA purity and concentration were determined 
by UV spectroscopy. Genomic DNA (1-2 µg) was subjected to hydrolysis with PDE I (3.6 
U, 5 g), PDE II (3.2 U), DNase I (50U), and alkaline phosphatase (10 U) in 10 mM Tris 
HCl/15 mM MgCl2 buffer (pH 7) at 37 °C overnight. The hydrolysates were spiked with 
13C1015N2-5-methyl-2′-deoxycytidine (1 pmol), 5-hydroxymethyl-d2-2′-deoxycytidine-6-d1 
(900 fmol), and 13C1015N2-5-formyl-2′-deoxycytidine (500 fmol) (internal standards for 
mass spectrometry synthesized in our laboratory, see Chapters II and IV)20 and filtered 
through Nanosep 10K Omega filters (Pall Corporation, Port Washington, NY).  
 DNA hydrolysates were dissolved in 100 mM ammonium acetate buffer (pH 4.5) 
containing 100 mM aniline and 400 µM of O-(biotinylcarbazoylmethyl) hydroxylamine 
(Cayman Chemical. Ann Arbor, MI) and allowed to react for 24 h to derivatize fC to 
biotinyl-fC.14 The resulting mixture was dried, followed by offline HPLC to enrich for 
MeC, hmC, biotinyl-fC, and caC using an Atlantis T3 column (Waters, 4.6 x 150 mm, 3 
µm) was eluted at a flow rate of 0.9 mL/min with a gradient of  5 mM ammonium formate 
buffer, pH 4.0 (A) and methanol (B). Solvent composition was changed linearly from 3 to 
30% B over 15 min, increased to 80% over the next 3 min, maintained at 80% B for the 
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next 2 min, and brought back to 3 % B. The column was equilibrated for 7 min prior to the 
next injection. dC was quantified by HPLC-UV using calibration curves obtained by 
analyzing authentic dC standards. HPLC fractions corresponding to MeC, hmC, caC, and 
biotinyl-fC (7-8.6 min for both hmC and caC, 9-10.5 min for MeC, and 18.7-20.2 min for 
biotinyl-fC) were combined, dried, and analyzed by isotope dilution HPLC-ESI-MS/MS. 
  Quantitation of MeC, hmC, and biotinyl-fC was performed using a Dionex 
Ultimate 3000UHPLC (Thermo Fisher, Waltham MA) interfaced with a Thermo TSQ 
Vantage mass spectrometer (Thermo Fisher). Chromatographic separation was achieved 
on a Zorbax SB-C18 column (0.5 x 150 mm, 3 µm, Agilent) eluted at a flow rate of 15 
L/min with a gradient of 2 mM ammonium formate (A) and methanol (B). Solvent 
composition was maintained at 5% B for the first 3 min and linearly changed from 5 to 
40% B for 7 min. Solvent composition was returned to initial conditions (5% B), and the 
column was re-equilibrated for 4 min. Under these conditions, MeC and 13C1015N2-MeC 
eluted at 4.1 min, both hmC and the internal standard d3-hmC eluted at 3.5 min, while 
biotinyl-fC and its internal standard (13C1015N2-biotinyl-fC) eluted at 7.0 min. Quantitation 
was achieved by monitoring the transitions m/z 258.1 [M + H+]  m/z 141.1 [M – 
deoxyribose + H+] for hmC, m/z 261.2 [M + H+]  m/z 145.1 [M – deoxyribose + H+] for 
D3-hmC, m/z 242.1 [M + H+]  m/z 126.1 [M + H+] for MeC, m/z 254.2 [M + H+]  m/z 
133.1 [M + H+] for 13C1015N2-MeC, m/z 569.1 [M + H+]  m/z 453.3 [M – deoxyribose + 
H+] for Biotinyl-5fC, m/z 581.2 [M + H+]  m/z 460.4 [M – deoxyribose + H+] for 
Biotinyl-13C1015N2-5fC. Mass spectrometer were determined by infusion of authentic 
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standards. Typical settings on the mass spectrometer were: a spray voltage of 2700 V, a 
sheath gas of 15 units, the declustering voltage was 5 V, and the ion transfer tube was 
maintained at 350 ℃. The full-width at half-maximum (FWHM) was maintained at 0.7 for 
both Q1 and Q3. Fragmentation was induced using a collision gas of 1.0 mTorr and a 
collision energy of 10.3 V. 
 
Histone acetylation analysis:  
 Type II alveolar cells isolated from the lungs of control and treated mice were 
homogenized with a glass douncer on ice. Total histones were extracted from the lysates 
as previously described.289-290 Histone proteins were acetylated with (13C2,d3)-acetyl N-
hydroxysuccinimide ester to block all unmodified lysines and then digested by trypsin.290 
The peptides were desalted with C18 Stage Tips (3M Corporation, St. Paul, MN) prior to 
analysis.356  
Tryptic peptides were analyzed by nano-flow liquid chromatography electrospray 
tandem mass spectrometry (nanoLC-ESI-MS/MS) using a Thermo Scientific Orbitrap 
Fusion mass spectrometer (Thermo Scientific, San Jose, CA) coupled to a Proxeon Easy 
nLC 1000 UPLC system (Thermo Fisher Scientific, Odense, Denmark). Each sample was 
resuspended in HPLC buffer A (0.1% formic acid in water) and loaded onto an in-house 
packed C18 column (25 cm x 75 m I.D.) packed with ReproSil-Pur Basic C18 beads (2.5 
μm, Dr. Maisch GmbH). Peptides were eluted with a gradient of 5% to 15% B (0.1% formic 
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acid in acetonitrile) over 26 minutes, then 15% to 35% HPLC buffer B over 16 minutes at 
300 nL/min.  
Tryptic peptides were analyzed using a FT survey scan from 300-1600 m/z at a 
resolution of FWHM 120,000 (at 200 m/z), followed by HCD MS/MS scans using the top 
speed mode (3 seconds per cycle) at a resolution of FWHM 15,000 (at 200 m/z) and a 
normalized collision energy at 35%. Targeted MS/MS data acquisition was achieved with 
an inclusion list for fully labeled histone tryptic peptides that covered known lysine 
acetylation sites. For each peptide, modification isomers with all possible combinations of 
light/heavy lysine acetylation (∆ M of 42.010565 and 47.036094 Da, respectively) at 
detectable charge states were considered in the inclusion list for targeted fragmentations.  
 MS data was searched against the Uniprot Mus musculus proteome database 
(http://www.uniprot.org) using MaxQuant search engine (v1.4.1.2) as previously 
described.357-358 Heavy and light acetylation on lysine as well as methionine oxidation 
were included as variable modifications, with 6 ppm specified as the precursor mass error 
and 0.025 Da as the fragment mass error. All peptide spectra matches were filtered at 1% 
False Discovery Rate with a minimum Andromeda score cutoff of 40. HPLC elution 
profiles were manually evaluated to ensure accurate quantifications. Only peptides that 
were confidently identified were selected for stoichiometry analysis. Acetylation 
stoichiometries of specific sites were calculated using in-house developed scripts based 
on the extracted peak areas of each modification isomer and quantification of 
modification-specific fragment ions.290 Statistical significance analysis of site-specific 
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acetylation stoichiometry dynamics between control and treated samples was conducted 
with two-sided Student’s t-test using SAS statistical software 9.3 (SAS Institute Inc., 
Cary, NC). 
 
RNA-Seq of type II cell mRNA:  
 Type II cells were stored in Trizol (Thermo Fisher) at -80 ℃to minimize RNA 
degradation. RNA was isolated using Qiagen miRNeasy kits (Qiagen, Hilden Germany) 
according to the manufacturer’s instructions. RNA was quantified using a fluorometric 
RiboGreen assay (Thermo Fisher). RNA integrity was confirmed using Agilent 
Bioanalyzer (Agilent, Santa Clara CA). Samples with RNA integrity score higher than 7 
were selected for RNA-Seq. Total RNA samples were converted to Illumina sequencing 
libraries using SMARTer Stranded Total RNA-Seq Kit – Pico Mammalian Input (Takara 
Bio USA, Mountain View CA).  RNA was reverse transcribed into cDNA, and Illumina 
adapters were added using PCR. rRNA was cleaved with ZapR and R-Probes, and the 
uncleaved fragments were enriched by PCR. Final library size distribution was validated 
using capillary electrophoresis and quantified using fluorimetry (PicoGreen) and via Q-
PCR.  Indexed libraries were normalized, pooled, and size selected to 320bp +/- 5% using 
Caliper’s XT instrument (PerkinElmer, Waltham MA).  Truseq libraries were hybridized 
to a single read flow cell, and individual fragments were clonally amplified by bridge 
amplification on the Illumina cBot using the HiSeq SR Cluster Kit v4 cBOT (Illumina, San 
Diego CA).  Sequencing was performed on the Illumina HiSeq 2000 sequencing system 
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using Illumina’s SBS chemistry.  Primary analysis and de-multiplexing are performed 
using Illumina’s CASAVA software 1.8.2. 
 Data was imported into CLC Bio Genomics Workbench 7 (CLC Bio, Qiagen, 
Boston, MA) for quality, mapping, and expression analysis. Principal component analysis 
was performed using Emperor.359 Significantly dysregulated genes were clustered with 
Cluster 3.0, visualized with Java TreeView, and input into Ingenuity Pathway Analysis 
(Qiagen, Boston MA).  
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5.3 Results 
Epigenetic changes in type II lung cells following intranasal treatment with LPS 
 Since our earlier data revealed that exposure to LPS induced epigenetic changes in 
the whole lung (Figure 4.6 in Chapter IV of this thesis), we hypothesized that epigenetic 
deregulation is also induced in type II alveolar cells, which possess a high proliferative 
potential.225 Alveolar cells Type II cells are considered the cells of origin for non-small cell 
lung cancer (NSCLC) development.225 Cell panning methodology was used to isolate type 
II alveolar cells from lung tissues of mice treated with LPS for 4 days and the corresponding 
controls. Total RNA and DNA of type II alveolar cells was extracted using Trizol (Thermo 
Fisher). Global cytosine methylation (MeC) levels in type II cells isolated from control and 
LPS treated mice was 5.19 ± 0.99 and 5.32 ± 0.71 % of Cs, respectively (Figure 5.1). 
Cytosine hydroxymethylation in genomes of type II cells was decreased in LPS treated 
mice as compared to controls (0.36 ± 0.08% of Cs vs 0.51 ± 0.26, p = 0.13). Similarly, the 
levels of fC in type II cells showed a statistically significant decrease in LPS treated 
animals relative to controls (0.0030 ± 0.002 vs 0.0009 ± 0.0005 % of Cs, respectively, p = 
0.039). These data suggest that LPS induced inflammation influences the global levels of 
hmC and fC in the type II alveolar cells. Similar trend was observed in type II cell depleted 
lung tissues, although fC changes were not statistically significant (Figure 5.2).  
241 
 
Figure 5.1. Global levels of MeC, hmC and fC, in genomic DNA isolated from type II 
alveolar lung cells of female A/J mice treated intranasally with LPS (4 µg/ day) for 4 days. 
Data represent mean values ± SD of at least three animals.  Statistics were calculated using 
the Wilcoxon-Mann-Whitney test, p-values: MeC (0.836), hmC (0.366), and fC (0.035).   
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Figure 5.2. Global levels of MeC, hmC and fC, in genomic DNA isolated from type II 
cell-depleted lung tissues of female A/J mice treated with LPS intranasally (4 µg/ day) for 
4 days. Data represent the mean ± SD of at least 4 animals. Statistics were calculated using 
the Wilcoxon-Mann-Whitney test, p-values: MeC (0.4), hmC (0.4), and fC (0.229).  
 
  
243 
 
Gene expression changes in type II cells from LPS treated A/J mice  
 To determine whether LPS-associated changes in cytosine methylation and 
hydroxymethylation lead to changes in gene expression, we conducted RNA-Seq analyses 
using mRNA isolated from the same sample. Total sequencing reads for each sample were 
within at least 95% of the targeted 20 million reads for each sample. One treated sample 
had 68.6 million total number of reads, with the rest ranging from 19.3 – 29.1 million reads. 
Using gene expression profiles, unsupervised principal component analysis was conducted. 
PCA analysis indicated that control and LPS treated samples separate into two distinct 
clusters (Figure 5.3C) indicative of significant gene expression changes associated with 
inflammation. 
 RNA-Seq data was interrogated using the Cuffdiff program available from the 
Broad Institute.360 A total of 1,064 genes exhibited altered levels of gene expression (fold 
change > 2) in Type II cells of LPS treated animals. A subset of dysregulated genes is 
shown in Figure 5.3A as an expression heatmap with clustering. Data for a subset of genes 
associated with tumor suppression, epigenetic regulation, and the inflammation response 
is shown in more detail in Figure 5.3B. Differentially expressed genes were annotated and 
analyzed using Ingenuity Pathway Analysis (IPA) to identify key biological processes, 
pathways (Figure 5.4A), and networks affected by LPS treatment. Top diseases and 
biological functions associated with LPS treatment in type II cells included immunological 
disease, metabolic disease, immune cell trafficking, cellular movement, and cell to cell 
signaling and interaction. The most upregulated genes were STFA2, STFA3, SAA3, and 
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LY6I (Figure 5.4B), while the most downregulated genes were CDH4, CHIL4, NXF7, and 
CYP2A5. The STFA2 and STFA3 genes are both protease inhibitors of papain-like 
cysteine proteases in the cytoplasm, which prevents the degradation of proteins.361 SAA3 
has been shown to be a protumorigenic mediator in fibroblasts associated with pancreatic 
cancer362 and the LY6I protein is associated with inflammation, but its function remains 
unknown.363 The downregulated gene CDH4 functions as a tumor suppressor gene in lung 
cancer364 and has been shown to be hypermethylated in other cancers.365 The CHIL4 gene 
is associated with tissue remodeling and wound healing.366  NXF7 is part of a family of 
nuclear export factors and function in mRNA processing in the cytoplasm.367 CYP2A5 is 
responsible for bioactivation of carcinogens such as NNK.368  
Of the 1064 genes dysregulated by exposure to LPS, 859 were identified as being 
related to cancer, including genes involved in cell proliferation and cell growth. Some 
examples included matrix metalloproteinase-9 (MMP9), interferon-γ (IFN-γ), and nitric 
oxide synthase 2 (NOS2).369 MMP9 assists in breaking down the extracellular matrix to 
allow for cell growth.370 NOS2 is an upstream regulator of MMP9 expression, and in 
increase in NOS2 expression results in an increase in MMP9 expression.369 IFN-γ is an 
inflammation response gene responsible for signaling and controlling the immune 
response.371 Another large group (N = 269) included genes associated with cell 
differentiation, such as NOS2 and DNMT3L and proliferation with 405 genes including 
DAPK1, CDH13, IL21, and MMP9. DNMT3L protein is a key scaffolding protein 
facilitates the formation of productive complexes with DNMT3A and DNMT3B, which 
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perform de novo DNA methylation.372 DAPK1 and CDH13 are tumor suppressor proteins 
that are involved in cell survival and adhesion respectively, and are typically inactivated 
in lung cancer.340, 373 IL21 is a cytokine that is induced in the inflammation response and 
signals CD8+-T cells to expand at the site of inflammation.374 
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Figure 5.3. Effects of LPS induced inflammation in the lungs of A/J mice on gene 
expression in type II alveolar cells. A, Gene expression heat map represented as row z-
score and unsupervised hierarchal clustering. B, Heat maps showing gene expression 
changes in tumor suppressor genes, epigenetic regulators, and inflammation-associated 
genes. C, Principle component analysis of the gene expression changes observed in type II 
cell (red and blue) and in lung tissue of A/J mice following chronic exposure to NNK, LPS, 
and NNK/LPS.142 
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Figure 5.4. LPS-induced gene expression changes in type II alveolar cells of female A/J 
mice. A, Enrichment of canonical pathways of the 1064 differentially expressed genes 
assessed by IPA software. Top 20 pathways are shown. B, Genes showing the largest 
changes in gene expression.  
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Histone acetylation changes in type II cells 
Acetylation of histone proteins is a key regulatory mechanism that maintains 
epigenetic memory in eukaryotic cells.297 Acetylation of histones H3 and H4 correlates 
site-specifically with the global gene expression profiles and transcriptional activation,298-
299 while the dysregulation of histone acetylation contributes to tumorigenesis and disease 
progression in lung cancer.298, 300 To determine whether LPS treatments induce global 
changes in histone acetylation in type II cells, we employed a chemical proteomics strategy 
that enables site-specific identification of the lysine acetylation.290  
Histone proteins were extracted from type II cells from A/J mice treated with LPS 
for 4 days and control mice, labeled, and analyzed by nano HPLC-ESI+-MS/MS as 
described previously.289 The data were analyzed by in-house developed scripts to calculate 
site-specific acetylation stoichiometries.290 Our data indicates that LPS treatment induced 
global deacetylation of H3K14 and H3K23 in type II cells (Figure 5.5), while H3K9, 
H3K18, and H4 showed no change. Acetylation of H3K14 and H3K23 are strongly 
associated with active gene expression.299, 301-304  
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Figure 5.5. LPS-induced changes in histone lysine acetylation stoichiometry observed in 
isolated type II cells of A/J mice intranasally treated with LPS. Data were expressed as 
percent acetylated and represents mean values ± SD of at least 3 animals. Statistical 
significance was evaluated between treated and control samples using a two-sided 
Student’s t-test (* p< 0.05, ** p<0.01). Histone acetylation stoichiometries were assessed 
to determine global gene activation by deacetylation due to exposure. Measured acetylation 
sites include lysines 5, 8, 12, and 16 on histone H4 and lysines 9, 14, 18, and 23 on Histone 
H3. 
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5.4 Discussion 
 The link between inflammation and the development of cancer is well established. 
Specifically, people with chronic inflammatory bowel diseases, such as ulcerative colitis, 
Lynch syndrome, and Crohn’s disease have an increased risk of colon cancer,132 and COPD 
patients are more likely to develop lung cancer.131, 375 Anti-inflammatory drugs as aspirin 
may reduce colorectal cancer risk.313, 376 In 2016, U.S. Preventive Services Task Force 
recommended the use of aspirin to prevent colorectal cancer among many U.S adults. 
However, the underlying mechanisms are not completely understood.131, 377  
In our earlier study, female A/J mice treated with inflammatory agent 
lipopolysaccharide, exhibited profound epigenetic changes in the lung including altered 
DNA hydroxymethylation, histone acetylation, and gene expression changes (Chapter IV 
of this Thesis). This led us to hypothesize that epigenetic deregulation could provide a link 
between inflammation and lung cancer. In the present study, we aimed to characterize LPS-
associated epigenetic changes in Type II alveolar cells, which are thought to be the cells of 
origin for non-small cell  lung cancer due to their high proliferative potential and stem-cell 
like nature.225  
Female A/J mice were intranasally treated with LPS for 4 days, and their lung 
tissues were harvested and subjected to cell panning to enrich for Type II cells. Isotope 
dilution cap HPLC-ESI-MS/MS was employed to accurately quantify global MeC, hmC, 
fC in DNA, while histone acetylation was accessed by mass spectrometry based 
proteomics, and overall changes in gene expression were characterized by RNA seq.  While 
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LPS treatment did not affect global levels of MeC in type II cells, a 30% decrease in hmC 
and 70% decrease in fC was observed (Figure 5.1). The type II depleted lung cells showed 
no change in hmC and a decrease in fC, which was not statistically significant. These 
results suggest that type II cells are more prone to inflammation mediated epigenetic 
deregulation the other cell types in the mouse lungs.  
RNA-Seq has revealed significant LPS induced gene expression for several tumor 
suppressor genes associated with lung tumorigenesis, e.g. decreased expression of DAPK1 
and CDH13 and increased expression of NOS2 (Figure 5.3A). The expression of 
cytochrome P450 1A1, 2A5, and 2F2 responsible for metabolism of cigarette smoke 
constituents were increased was decreased. Additionally, expression levels of many 
proinflammatory genes such as IFN-γ, CCL4, IL21, CXCL9, and CXCL10 were increased 
(Figure 5.3B). Interestingly, DNMT3L, which is a scaffolding protein for DNA 
methyltransferases DNMT3A/B, showed a significant 18-fold increase in expression upon 
LPS treatment (Figure 5.4B). Overall, the list of deregulated genes was enriched in tumor 
suppressors, epigenetic regulators, and genes associated with inflammation response. 
which are consistent with LPS causing epigenetic changes that contribute to the etiology 
of lung cancer.  
Our RNA-Seq data for type II cells was compared with published whole lung data 
from Qian et al. in the same mouse model treated with LPS and NNK.142 Principal 
component analysis (Figure 5.3C) of the data sets indicates that the type II cells (red and 
blue) are distinct from their whole tissue counterparts (orange and purple) and that 
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exposure to LPS causes a shift up and to the left for both type II cells (blue) and whole 
tissue (purple) relative to the respective controls (red and orange). To compare the results 
from isolated cells and whole tissue RNA-Seq, we analyzed the published data alongside 
the type II cell data using Ingenuity Pathway Analysis. We directly compared upstream 
regulators for LPS treated type II cells and whole lungs treated with NNK, LPS, or NNK 
and LPS and found that many of the top regulators are indeed the same, such as MYD88, 
NOS2, TNF and many interleukins (Figure 5.6A). We also noted that the isolated type II 
cells shared many upregulated genes with lung tissue exposed to chronic LPS (Figure 
5.6B). Even though there were many similarities, there were also many upstream regulators 
that were identified in whole tissue experiments that were not considered upstream 
regulators in type II cells by IPA including TET2, EGF, MEK, and FOX01 (Figure 5.6A). 
Taken together, the type II cells isolated from mice treated with LPS for a single week 
present many characteristics similar to long term inflammation exposure mediated by LPS 
and these gene expression changes occur prior to large changes in epigenetics at the global 
level. These changes in gene expression of type II cells indicate that the effects of 
inflammation on transcription occur rapidly in these important cells and that inflammation 
could contribute to an altered epigenetic state pushing the type II cells toward a cancerous 
phenotype.  
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Figure 5.6. Comparison of RNA-Seq data obtained in this study (type II cells) to 
previously published data of Qian et al. exploring chronic exposure to NNK, LPS, or NNK 
and LPS in whole lung tissue.142 (A) Ingenuity Pathway Analysis of upstream regulators 
increased or decreased in type II cells and whole lung chronic treatment. (B) Venn diagram 
of the significantly upregulated genes (4-fold increased and q < 0.05)) in the combined data 
set with type II cells with LPS (T2 cells LPS) and whole lung RNA-Seq after chronic 
administration of LPS, NNK, or NNK and LPS. 
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To understand how gene expression changes in the lung could be influenced by 
changes in site-specific DNA methylation and hydroxymethylation, we compared RNA-
Seq expression data to RRBS data described in Chapter IV of this Thesis. RRBS and 
oxoRRBS were used to determine the site-specific methylation and hydroxymethylation 
levels in lung DNA from A/J mice exposed to environmental tobacco smoke for 10 weeks 
or controls. These data are based on sequencing of DNA from whole lung tissue and 
represent a heterogenous lung cell population compared to isolated type II cells used for 
RNA-Seq analysis. In addition, the DNA used for RRBS data collection come from mice 
exposed to cigarette smoke, a complex mixture of carcinogens and co-carcinogens, while 
RNA-Seq was performed on cells from mice treated with LPS. The differences between 
the sample composition and treatment strategy allow the drawing of tenuous conclusions.  
To compare the RRBS and RNA-Seq data, the changes in gene expression observed 
in type II cells were associated with changes in DNA epigenetic marks, genes that exhibited 
altered DNA methylation and hydroxymethylation in A/J mice treated with environmental 
tobacco smoke for 10 weeks140, 291 (Figure 4.2 in Chapter II of this thesis) were plotted 
against the gene expression heat map for type II cells of A/J mice treated with LPS. Using 
this analysis, genes exhibiting increased methylation show an enrichment for genes with 
reduced transcription (Figure 5.7A). Similarly, genes with increased hmC also show an 
enrichment for genes with reduced transcription (Figure 5.8A). For both set of genes 
having decreased levels of MeC or hmC, there is little enrichment for gene expression 
changes showing an increase or decrease (Figure 5.7B and Figure 5.8B, respectively). A 
255 
 
correlation of DNA methylation and reduced gene expression is well known in the 
literature.318, 336-337, 339 More interesting are the increases in hydroxymethylation, which 
shows an enrichment for reduced gene expression, while the decreases in hmC show little 
enrichment for changes in expression (Figure 5.8). The lack of clear association could be 
due to the prevalence of hmC in promoters and enhancer sequences, affecting transcription 
in a different way than MeC.378 
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Figure 5.7. Correlation of type II cell gene expression (Figure 5.3A) and genes with 
altered methylation identified by oxoRRBS in A/J mice exposed to cigarette smoke 
(Figure 4.2A from Chapter IV of this thesis). The top 100 increases and decreases in MeC 
were correlated with type II cell expression. A, Genes with increased levels of MeC 
(labeled on the right) show an enrichment for reduced gene expression in type II cells. B, 
Genes with decreased MeC (labeled on the right), show an enrichment for decreased gene 
expression in type II cells.  
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Figure 5.8. Correlation of type II cell gene expression (Figure 5.3A) and genes with 
altered methylation identified by RRBS and oxoRRBS in mice exposed to cigarette smoke 
(Figure 4.2A from Chapter IV of this thesis). The top 100 increases and decreases in hmC 
were correlated with type II cell expression. A, Increased amounts of hmC (labeled on the 
right) are enriched for genes with reduced gene expression (heatmap). B, Decreasing levels 
of hmC (labeled on the right) show no enrichment for the gene expression changes in type 
II cells.  
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 In summary, we elucidated the effects of LPS on the global levels of DNA 
epigenetic marks, histone acetylation, and transcriptome of type II cells from A/J mice. We 
found that short term exposure to LPS reduces the levels of hmC and fC in type II cells, 
which occurs in conjunction with the loss of H3K14 and H3K23 acetylation. Our study 
also explored the transcriptomic changes induced by acute LPS exposure and found tumor 
suppressor proteins CDH13 and DAPK1 having reduced expression. The most enriched 
upstream regulators in type II cells are the same as those observed following chronic 
exposure to LPS (Figure 5.6). Taken together these findings support type II cells as the 
sites of lung carcinogenesis and indicate epigenetic changes as a potential mechanism of 
type II cell driven lung carcinogenesis.  
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VI. AFFINITY BASED PROTEOMICS TO IDENTIFY THE READERS OF 
EPIGENETIC DNA MODIFICATIONS IN HUMAN LUNG 
 
Seiler, C.L.; Fernandez, J.; Rajczewski, A.; Trisko, P.; Andersen, M.; Han, Q.; and 
Tretyakova, N.Y. 
 
This is a collaborative work between Christopher Seiler, Jenna Fernandez, Andrew 
Rajczewski, Paul Trisko, Molly Andersen, and Qiyuan Han under the direction of Professor 
Natalia Tretyakova. Christopher Seiler performed sample preparation and LC-MS/MS and 
LC-MS/MS/MS of TMT-tagged proteomics with the assistance of Jenna Fernandez, 
Andrew Rajczewski. Paul Trisko, and Molly Andersen. Christopher Seiler analyzed the 
MS data using PD 1.4, 2.1, Scaffold, Cluster 3.0, and Java Tree View. Christopher Seiler 
and Paul Trisko utilized the DAVID informatics platform for analysis of protein readers. 
Christopher Seiler, Jenna Fernandez, Andrew Rajczewski, Paul Trisko, and Molly 
Andersen developed the methodology described herein. Christopher Seiler, Paul Trisko, 
and Molly Andersen synthesized and purified original DNA capture sequence. Qiyuan Han 
laid the ground work for and provided advice for developing the PCR amplification 
techniques for producing longer DNAs as protein pull-down baits. 
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6.1 Introduction 
 Epigenetic control of gene expression is critical in cellular differentiation and is 
required for the maintenance of cellular identity. 5-methylcytosine (MeC) is the most 
abundant and the most widely studied epigenetic modification in DNA.11 The presence of 
MeC in promoter regions of genes is generally associated with gene repression, while 
cytosine methylation in gene bodies can be associated with active transcription.11 In 2009, 
it was discovered that MeC can be oxidized to 5-hydroxymethyl-2ʹ-deoxycytidine (hmC) 
by the Ten Eleven Translocation (TET) family of proteins.13 hmC can be further oxidized 
to 5-formyl-2ʹ-deoxycytidine (fC) and 5-carboxyl-2ʹ-deoxycytidine (caC) (Figure 1.2 in 
Chapter I of this Thesis).15-16 The oxidized forms of MeC (oxiMeC) can be enzymatically 
removed by Srap1 endonuclease (SOS associated peptidase 1).21 In addition, fC and caC 
can both be excised by thymine DNA glycosylase (TDG) and subsequently replaced with 
C, leading to active demethylation and gene reactivitation.16  
In addition to their role as demethylation intermediates, oxiMeC have been 
hypothesized to possess unique epigenetic functions.14 This hypothesis is supported by 
recent studies identifying unique protein readers of MeC, hmC, fC, and caC in mouse 
embryonic stem cells (ESC) and in brain cells using synthetic DNA constructs and PCR 
amplicons.26-27 However, cellular proteomes vary greatly across different cell types, and 
protein readers of MeC, hmC, fC, and caC in tissues other than brain and cell types other 
than ESC have not previously been investigated. Because of the importance of epigenetic 
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changes in lung cancer etiology335-336, 340, 344 proteins interacting with epigenetic DNA 
marks in the lung are of interest.  
In the present report, a mass spectrometry-based approach was used to identify 
protein readers of MeC, hmC, fC, and caC in normal human bronchial epithelial cells. 
Synthetic DNA constructs derived from the WTH3 gene and containing MeC or its 
oxidized variants was used as a DNA “bait” to pull down specific protein readers from 
nuclear extracts from human bronchial epithelial cells, and the protein binders were 
identified and quantified using based mass spectrometry-based proteomics with TMT 
tags.379  
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6.2 Materials and Methods 
Materials 
 All nucleoside phosphoramidites, solvents, and solid supports for solid phase DNA 
synthesis were purchased from Glen Research Corporation (Sterling, VA). Pre-cast SDS-
PAGE gels, Pierce™ BCA Protein Assay kit, Pierce™ Quantitative Colorimetric Peptide 
Assay, Pierce™ Quantitative Colorimetric Peptide Assay, Pierce™ C18 spin columns, 
Pierce™ High pH Reversed-Phase Peptide Fractionation Kit, and TMT 6-plex reagents 
were purchased from Thermo Fisher Scientific (Waltham, MA). Mass spectrometry grade 
water and acetonitrile were purchased from Fisher Scientific (Hampton, NH). Mass 
spectrometry grade formic acid, nuclear extraction kit, and Amicon 3K filters were 
purchased from Millapore-Sigma (Burlington, MA). 
 
Solid phase DNA synthesis and purification 
 The synthetic DNA sequences used in this study were derived from the WTH3 
promoter, sequence 5ʹ-BTGTTTTCACXGCACCATTGTTTTTAGTACATATGTT-3ʹ 
(where B = biotinylated thymidine, and X = C, MeC, hmC, fC, or caC, Table 6.1). 
Oligodeoxynucleotides containing modified cytosines were synthesized on an ABI 394 
automated DNA synthesizer (Applied Biosystems, CA) according to the manufacturer’s 
recommendations. Synthetic DNA was deprotected and cleaved from solid support 
according the manufacturer’s directions. To increase DNA yields, the solid support was 
sonicated for 30 min twice in water.  
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 Synthetic DNA oligodeoxynucleotides were purified by reverse phase HPLC on an 
Agilent 1100 system interfaced with UV-VWD detector and equipped with an autosampler 
and automated fraction collector. DNA strands containing Biotin-T were purified using a 
Varian Pursuit C18 column (250 mm x 10 mm x 5 µm, Supelco, Bellafonte, PA). The 
column was eluted at 40 ℃ with a gradient of 100 mM triethylammonium acetate, pH 7 
(A) and 100% ACN (B) at a flow rate of 3 mL/min. A linear gradient of 12-22.5% B over 
36 min was employed, and the column was equilibrated for 13 min. DNA strands of interest 
typically eluted between 21-22 minutes.  
For DNA strands which did not contain biotin, a Synergi Hydro RP column (250 
mm x 10 mm x 4 µm, Phenomenex, Torrance, CA) was used. The DNA were purified 
using a gradient of 100 mM triethylammonium acetate, pH 7 and ACN. The column was 
eluted at 3 mL/min with a linear gradient from 10 to 22% B over 30 min, followed by re-
equilibration for 15 min. DNA strands of interest typically eluted at 15 min. Following 
purification, the DNA was desalted using NAP-5-Illustra™ size exclusion columns (GE 
Healthcare, Piscataway, NJ) according to the manufacturer’s protocols. The presence of 
MeC, hmC, fC, or caC in DNA strands was confirmed by capillary-HPLC-ESI—MS, and 
DNA concentrations were determined from the amount of 2ʹ-deoxyguanosine in enzymatic 
digests using previously published HPLC-UV protocols.239-241 
 Double stranded DNA was obtained by combining equal amounts of the 
complementary strands in 10 mM Tris, pH 8.0, and 50 mM NaCl buffer. DNA was heated 
to 90 ℃ for 5 min and then allowed to slowly cool to room temperature.   
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Table 6.1. Nucleotide sequences and mass spectrometry characterization of synthetic 
DNA 37-mers employed for affinity proteomics experiments. Sequences were derived 
from WTH3 gene promoter using UCSC genome browser.380 b = biotin. Molecular 
weights were obtained from HPLC-ESI--MS/MS on an Agilent MSD ion trap operating 
in the negative ion mode. 
Strand Sequence 5'-3' 
Expected 
Mass (Da) 
Experimental 
Mass (Da) 
Biotin-C bTTGTTTTCACCGCACCATTGTTTTTAGTACATATGTT 11,659.0 11,658.9 
Biotin-MeC bTTGTTTTCACMeCGCACCATTGTTTTTAGTACATATGTT 11,674.2 11,674.0 
Biotin-hmC bTTGTTTTCAChmCGCACCATTGTTTTTAGTACATATGTT 11,688.3 11,688.9 
Biotin-fC bTTGTTTTCACfCGCACCATTGTTTTTAGTACATATGTT 11,686.2 11,686.9 
Biotin-caC bTTGTTTTCACcaCGCACCATTGTTTTTAGTACATATGTT 11,702.3 11,702.0 
C AACATATGTACTAAAAACAATGGTGCGGTGAAAACAA 11,449.3 11,449.0 
MeC AACATATGTACTAAAAACAATGGTGMeCGGTGAAAACAA 11,464.3 11,464.1 
hmC AACATATGTACTAAAAACAATGGTGhmCGGTGAAAACAA 11,480.3 11,480.0 
fC AACATATGTACTAAAAACAATGGTGfCGGTGAAAACAA 11,478.2 11,478.0 
caC AACATATGTACTAAAAACAATGGTGcaCGGTGAAAACAA 11,494.3 11,494.1 
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Nuclear extract preparation 
 Human bronchial epithelial cells (HBEC) were cultured in keratinocyte serum free 
medium to 70-80% confluency at 37 ℃ with 5% CO2. Cells with a maximum passage 
number of 9 were harvested using trypsin. The cells were washed with ice cold PBS three 
times, and nuclear extracts were prepared with a Nuclear Extraction Kit (Millipore-Sigma, 
Burlington, MA) according to the manufacturer’s instructions.  
 Nuclear extract protein concentrations were determined using Pierce BCA Protein 
Assay Kit. Extracts were used immediately or aliquoted, snap frozen in dry ice/acetone and 
stored at -80 ℃ for up to three months.  
 
Protein pull-downs to identify specific readers of oxiMeC 
Preparing the streptavidin beads 
Streptavidin beads (450 µL, GE Healthcare, Piscataway, NJ) were washed three 
times with 9 mL of freshly prepared DNA Binding Buffer (DBB, 1M NaCl, 10 mM Tris, 
1 mM EDTA, 0.0005% NP40, pH 8.0). Following the third wash, the beads were re-
suspended in 10.5 mL of DBB and split into two equal aliquots, the first one for binding 
biotinylated DNA and the second one for clearing the nuclear extract of biotinylated 
molecules and proteins.  
 
Removing endogenously biotinylated molecules and proteins from the nuclear extract 
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The first aliquot was spun down to remove DBB was removed, and the beads were 
resuspended in 9 mL of Protein Binding Buffer (PBB, 150 mM NaCl, 50 mM Tris, 1 mM 
DTT, 0.0025% NP40, pH 8.0). To this first aliquot was added 12 mg of nuclear extracted 
proteins. The beads and protein mixture were inverted at 4 ℃ for 2 h to remove any 
endogenously biotinylated molecules. Following incubation, the supernatant was removed 
and placed into a clean Eppendorf tube and stored until use in affinity purification.  
 
Binding DNA to the beads 
 The second aliquot of beads from above was divided into 5 equal portions. To each 
aliquot of beads, 19.5 nmol (3 x 6.5 nmol) of the corresponding biotinylated dsDNA (C, 
MeC, hmC, fC, or caC) was added (Table 6.1). DNA was incubated with beads for 1 h at 
room temperature with continuous inverting. Following incubation, DNA-functionalized 
beads were divided into 3 equal parts and centrifugated on a table-top centrifuge to remove 
the supernatant. The beads were resuspended in 300 µL of PBB.  
 
Capture of specific protein readers 
An aliquot of HBEC nuclear protein extract (800 µg), which was cleared of 
endogenously biotinylated molecules as described above, was added to each sample. 
Proteins were incubated with DNA bound to beads for 2 h at 4 ℃. After the incubation, 
the beads were washed three times with 300 µL of PBB. Protein binders were eluted by 
adding 0.1% SDS and heating the sample at 90 ℃ for 10 min. The sample was briefly 
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centrifuged, and the supernatant was transferred to an Amicon 3K filter for processing. A 
detailed protocol for the pull-down methodology can be found in Appendix A4.  
 
Reduction, alkylation, and protein digestion using filter aided sample preparation 
(FASP) methodology 
 To prepare the proteins for mass spectrometry analysis, the eluted proteins, which 
were loaded onto Amicon 3K filters, were centrifuged at 14,000g for 10 min, washed three 
times with 100 µL 50 mM HEPES (pH 8), and resuspended in 100 µL 50 mM HEPES. To 
the solution, 1 µL of 200 mM DTT/0.1% SDS in 50 mM HEPES was added and the 
incubated for 1 hour at 55 ℃. Immediately before use, 9 mg of iodoacetamide was 
dissolved in 132 µL of water to a concentration of 375 mM. To each pulled-down protein 
sample, 1 µL of the iodoacetamide solution was added and the proteins were incubated for 
30 min at room temperature in the dark. Following the alkylation, samples were centrifuged 
at 14,000g for 10 min. Samples were washed three times with 100 µL of 50 mM HEPES. 
The proteins were suspended in 50 µL of 50 mM HEPES and incubated with 1 µg of trypsin 
overnight at 37 ℃. The resulting tryptic peptides were recovered by centrifugation at 
14,000g for 10 min into a clean Amicon collection tube. Amicon 3K filters were washed 
three times with 50 µL 0.1% formic acid added and centrifuged at 14,000g for 10 min to 
ensure peptides did not stick to the filter. An additional centrifugation was performed with 
50 µL of 0.1% formic acid in 70% ACN. A protocol for the FASP methodology can be 
found in the Appendix A4. 
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Gel-based sample preparation (alternative to FASP) 
 Proteins eluted from streptavidin beads were run into an SDS-PAGE gel for 10 min 
at 140 V. The top 1 cm of gel, containing protein was diced into 1 mm cubes. The gel 
pieces were washed with water and then twice with a 1:1 mixture of 25 mM ammonium 
bicarbonate and ACN. The gel was dehydrated with ACN for 30 s. The gel pieces were 
rehydrated in 25 mM ammonium bicarbonate containing 10 mM DTT and incubated at 56 
℃ for 1 hour. After incubation, the supernatant was removed and replaced with 55 mM 
iodoacetamide in 25 mM ammonium bicarbonate. The gel pieces were incubated for 30 
min at room temperature in the dark to alkylate the free cysteines. The gel pieces were 
washed twice with 1:1 25 mM ammonium bicarbonate and ACN, and then dehydrated with 
ACN for 30 s. The gel pieces were rehydrated with 25 mM ammonium bicarbonate 
containing 1 µg of Trypsin and digested overnight at 37 ℃. Peptides were extracted from 
the gel pieces by two incubations with 50% ACN, 0.3 % formic acid, and another 
incubation with 80% ACN, 0.3% formic acid.  
 
TMT labeling of tryptic peptides 
 The eluted peptides were dried and reconstituted in 5% ACN/0.5% TFA. The 
reconstituted peptides were desalted using Pierce™ C18 Spin Columns according to the 
manufacturer’s instructions. After desalting, the peptides were quantified using Pierce™ 
Quantitative Colorimetric Peptide Assay. Equal peptide amounts (2.5 µg) were aliquoted 
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to a fresh tube and labeled with TMT-sixplex reagent (Thermo-Fisher) in 30% ACN in 50 
µL total volume. The samples were incubated for 2 h at room temperature. The reactions 
were quenched by the addition of 4 µL of 5% hydroxylamine followed by 15 min 
incubation. Differentially tagged samples were combined and concentrated to dryness on 
speed vac. The combined peptide samples were fractionated using Pierce™ High pH 
Reversed-Phase Peptide Fractionation Kit according to the manufacturer’s instructions for 
TMT-labeled peptides. The resulting 8 fractions were concatenated to 4 fractions and the 
dried prior to LC-MS/MS. A detailed protocol for the TMT labeling can be found in the 
Appendix A4. 
 
NanoLC-ESI+-MS/MS Identification and Relative Quantitation of Protein Readers 
 TMT-labeled peptides were reconstituted at a concentration of 0.5 µg/µL in 5% 
ACN and 0.1% formic acid. Peptides were analyzed with an LTQ Orbitrap Fusion Tribrid 
mass spectrometer interfaced with a Dionex Ultimate3000 HPLC system. The samples 
were loaded onto a pulled-tip fused silica column with a 100 µm inner diameter packed in-
house with 20 cm of 3 µm ProntoSIL-C18AQ resin (120 Å, Bischoff Chromatography, 
Leonberg, Germany) that served both as the analytical column and as a nanospray 
ionization emitter. HPLC flow rate was maintained at 1 µL/min for the first 5.5 minutes, 
reduced to 300 nL/min for the next 132 min, and returned to 1 µL/min for the final 7.5 min 
of the run. HPLC solvents were comprised of 0.1% formic acid in water (solvent A) and 
0.1% formic acid in acetonitrile (solvent B). Solvent composition was held at 5% solvent 
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B for 6 min, followed by an increase to 7% over 2 min, 25% over 99 min, 60% over 20 min, 
and finally to 95% over 1 min. The solvent composition was held at 95% for 8 min, and 
returned to 5% over 1 min and re-equilibration for 8 min. 
The peptides were introduced to the mass spectrometer using a spray voltage of 
2200 V, with an ion transfer tube temperature of 350 ℃, and an RF Lens value of 60%. 
The mass spectrometer was operated in top speed mode (3 s), in which the instrument 
collected as many unique MS2 spectra as possible during the 3 s time window. The method 
utilized data dependent acquisition with dynamic exclusion (repeat count: 1, exclusion 
duration: 15 s). For every scan cycle, one full MS scan (m/z 320–2000) was collected at a 
resolution of 120,000 with an automatic gain control (AGC) target value of 2×105, followed 
by MS2 scans of as many dependent scans as possible within a cycle time of 3 s with HCD 
(normalized collision energy = 38%, isolation width = 0.7 m/z, resolution = 30,000) at an 
AGC target value of 1×105. Ions with a charge state of 2-7 were included from the analysis. 
 
Data analysis 
 Peptide sequences were determined from their MS2 spectra using Proteome 
Discoverer 2.1 (Thermo Fisher Scientific, Waltham, MA) using the Uniprot human protein 
database.381 Precursor ion m/z mass tolerance was set at ± 10 ppm, with fragment ion m/z 
tolerance at ± 0.06 Da, and up to two missed cleavages were allowed. Static modifications 
included carbamidomethylation of cysteine (+57.021 Da) and TMT 6-plex (+219.163 Da) 
groups on lysines and peptide N-termini. Dynamic modifications included oxidation 
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(+15.995 Da, M), deamidation (+0.984 Da, N and Q), acetylation (+42.011 Da, K and S), 
and phosphorylation (+79.966 Da, S, T, and Y). Identified peptides were filtered using a 
1% false discovery rate for high confidence and a 5% false discovery rate for medium 
confidence. At least 1 unique peptide fragment was required for identification. Isotope 
impurities for all six TMT reporter ions, provided by the manufacturer, were included in 
the analysis.  
From the identified peptides, the relative affinity of a protein for a corresponding 
DNA bait is proportional to the TMT tag abundance in the multiplexed sample. To allow 
for relative quantitation of pulmonary proteins with affinity for MeC, hmC, fC, and caC in 
DNA, TMT-sixplex reporter ion intensities were extracted by Proteome Discoverer 2.1. 
The mass tolerance for the extracted ion was set to 0.01 Da, and the signal to noise ratio of 
the reporter ion was at least 10. Top 3 peptides were used to establish the relative protein 
abundances. Quantitation was performed relative to the TMT-tagged reference sample, 
which served as an internal control and was created by mixing equal amounts of all 15 
samples to facilitate comparisons of protein levels across multiple LC-MS/MS runs and 
replicates.  
 
Bioinformatics analysis 
Protein abundance data was processed by Ingenuity Pathway Analysis (IPA, 
Qiagen, Hilden, Germany), the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID),382-383 and Cluster 3.0. Proteins with increased affinity were input into 
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IPA and a core expression analysis was performed. The core expression analyses were 
compared across groups using the comparison analysis tool. Whole protein TMT 
abundance data was clustered using Cluster 3.0 using average linkage. Clustering analysis 
results were visualized with Java TreeView. 
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6.3 Developing methodology to profile protein readers of oxiMeC 
 DNA sequence employed in these experiments was derived from the WTH3 
promoter and contained one site-specific cytosine modification at a centrally located CpG 
site (5ʹ- bTTGTTTTCACXGCACCATTGTTTTTAGTACATATGTT -3ʹ, where b = 
biotin, and X = C, MeC, hmC, fC, or caC, Table 6.1). DNA strands were synthesized using 
solid phase synthesis with commercial nucleoside phosphoramidites. Biotinylated DNA 
strands were attached to streptavidin coated beads, which were subsequently incubated 
with nuclear extract from human bronchial cells to capture protein readers of each DNA 
epigenetic mark (Scheme 6.1).  
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Scheme 6.1. Schematic representation of the affinity pull-down procedure. Streptavidin 
coated beads are incubated with biotinylated DNA. DNA functionalized beads are 
incubated with nuclear protein extracts from human bronchial epithelial cells (HBEC). 
Weak protein binders were washed away, while strongly binding proteins were eluted with 
SDS/heat. To identify protein readers of epigenetic marks and to quantify their relative 
affinity for MeC, hmC, fC, and caC, proteins were digested with trypsin and labeled with 
TMT isotope tags. The resulting peptides were identified and quantified using nano HPLC-
NSI-MS/MS on an Orbitrap Fusion mass spectrometer. 
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 Initial tests of our affinity capture methodology were performed using three DNA 
duplexes containing a central CG, MeCG, or caCG dinucleotide (Figure 6.1). In this 
experiment (Experiment 1, Table 6.2), 400 µg of protein was incubated with 4 nmol of 
DNA bound to 30 µL of streptavidin coated beads. Captured proteins were eluted with 100 
mM sodium chloride solution heated at 90 ℃ for 20 min and run into a SDS-PAGE gel. 
Proteins were imaged using Coomassie Blue staining (Figure 6.1). From the gel image, we 
observed weak protein bands at the middle range of the gel, darker bands in the high 
molecular weight region, and a strong band around 13 kDa corresponding to streptavidin 
(Figure 6.1). The proteins were subjected to an in-gel digestion, followed by dithiothreitol 
treatment to reduce disulfide bonds, and iodoacetamide to alkylate the free cysteines 
(Figure 6.1). The resulting peptides were analyzed by nanoLC-NSI-MS/MS on an Orbitrap 
Velos mass spectrometer, and the proteins were identified using TINT proteomics software 
pipeline at the Minnesota Supercomputing Institute. The most abundant proteins detected 
were keratins, streptavidin, and trypsin, which are all artifacts of sample preparation. In 
addition to protein artifacts, we were able to identify some lower abundance proteins which 
were found only in the sample prepared from the caC pull-down (Table 6.3). This initial 
experiment showed that our protocol was capable of capturing DNA binding proteins, and 
their identification was possible. However, very few meaningful proteins were detected, 
suggesting that the procedure needed to be optimized. Furthermore, the requirement for 
separate LC-MS/MS runs required for each pull-down limited our ability to perform 
relative quantitation of proteins that bind to more than one epigenetic mark.  
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Figure 6.1. PAGE- of proteins pulled down using the WTH3 DNA duplexes containing C, 
MeC, and caC. Gel was gut into 5 MW fractions prior to tryptic digestion and LC-MS/MS 
analysis.  
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Table 6.2. A summary of affinity pull-down experiments. 
 Input Output 
Experiment DNA Protein 
Amount 
Peptides 
(µg) 
Protein IDs 
1 4 nmol 400 µg ND* ND* 
2 4 nmol 400 µg ND* ND* 
3 4 nmol 400 µg 7-9 28 
4 4 nmol 800 µg 2.8 371 
5 5 nmol 800 µg 2.8 ND* 
6 2 nmol 200 µg 4 61 
7 3 nmol 900 µg ND* 288 (MeC), 146 (hmC) 
8 3 nmol 900 µg ND* 74 
9 3 nmol 900 µg ND* ND* 
10 NA** NA** 2.5 1600 
11 50 ng 75 µg 1.7 86 
* ND – Amounts were not determined.  
** NA – Experiment 10 did not include a protein pull-down component and instead 
tested cytoplasmic proteins processed using an in-gel sample preparation.  
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Table 6.3. Proteins pulled down with caC beads (Experiment 1). 
Name UniProt ID Biological Process 
Number of  
Unique 
Peptides 
Regulator of nonsense transcripts 1 Q92900 DNA replication 2 
Polymeric immunoglobulin receptor P01833 immune response 4 
Far upstream element-binding protein 2 Q92945 mRNA/RNA splicing 22 
Heat shock 70 kDa protein 1-like P34931 cellular homeostasis 2 
Cleavage stimulation factor subunit 2 P33240 mRNA/RNA splicing 5 
Lupus la protein P05455 tRNA metabolic process 5 
Splicing factor 3B subunit 4 Q15427 DNA replication 2 
Ig gamma-1 chain C region P01857 immune response 3 
Transcriptional activator protein pur-alpha Q00577 transcriptional regulation 3 
Zinc-alpha-2-clycoprotein P25311 immune response 6 
Cellular nucleic acid-binding protein P62633 transcriptional regulation 2 
Putative lipocalin 1-like protein 1 Q5VSP4 unknown 2 
Embryonic stem cell-specific 5-
hydroxymethylcytosine-binding protein 
Q96FZ2 unknown 2 
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  Further testing of the affinity pull-down methodology has focused on improving 
the specificity of proteins for epigenetic marks (Experiment 2, Table 6.2). Competitor 
DNA was added during the binding step to minimize non-specific binding. We employed 
synthetic poly dAdT and calf thymus DNA. The proteins non-specifically binding to any 
DNA would also bind to the competitor DNA. Our intent was to depleting general DNA 
binding proteins, allowing for proteins with specific affinity for epigenetic DNA marks to 
be detected. The resulting proteins were analyzed by gel electrophoresis and Coomassie 
staining, but we did not observe any protein bands on the gel (not shown). The lack of 
sufficient protein for staining indicated that we needed to scale up the nuclear extract input 
for the pull-down to have enough sample for the proteomics experiments.  
 The first trial attempt using all five DNA baits (C, MeC, hmC, fC, and caC) was 
performed with N = 1 using the methodology of Spruijt et al (Experiment 3, Table 6.2).26 
This experiment employed 400 µg of nuclear protein extract incubated with 4 nmol of each 
DNA for a period of 2 hours at 4 ℃. Proteins were eluted by heating at 90 ℃ in 100 mM 
NaCl for 10 min, and were further processed by filter aided sample preparation (FASP) 
(Scheme 6.1).384 The FASP procedure allows protein desalting prior to the necessary 
protein quantitation, reduction, and alkylation steps prior to digestion. Each of the capture 
reactions yielded less than 50 µg of total protein, which was digested using trypsin (1 µg) 
overnight. The peptides are then quantified prior to TMT labeling. The peptides were 
labeled by scaling down the amount of TMT reagent in a total volume of 45 µL. The labeled 
peptides were combined in equal microgram amounts, which is the most common way of 
280 
 
combining peptide samples. These samples showed very poor labeling when analyzed. The 
remaining peptides were re-labeled in an attempt to get better yields and re-analyzed. The 
reanalysis showed only 28 proteins, which were found labeled in four out of the five tags. 
These poor labeling resulting from too little tag being used relative to the quantity of 
peptides being labeled. From subsequent experiments, we learned that labeling of peptides 
requires a final concentration of 30% ACN to be successful.  
 In our next experiment, we pull-down experiments were conducted in triplicate 
using synthetic DNA duplexes containing C, MeC, hmC, fC, and caC (Table 6.1). The 
pull-down experiment utilized 30 µL of beads, 4 nmol of DNA, and the amount of nuclear 
extract protein was increased to 800 µg to increase the quantity of protein pulled down by 
each DNA bait (Experiment 4, Table 6.2). These samples were processed using the FASP 
methodology and the peptides quantified. To facilitate protein quantification across 
multiple runs, a reference sample was created. The reference sample was composed of 0.4 
µg of peptides taken from each FASP prepared sample (Scheme 6.2). TMT-sixplex labels 
were used to label 2.4 µg of peptides from each sample and the reference sample. These 
labeled peptides were analyzed using a nanoLC-MS3 method on an Orbitrap Fusion mass 
spectrometer.379 In this analysis, 371 proteins were identified, however only 81% of the 
peptides were labeled. After further experiments, we learned the insufficient peptide 
labeling was due to the need for a 30% final concentration of ACN during the labeling 
reaction. 
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 TMT quantitation results were processed using Proteome Discoverer (Thermo 
Fisher) compiled into Venn diagram using a tool available from Bioinformatics and 
Evolutionary Genomics (http://bioinformatics.psb.ugent.be/webtools/Venn/) (Figure 
6.2A). Each epigenetic mark-containing DNA strand was recognized by a similar number 
of protein readers (Figure 6.2A). The quantitative results were averaged over the three 
replicates to generate a heat map of protein affinity (Figure 6.3). The heat map shows a 
range of binding affinities for each protein, from the most preferred epigenetic marks (in 
yellow) to the least preferential modification (in blue). The relative quantitation data were 
also graphed as log plots which report the fold-change binding preference for one 
modification over another on the x-axis and another pair of modifications on the y-axis 
(Figure 6.4). A full list of proteins specifically exhibiting different binding affinities are 
detailed in Appendix A5. 
 The proteins identified in the pull-downs as having an increased affinity toward 
specific epigenetic marks were analyzed using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) to identify any enrichment for biological processes.382 
From the input proteins, DAVID identified the biological processes associated with each 
protein. The biological processes which had an enrichment p-value less than 0.05 were 
graphed into pie charts to show the relative contribution of each biological process (Figure 
6.5). The proteins which preferentially bound to hmC showed an increase in the biological 
processes for DNA damage repair, transcription, and the immune response. Proteins 
pulled-down by fC containing DNA were enriched for the biological processes associated 
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with DNA repair, DNA metabolic processes, and cellular response to stress. caC containing 
DNA baits pulled-down proteins associated with DNA repair processes, RNA processing, 
and response to stress (Figure 6.5). 
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Scheme 6.2. TMT labeling scheme and the use of a reference sample for relative 
quantification. Samples from three replicates are assigned mass tags (126, 127, 128, 129, 
or 130). Preparation of the reference sample, right side, is accomplished by combining 
equal amounts of each sample and labeling with the same tag (131). This reference sample 
was included in each group of samples to allow for relative quantitation across all samples.  
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Figure 6.2. Proteins identified in affinity pull down experiments with DNA containing 
specific epigenetic marks. A. Venn diagram of protein binding showing protein numbers 
for each group. B. Total numbers of proteins found bound to each DNA duplex.  
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Figure 6.3. Heatmap of proteins pulled down with each DNA probe and analyzed using 
nanoLC-NSI-MS3 methodology using TMT tags for quantification. Three replicates were 
averaged to a single value normalized using Cluster 3.0. The quantitation was visualized 
using Java TreeView. Gray spaces are samples in which the protein was not quantified.  
  
286 
 
Figure 6.4. Relative protein affinity towards each epigenetic mark defined by log plots. In 
these plots, an increase in affinity for a specific modification is observed in movement to 
the right on the x-axis, or up on the y-axis. A. Affinity toward MeC and hmC. B. Affinity 
toward MeC and fC. C. Affinity toward MeC and caC. D. Affinity toward fC and caC. E. 
Affinity toward hmC and fC. F. Affinity toward hmC and caC. 
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Figure 6.5. Biological processes associated with readers of oxiMeC as determined by the 
DAVID analysis tools. A. Readers of hmC containing DNA. B. readers of fC containing 
DNA. C. Readers of caC containing DNA. 
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In Experiment 5, the same experiment was repeated in triplicate using a freshly 
prepared nuclear extract (Experiment 5, Table 6.2). The pull-downs were conducted using 
30 µL of beads, 5 nmol of DNA, and 800 µg of nuclear extract. The proteins captured were 
processed with the FASP procedure with some modifications. Specifically, the FASP 
filters were passivated with a solution of 5% Tween 20 overnight to reduce protein loss 
during sample preparation. The buffer from the bead elution was exchanged with 8 M urea, 
0.2% deoxycholic acid (DCA), 100 mM ammonium bicarbonate pH 8. Digestion was 
carried out in the presence of 0.2% DCA with trypsin. The DCA was added to prevent 
sticking of peptides to plastics during the processing and was removed during the stop and 
go extraction procedure (STAGE) for desalting peptides. The peptides were quantified and 
labeled as in Experiment 4, including the reference sample. These peptides were 
fractionated using basic reverse phase HPLC, and the eluted peptides were concatenated to 
3 samples. When analyzed on an Orbitrap Fusion mass spectrometer, there were very few 
peptides found. From these experiments we learned that we needed to minimize the sample 
handling steps to reduce sample loss. Additionally, same day preparation of a nuclear 
extract is possible, but increases the difficulty of getting good samples with the lengthy 
pull-down procedure.  
 A follow-up experiment was carried out in which 4 of the DNA baits (C, MeC, 
hmC, and fC) were employed in triplicate at 2 nmol each bound to magnetic beads and 200 
µg of protein (Experiment 6, Table 6.2). Captured and eluted proteins were prepared using 
the FASP methodology as described in the methods section. Following reduction, 
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alkylation, and digestion, there were very few peptides that moved through the filter 
membrane, and a second digestion was performed. Even after two successive digestions, a 
limited number of peptides were found in the triplicate samples. These were combined to 
afford 4 µg for each sample. Peptides were labeled with 4 µL of the reconstituted TMT 
reagent in a final 30% ACN and then STAGE tipped to desalt and remove extra reagents. 
These samples did show effective labeling efficiency (over 97%) indicating that the 30% 
ACN using in the labeling reaction is necessary to facilitate the reaction. Following the 
experiment, we directly compared the streptavidin coated magnetic beads (Thermo Fisher) 
to sepharose coated beads (GE Healthcare) in terms of non-specific binding. Using the 
magnetic beads, we found significant non-specific binding to the beads themselves and 
larger amounts of streptavidin released with our elution conditions as compared to 
streptavidin coated sepharose (Figure 6.6). The increased non-specific binding and greater 
leaching of streptavidin from magnetic beads during the elution indicates that sepharose 
beads are a better option for affinity pull downs.   
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Figure 6.6. Gel electrophoresis of proteins captured on different types of beads without 
DNA. 800 µg of nuclear extract for human bronchial epithelial cells was incubated with 
magnetic (Dynabeads, Thermo Fisher) or sepharose streptavidin coated beads (GE 
Healthcare), washed, and eluted with 100 mM NaCl. The eluted proteins were run out on 
the gel and stained with Coomassie stain. Lanes 1 and 6 are a protein MW ladder. Proteins 
pulled-down using streptavidin coated sepharose beads is in lanes 2 and 3. Proteins which 
bound to magnetic Dynabeads were run in lanes 4 and 5. Lanes 7 and 8 contain the whole 
nuclear protein extract. 
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 We next explored the use of gel-based sample preparation methods for proteins 
captured by incubation with DNA baits as reported by Shevchenko et al.385 Three synthetic 
DNA duplexes containing C, MeC, and hmC, were chosen for their selectivity in binding 
known proteins, specifically Tet1 for MeC and hmC and Uhrf2 for hmC. Three nanomoles 
of DNA was incubated with 900 µg of nuclear proteins using the methodology detailed in 
the methods section above (Experiment 7, Table 6.2). Proteins were eluted from the beads 
using 1X LDS, and each sample was split into three parts for further analysis. The first part 
was processed for western blotting against Tet1 and Uhrf2 to look for them in the pull-
down solutions. The western blot was unable to identify either protein. Another portion of 
the protein extract was run into a gel for 10 minutes to desalt the proteins. The gel was 
processed using an adaption of Shevchenko et al.385 The sections were cut from the gel and 
diced into 1 mm cubes. The gel cubes were washed using a solution of 25 mM ammonium 
bicarbonate and acetonitrile (1:1) and dehydrated with 100% ACN for 30 s. The gel pieces 
were rehydrated with 10 mM dithiothreitol in 20 mM ammonium bicarbonate and 
incubated at 56 ℃ for 1 h to reduce disulfide bonds. The supernatant was removed, 55 mM 
iodoacetamide in 25 mM ammonium bicarbonate was added, and then incubated for 30 
min at room temperature. Following alkylation, the gel pieces were dehydrated and then 
rehydrated in 25 mM ammonium bicarbonate containing 2 µg of trypsin. Proteins were 
digested overnight at 37 ℃. Peptides were extracted by two successive incubations of the 
gel pieces with 50% ACN with 0.3% formic acid for 15 min each. Another extraction of 
the gel pieces was performed using 80% ACN with 0.3% formic acid. The extracts were 
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combined and dried to remove the formic acid. These peptides were labeled with 10 µL of 
TMT-0 reagent to test labeling efficiency in a single sample using the methodology 
described above. Excess reagent and salts were removed using C18 spin tips according the 
manufacturer’s direction as described above. The remaining sample was run out on a gel 
and cut into 5 MW regions (more than 160 kDa, 80 – 160 kDa, 40 – 80 kDa, 20 – 40 kDa, 
and less than 20 kDa), digested using the procedure outlined above, and desalted using the 
C18 spin columns.  Because of extensive mass spectrometry time needed to analyze a large 
number of samples arising from gel-based fractionation, only the unfractionated MeC, 
hmC, and the five fractions from the hmC gel were analyzed. These samples were analyzed 
using the Orbitrap Fusion mass spectrometer in an LC-MS/MS method. In this experiment, 
we were able to find a large number of proteins: 288 proteins in MeC DNA pull downs, 
146 proteins in hmC DNA pull downs, and 288 proteins across the 5 fractions of hmC pull 
downs. Importantly, proteins identified in the gel-fractionated sample pulled down by hmC 
included key proteins of interest including Tet1, Uhrf2, Uhrf1, and Thy28 (Table 6.4). 
This indicates that fractionation of samples is necessary to facilitate detection of low 
abundance proteins.  
  
293 
 
Table 6.4. Unique peptides of key protein readers of hmC containing DNA identified via 
nanoHPLC-ESI+-MS/MS.  
  
Protein (MW) Unique peptides 
(fractionation) 
Unique Peptides 
(without fractionation) 
Uhrf1 (91 kDa) 4 0 
Thy28 (26 kDa) 10 5 
RBM14 (69 kDa) 16 10 
RPL26 (17 kDa) 1 2 
PNKP (57 kDa) 8 0 
Uhrf2 (90 kDa) 1 0 
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Following the promising detection of Tet1 and Uhrf2 peptides in the hmC pull-
down, the same pull-down was repeated in triplicate in order to examine the reproducibility 
of the method (Experiment 8, Table 6.2). Sections of the gel were labeled with different 
TMT-sixplex tags and analyzed using the Orbitrap Fusion mass spectrometer. Following 
TMT labeling, samples were analyzed by nanoHPLC-NSI-MS2 on Orbitrap Fusion. 
However, we were unable to identify the majority of proteins identified from the previous 
fractionation experiment (Experiment 7), and there was poor reproducibility across three 
replicates using gel fractionation. Significant loss of key proteins after TMT-labeling was 
concerning. We investigated the loss of proteins by labeling the fraction from the previous 
experiment which had indicated the presence of Tet1 and Uhrf2. The TMT-labeled peptides 
are more hydrophobic and their respective retention times were shifted much later in the 
LC-MS/MS gradient. A possible cause of the loss of these key signals due to the later 
retention of all peptides is the co-elution of more abundant peptides at these later times.  
 After the repeated poor-quality samples resulting from using the methodology 
described by Spruijt et al.,26 we decided to test the competing method from Iularo et al. 
(Experiment 9, Table 6.2).26-27 Iularo et al. bound DNA to the beads overnight at 4 ℃.27 
The pull-down with nuclear protein extract was carried out for 15 min.27 In addition to 
significantly different timing used for the experiment, Iularo et al. used different buffers 
for each step.27 Using cytosine containing DNA in duplicate, the two sets of samples were 
processed according to their respective procedures. Proteins were eluted using 0.1% SDS 
and heating at 90 ℃ for 10 min. The eluted proteins were processed using FASP, the 
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peptides desalted with C18 spin columns, labeled with TMT-sixplex, combined, and 
cleaned-up using a second C18 spin column. The samples were analyzed on an Orbitrap 
Fusion mass spectrometer using the LC-MS/MS methodology described above. After the 
sample preparation, the LC-MS/MS runs showed no peptides in the samples. This is not 
consistent with results of an earlier experiment utilizing the same nuclear extract 
(Experiment 8), in which proteins were identified following analysis. It is unclear at this 
time what prevented the successful preparation of these samples.  
 Following the poor samples from the prior experiment, we set out to test the ability 
of the methodology to successfully prepare samples that had been digested in gel, which 
was thus far the most promising experimental methodology thus far (Experiment 10, Table 
6.2). Cytosolic protein extract produced while preparing the nuclear extract was run into a 
gel in 6 separate lanes for 10 min. The proteins were digested using the in-gel digestion 
described above. The peptides were cleaned up using reverse phase SPE on Strata-X 
polymeric reverse phase cartridges. SPE were conditioned using 1 mL of acetonitrile then 
1 mL of water, each with 0.1% formic acid. The samples were loaded, washed with 1 mL 
of 0.1% formic acid, and eluted with 0.1% formic acid in acetonitrile. An equal amount of 
peptides, 2.5 µg, was labeled with TMT-sixplex reagent as described above. The labeled 
peptides were combined, and desalted and fractionated with the basic reverse phase 
fractionation kit. The 8 elutions for TMT reagents were concatenated to 4 fractions. The 
four fractions were analyzed on an Orbitrap Fusion mass spectrometer using the nanoLC-
MS/MS method described above. The data was analyzed using Proteome Discoverer 2.1 
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and the relative amount of protein in each sample quantified. These quantifier ion 
abundancies were normalized and clustered using Cluster 3.0 and visualized in a heatmap 
using Java TreeView (Figure 6.7). In this experiment, 1600 proteins were identified, with 
labeling efficiency of 99.3%. This experiment shows that the steps for processing samples 
after the pull-down are working and labeling with TMT reagent can be successfully carried 
out with a low microgram amount of peptides.  
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Figure 6.7. Heatmap of protein quantitation from cytoplasmic proteins using in-gel 
digestion, C18 clean-up, TMT labeling, and basic reverse phase fractionation. The protein 
quantitation is normalized to the mean for each protein in the channel.  
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 Overall, the results of Experiment 10 indicate that the proteomics part of the assay 
is working, however our procedure may not pull down sufficient amounts of low 
abundance proteins such as known binders of oxiMeC such as Tet1 and Uhrf2. The next 
aspect of the pull-down tested focused on the DNA baits (Experiment 11, Table 6.2). Up 
to this point, DNA baits were prepared by solid phase synthesis on a DNA synthesizer and 
required significant efforts to purify and quantify them. We drew inspiration from the 
Iularo et al. work, which employed PCR to produce DNA baits.27 Our DNA baits were 
made using a biotinylated primer and focused on the promoter region of the Rassf1 gene 
(Sequence: 5ʹ-
GGAAGGAGCTGAGGAGAGCCGCGCAATGGAAACCTGGGTGCAGGGACTGTG
GGGCCCGAAGGCGGGGCTGGGCGCGCTCTCGCAGAGCCCCCCCCGCCTTGCC
CTTCCTTCCCTCCTTCGTCCCCTCCTCACACCCCACCCCGGACGGCCACAACG
ACGGCGACCGCAAAGCACCACGCGGAGATACCCGTGTTTCTGGAGGCCAGCT
TTAC-3ʹ). We employed 50 ng of DNA for each pull-down replicate which was bound 
overnight at 4 oC. The bound DNA was incubated with 75 µg of protein for 15 min, and 
the beads were washed 6 times (0.2 mM EDTA, 20% Glycerol, 20 mM Hepes-KOH pH 
7.9, 0.1 M KCl, 1 mM DTT, 1 mM protease inhibitor PMSF, 0.1% Triton X-100).27 The 
proteins were eluted with 0.1% SDS and processed using standard FASP methodology. 
Peptides were cleaned-up with C18 spin columns, TMT tagged, combined, and desalted 
and fractionated using the basic reverse phase fractionation kit. The TMT specific fractions 
were concatenated to 4 fractions and analyzed by nanoLC-MS/MS. Using the new capture 
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system, 86 proteins were identified, which is much less than expected, and TMT labeling 
was 96%. The quantitative results were clustered using Cluster 3.0 and visualized using 
Java TreeView (Figure 6.8). From this figure we can see that although 86 proteins were 
identified, there are many gaps in the quantitative data, suggesting that insufficient protein 
amounts were captured.  
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Figure 6.8. Heatmap of proteins identified and quantified in a protein pull-down using 212 
BP DNA duplexes representing promoter region of the Rassf1 gene synthesized by PCR. 
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Several additional observations were made that could have a potentially significant 
impact in the methodology. While the published protocols384 suggest washing the FASP 
filters with 0.1% FA in ACN, we found that these conditions can split the plastic filter 
devices along the seam. This was observed one time in 13 out of the 17 filter devices used, 
which had to be replaced with new Amicon 3k filters. Washing with 50:50 water:ACN 
with 0.1% FA avoids these issues. During the basic reverse phase fractionation kit sample 
preparation, each plastic tube was washed with 100 µL of 0.1% FA in can with vortexing 
in order to rinse away easily dissolved plastics and polymers from the tube surface. Thus 
far this appears to work, although a direct comparison has not been made at this time.   
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6.4 Conclusions and future directions 
 Our efforts directed toward a quantitative proteomics methodology for protein 
readers of oxiMeC in the lung has not yet yielded a finalized, reliable method for 
identifying epigenetic readers in the lung. In the process of developing this methodology, 
many aspects of the affinity pull-down have been explored and refined. In the areas of TMT 
labeling, sample processing, and data analysis we have identified effective processes. To 
achieve good labeling of peptides with TMT reagent requires the reaction to have 30% 
acetonitrile during the reaction. Many tests with in-gel digestion and FASP have been 
utilized. At this time, the high variability of peptide extraction from the gel at the levels 
present in these samples precludes the use of gel-based method. FASP has been more 
successful than gels in terms of peptide recovery for downstream processing and is 
recommended for future experiments. Although the complexity of pulled-down proteins is 
significantly less than a total proteome from whole tissue or nuclear extract, significantly 
better data has been collected using the Pierce™ high pH reversed-phase peptide 
fractionation kit and concatenation to a smaller number of fractions. This kit has the benefit 
of both desalting the sample, a necessary step, and orthogonally fractionating the peptides. 
Advances in the software for analyzing protein samples, especially the newer versions of 
Proteome Discoverer (version 2.1 and later) have allowed more complex quantitation 
calculations including using a reference sample to compare across multiple runs. Using 
programs such as Cluster 3.0, Java TreeView, and IPA improve understanding of the data 
with respect to reproducibility for Cluster 3.0 and Java TreeView and biological 
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significance with IPA. The application of multinotch MS3 methodology has thus far proven 
detrimental to collecting good data due to the signal loss.379 Instead, in our hands MS2 
based methodology provided better protein IDs.  
 Future work for this project broadly includes completing an effective pull-down 
with reproducible quantitation and identifying of protein readers of all four epigenetic 
marks. The next steps in completing this goal are to produce biotinylated DNA strands in 
large quantities using PCR or solid phase DNA synthesis. Data reproducibility is the 
second challenge and is reliant on the consistency of the technique used to prepare samples 
prior to combining after labeling. This can be achieved by reducing unnecessary steps prior 
to TMT tagging, or by changing the quantitative method altogether, for example by using 
label-free proteomics or by introducing stable isotope labeling of amino acids in cell culture 
(SILAC). Finally, identifying new readers of oxiMeC requires a secondary assay to 
validate those proteins such as electrophoretic mobility shift assays or western blotting. An 
optimized pulldown protocol taking into accounts all of our previous tests in given in 
Appendix A4. 
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VII. CONCLUSIONS 
Epigenetic regulation describes changes in gene expression that do not result from 
changes in the gene sequence.1 The ability of cells to maintain precise control over tissue 
specific gene expression patterns and to modify them as needed is critical for normal 
cellular development and homeostasis.11, 386 Epigenetic regulation is achieved through 
reversible modification of DNA, RNA, and histones.1 The primary epigenetic modification 
of DNA is methylation of cytosine at the C5 position to generate MeC.11 Methylation on 
DNA is introduced via de novo methyltransferases DNMT3a/b and maintained through cell 
division by maintenance methyltransferase DNMT1.11 MeC can be oxidized by TET to 
hmC, fC, and caC, a process known to induce DNA demethylation and gene reactivation 
(Figure 1.2).13-14, 16, 21 Enrichment of oxiMeC at specific gene elements identified by DNA 
sequencing and proteomics studies support the idea that each oxidized form of MeC may 
have its own epigenetic function.26-27, 205-206, 209-210 The precise balance of DNA methylation 
and demethylation can be influenced by chemical exposures to exogenous agents such as 
inflammatory agents present in cigarette smoke. 
In Chapter II of this thesis, a kinetic assay of DNMT1 mediated methylation was 
developed to investigate the effects of extended C5-alkyl substituents such as ethyl, vinyl, 
and propyl groups on DNMT1 maintenance methylase activity (Scheme 2.1).  We utilized 
synthetic DNA duplexes containing site-specific modification containing the extended C5-
alkyl substituents (Table 2.2) to evaluate the enzymatic activity of DNMT1. We employed 
SPE enrichment coupled with HPLC-ESI+-MS/MS to quantify the kinetics of methyl 
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transfer by isotope dilution tandem mass spectrometry (Scheme 2.6). Using this 
methodology, we found that DNMT1 was capable of methylating DNA containing the 
native substrate (MeC) and 5-ethyl-dC (Vmax = 9.6 x 10-2 nM/min vs. 2.4 x 10-2 nM/min, 
respectively), but not 5-vinyl-dC or 5-propyl-dC (Figure 2.6). We created a homology 
model of the human DNMT1 protein and employed molecular mechanics calculations to 
assess the effects of increasing C5-alkyl side chain on the target recognition domain of the 
protein. From these analyses, we found that both 5-vinyl-dC and 5-propyl-dC disrupt the 
interactions of the target recognition domain of the enzyme with DNA, preventing the 
formation of a catalytically active conformation required for methyl transfer. This is 
consistent with the results from previous work showing that large side chains such 5-
propyne-dC interfered with DNMT1 acitivity.19 
In Chapter III of this thesis, we utilized the kinetic assay developed in Chapter II to 
investigate the kinetics of DNMT1 maintenance methylation toward DNA duplexes 
containing oxidized forms of MeC (Table 3.2). We employed offline HPLC clean-up 
coupled with the HPLC-ESI+-MS/MS developed in Chapter II to determine the kinetics of 
DNMT1 activity (Scheme 3.2). We observed that DNMT1 was able to methylate DNA 
containing MeC, hmC, and fC with a reduced efficiency as the C5-methyl group was 
oxidized (Vmax/Km = 6.7, 2.1, and 0.85, x10-2 min-1M-1, Table 3.3). We employed 
homology model developed in Chapter II to carry out molecular dynamics simulations of 
DNA bound to the protein. Using this model, we observed changes in DNA and protein 
structure over 100 ns and found that hydrophilic nature of oxiMeC interferes with 
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hydrophobic interactions between TRD and MeC. These findings support the idea that 
formation of oxiMeC contributes to passive DNA demethylation by hindering the activity 
of DNMT1.  
In Chapters IV and V of this thesis, we investigated epigenetic changes in the A/J 
mouse model of smoking induced lung cancer. Smoking induced lung tumors are 
characterized by profound epigenetic changes such as aberrant patterns of DNA 
methylation and hydroxymethylation, deregulated histone acetylation, and altered gene 
expression levels.4, 107-108 These epigenetic alterations are likely to represent an important 
event in lung tumor development.108 However, the origins and the timing of smoking-
mediated epigenetic dysregulation in the lung remain largely unknown. DNA isolated form 
lung tissues of from A/J mice exposed to cigarette smoke for 10 weeks was subjected to 
RRBS and oxoRRBS analyses to determine site-specific changes in MeC and hmC.140 We 
found that cigarette smoke exposure altered site specific methylation and 
hydroxymethylation patterns of many cancer related genes (Figure 4.2). To identify ETS 
components responsible for these effects, A/J  mice were exposed to NNK, LPS, or NNK 
and LPS for 2, 6, or 27 weeks. Lung DNA was isolated and used to quantify the global 
levels of MeC, hmC, and fC. To facilitate quantitation, we synthesized the necessary stable 
isotope labeled internal standards and employed an HPLC enrichment, which was coupled 
to a novel HPLC-ESI+-MS/MS method developed in our laboratory (Figure 4.1 and 4.3). 
In mice treated for 6 weeks with LPS, we observed a 0.2% increase in MeC, and a decrease 
in hmC (Figure 4.6), while the amounts of fC were increased (Figure 4.6). In the 6-week 
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treatment we also observed a decrease in global histone acetylation at H3K14 and H3K23 
with LPS treatment (Figure 4.11). To determine whether these epigenetic changes 
observed in whole lung were representative of the type II cells of the lung, we treated mice 
with LPS along and isolated the type II lung cells by panning (Chapter V). Histone 
acetylation analysis of the type II cells revealed acetylation changes that matched those 
observed in whole lung (Figure 5.5). The RNA from type II cells was subjected to RNA-
Seq analysis to identify changes transcription (Figure 5.3). The transcriptional changes 
observed are in agreement with previous work (Figure 5.6).142 Correlating DNA 
methylation and hydroxymethylation changes observed in mice exposed to ETS to gene 
expression changed in LPS-treated mice using IPA showed an enrichment in cancer related 
genes (Tables 4.3 – 4.6). These results provide initial evidence that cigarette smoke alters 
site-specific methylation and hydroxymethylation of genes that are associated with the 
cancer phenotype. In addition, 100 most deregulated methylation and hydroxymethylation 
sites were correlated with gene expression from type II cells to look for enrichment 
(Figures 5.7 and 5.8). Increases in MeC and hmC were enriched for genes with decreasing 
expression.   
In Chapter VI of this thesis, we set out to develop an affinity proteomics 
methodology to identify the lung nuclear protein readers that preferentially bind oxidized 
forms of MeC in DNA. To identify these epigenetic readers of epigenetic marks in DNA, 
we designed dsDNA containing site-specific C, MeC, hmC, fC, and caC (Table 6.1). 
Multiple conditions were tested to facilitate the identification of protein readers (Table 
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6.2). While the downstream sample processing steps (TMT labeling, sample cleanup, and 
mass spectrometry analysis) have been well refined to give consistent results (Figure 6.7), 
effective affinity capture remained elusive. This chapter details the development of a 
method for carrying out the affinity proteomics including: the use of MS2 based 
methodology, efficient peptide tagging, sample clean-up, and fractionation. 
 In summary, the research detailed in this Thesis provides novel information about 
the kinetics of DNA methylation and possible demethylation mechanisms (Chapters II and 
III), epigenetic changes associated with smoking and inflammation (Chapters IV and V), 
and the identities of protein readers of various epigenetic marks in human lung (Chapter 
VI). These findings pave the way for future work to identify epigenetic mechanisms of 
cancer and to develop novel epigenetic modulators as future therapeutic agents.    
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VIII. FUTURE DIRECTIONS 
8.1 Integrated ‘omics approach to investigate epigenetic changes in type II pulmonary 
cells following exposure to cigarette smoke 
 As described in chapter IV, lung cancer is responsible for over 30% of cancer 
related deaths worldwide, and cigarette smoking is a major contributor to the prevalence 
of lung cancer.101 Epigenetic deregulation in likely to play a major role in lung cancer 
etiology. Our previous animal studies utilized whole lung tissue comprised of a diverse 
mixture of cells. Within these experiments, the epigenetic changes in a single cell type may 
be masked by the other cells, or immune cell infiltration. Additionally, the effects of 
cigarette smoke exposure on type II lung cells, which are expected to be sites of lung cancer 
initiation, has not been systematically studied.225 By using flow cytometry to isolate type 
II cells in mice exposed to cigarette smoke and single agents, it is possible to systematically 
study the effects of cigarette smoke on this key cell population. To study epigenetic 
changes in type II cells, laboratory A/J mice of both sexes can be exposed to cigarette 
smoke, or LPS to induce epigenetic changes. After isolation of the type II cells from the 
lung, DNA, RNA, and proteins can be extracted to facilitate a thorough investigation of 
epigenetic changes. The DNA can be used in global HPLC-ESI-MS/MS quantitation of 
epigenetic changes as well as RRBS and oxoRRBS to determine site-specific changes of 
DNA methylation and hydroxymethylation. The RNA can be used for RNA-Seq analysis 
of the transcriptional changes. A global, quantitative proteomics approach can be used to 
investigate changes in protein abundance. Integrating genomics, transcriptomics, and 
310 
 
proteomics would provide a comprehensive analysis of the epigenetic changes and their 
outcomes occurring in type II cells following exposure to cigarette smoke.  
 
8.2 Investigation of protein readers of MeC, hmC, fC, and caC in the lung and lung 
tumors 
 Although protein readers of MeC and its oxidized forms in the brain have been 
investigated,26 little is known about the proteins interacting with these epigenetics marks 
in other tissue types.   Proteomes of different cell and tissue types vary significantly, and 
the same mark can be recognized by a different set of readers. In Chapter VI of this thesis, 
we discussed the development of quantitative affinity proteomics methodology to identify 
nuclear protein readers in human bronchial epithelial cells. The current methodology has 
well established steps for protein and peptide processing following the affinity purification. 
Section 6.4 of Chapter VI lays out the immediate steps to progress the current state of the 
project such as efficient pull downs, minimization of steps, and validation of targets with 
secondary assays. Further developments in determining the readers of epigenetic 
modifications by quantitative proteomics could implement additional genomic regions, 
such as enhancers, as the region of choice can have an effect on the proteins bound.27 
Additionally, the use of recently discovered epigenetic modifications such as N6MedA36 
or 4mC as DNA targets would provide additional insight on the functions of those 
modifications in human lung. Protein pull-downs can be further expanded to explore the 
composition of readers in tumors induced by carcinogens and cigarette smoke.   
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8.3 Improved analytical methods for quantitation of epigenetic modifications of DNA, 
MeC, hmC, fC, and caC  
 Epigenetic modifications of DNA (MeC, hmC, fC, and caC) vary significantly in 
their cellular abundance, ranging from 5% of total Cs for MeC to 5 x 10-5 % of total Cs for 
caC.13-14, 16 This creates a problem with instrument dynamic range and accurate 
quantification. To make things more challenging, these cytidine analogues are very polar 
molecules and do not retain well on typical reverse phase HPLC columns. Sample 
preparation requirements for these analytes has proven difficult due to requirements for 
time consuming sample enrichment by offline HPLC (see Chapter IV). Recently reported 
efforts to use a 2D-HPLC-ESI-MS/MS method caught our attention as a potential way to 
eliminate derivatization and pre-enrichment needed to analyze these modifications.159 A 
similar methodology can be employed with reduced solvent flow rates to improve 
sensitivity and conform to the technical specifications of available equipment. 
Alternatively, the described 2D-HPLC-ESI-MS/MS method could be adapted to employ 
nanoLC for the second dimension and nanospray ionization for a greater increase in 
sensitivity.  
 
8.4 Epigenetic changes following exposure to E-liquid vapor 
 The rise of electronic cigarettes as an alternative to smoking creates new public 
health risks.387 The public perceives electronic cigarette use as safer than traditional 
smoking and this can contribute to freer use when normal cigarettes would be avoided, 
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such as during pregnancy.387 The electronic cigarette liquid has been shown to cause DNA 
damage in the lungs, heart, and bladder of exposed mice.388 Further, the use of electronic 
cigarettes has been shown to suppress immune and inflammatory response genes in nasal 
epithelial cells of smokers in a similar manner to smoking.389 There are many varieties of 
E-liquids on the market. These E-liquids contain many different components in addition to 
nicotine, such as flavorants and humectants, which can create additional risks.390-393 It 
would be interesting to identify  epigenetic changes (global DNA epigenetic modifications, 
RRBS, RNA-Seq, and histone modifications) in the lung of  A/J mice exposed to E-cig 
vapor. These experiments would reveal whether the use of electronic cigarettes induces 
epigenetic changes similar to those caused by traditional tobacco smoking.  
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APPENDICES 
A1. Chapter II: NMR Spectra 
Figure A1.1. 1H-NMR of 5-iodo-2ʹ-deoxycytidine (1). 
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Figure A1.2. 1H-NMR of 5-ethyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (3). 
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Figure A1.3. 1H-NMR of 5-(Trimethylsilyl)-ethynyl-3′,5′-O-t-butyldimethylsilyl-2′-
deoxycytidine (3). 
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Figure A1.4. 1H-NMR of 5-Ethynyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (4). 
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Figure A1.5. 1H-NMR of 5-Ethyl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine (5). 
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Figure A1.6. 1H-NMR of 4-N-Benzoyl-5-ethyl-3′,5′-O-t-butyldimethylsilyl-2′-
deoxycytidine (6). 
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Figure A1.7. 1H-NMR of 4-N-Benzoyl-5-ethyl-2′-deoxycytidine (7). 
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Figure A1.8. 1H-NMR of 4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-ethyl-2′-deoxycytidine 
(8). 
 
 
  
351 
 
Figure A1.9. 31P-NMR of 4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-ethyl-2-deoxycytidine-
3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (9). 
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Figure A1.10. 1H-NMR of 5-Propyn-1-yl-3′,5′-O-t-butyldimethylsilyl-2′-deoxycytidine 
(10). 
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Figure A1.11. 1H-NMR and COSY of 5-Propyl-3′,5′-O-t-butyldimethylsilyl-2′-
deoxycytidine (11). 
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Figure A1.12. 1H-NMR of 4-N-Benzoyl-5-propyl-3′,5′-O-t-butyldimethylsilyl-2′-
deoxycytidine (12). 
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Figure A1.13. 1H-NMR of 4-N-Benzoyl-5-propyl-2′-deoxycytidine (13). 
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Figure A1.14. 1H-NMR of 4-N-Benzoyl-5′-O-(dimethoxytrityl)-5-propyl-2′-
deoxycytidine (14). 
 
 
  
357 
 
Figure A1.15. 1H-NMR of 3′,5′-O-t-butyldimethylsilyl-5-vinyl-2′-deoxycytidine (16). 
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Figure A1.16. 1H-NMR of 4-N-Benzoyl-3ʹ,5ʹ-O-(t-butyldimethylsilyl)- 5-vinyl-2ʹ-
deoxycytidine (17). 
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Figure A1.17. 1H-NMR and COSY of 4-N-Benzoyl-5-vinyl-2ʹ-deoxycytidine (18). 
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Figure A1.18. 1H-NMR of 4-N-Benzoyl-5ʹ-O-(dimethoxytrityl)-5-vinyl- 2ʹdeoxycytidine 
(19). 
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Figure A1.19. 31P-NMR of 4-N-Benzoyl-5ʹ-O-(dimethoxytrityl)-5-vinyl-2ʹdeoxycytidine 
3ʹ-(2-cyanoethyl)-N, Nʹ-diisopropyl phosphoramidite (20). 
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A2. Chapter III: Homology Model 
Figure A2.1: Sequence alignment for hDNMT1 homology model. Modeling of hDNMT1 
was carried out using the published crystal structure of mDNMT1 (PDB: 4DA4) in 
complex with hemi-methylated DNA10 with the hDNMT1 reference sequence 
(NP_001124295.1). Alignment of the hDNMT1 reference sequence with the sequence of 
the mDNMT1 crystal structure reveals an 85% identity.  
363 
 
 
364 
 
 
365 
 
 
  
366 
 
A3. Chapter IV: Scripts and code used to analyze RRBS and oxo-RRBS data in 
Chapter IV 
A3.1. Generating scripts for primary sample analysis 
Using Perl, the first script is called METH_SHOT.pl. The Perl script will write job 
scripts for each sample that can then perform the following transformations: trimming the 
adapters, removing the diversity sequences from the sequencing adapters, mapping the 
bisulfite reads with Bismark, converting the mapped output to a methylated reads input, 
calculate the bisulfite conversion rate, and calculate the methylated sites. To use the script 
type “perl METH_SHOT.pl” in the command line, in the same location, you also must 
have a file “Indexing.txt”. The information contained in Indexing.txt are as follows: 
column 1 contains the path to locate your fastq files if they are not in the working directory, 
column 2 contains the name of the R1 file, column 3 contains the name of the R3 file, and 
column 4 contains the short name which will be the output of the mapping process. The 
output of the Perl script will be a series of scripts named “scriptA#.pbs”, where # is a 
number between 1 and the number of rows included in “Indexing.txt”. These PBS scripts 
can be run using the following command in the command line, “qsub scriptA#.pbs”. 
 
Code for METH_SHOT.pl: 
$n=1; 
open SOURCE, "< Indexing.txt"; 
while (defined($line = <SOURCE>)) { 
    chomp $line; 
    print "$line\t"; 
    @field= split(/\t/, $line); 
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    open OUT, "> scriptA$n.pbs"; 
    print OUT " 
 
#!/bin/bash -l 
#PBS -l nodes=1:ppn=24,mem=62GB,walltime=4:00:00 
#PBS -m abe 
#PBS -M seile053@umn.edu 
module load cutadapt/1.8.1 
module load fastqc/0.11.7 
cd /home/tretyako/shared/Project_006/Analysis/2018-June-01 
/home/tretyako/shared/TrimGalore/TrimGalore-0.4.5/trim_galore --paired -a 
AGATCGGGAAGAGC -a2 AAATCAAAAAAAC $field[0]$field[1].fastq 
$field[0]$field[2].fastq 
python /home/tretyako/shared/PythonScripts/trimRRBSdiversityAdaptCustomers.py -1 
$field[1]_val_1.fq -2 $field[2]_val_2.fq 
module unload cutadapt/1.8.1 
module unload fastqc/0.11.7 
module load gcc/4.7.2 
module load bowtie2 
#Test that we can understand MethPipe math with defined data sets 
/home/tretyako/shared/Bismark/Bismark_v0.19.0/bismark --multicore 4 --bowtie2 
/home/tretyako/shared/Genomes/Mouse-MM10/ -1 $field[1]_val_1_trimmed.fq -2 
$field[2]_val_2_trimmed.fq 
module unload gcc/4.7.2 
module unload bowtie2 
#begin conversion to mr files 
module load gcc/7.2.0 
#GCC version 7.2.0 allows proper calculations. 
module load gsl/2.3 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/to-mr -o $field[3].mr -m 
bismark $field[4] -v 
#Take the mr and sort the file 
sort -k1,1 -k2,2n -k3,3n -k6,6 $field[3].mr -o $field[3].t.mr 
#Estimate methylation levels 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/methcounts -o 
$field[3].meth -c /home/tretyako/shared/Genomes/Mouse-MM10/ -v $field[3].t.mr 
#calculate bisulfite conversion levels - these do not need to be 100%, but instead uniform 
across samples. 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/bsrate -o $field[3].bsrate -
c /home/tretyako/shared/Genomes/Mouse-MM10/ -v $field[3].t.mr 
#END"; 
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$n++; 
}  
A3.2. Calculating hmC from BS and oxoBS data 
 The second script uses the BS data and oxoBS data to calculate the levels of hmC 
at CpG sites. This script is titled “Part2-MLML.pl” and can be executed by typing “perl 
Part2-MLML.pl” into the command line. Executing the script requires a text file titled 
“Index-hmC.txt” in the same location. The contents of the text file include a column of the 
methylated files, the bisulfite sequencing files, and a column of the desired output names.  
Code for Part2-MLML.pl: 
$n=1; 
open SOURCE, "< Index-hmC.txt"; 
while (defined($line = <SOURCE>)) { 
    chomp $line; 
    print "$line\t"; 
    @field= split(/\t/, $line); 
 
    open OUT, "> scriptB$n.pbs"; 
    print OUT " 
 
#!/bin/bash -l 
#PBS -l nodes=1:ppn=12,mem=32GB,walltime=12:00:00 
#PBS -m abe 
#PBS -M seile053@umn.edu 
#All of the information above is needed to properly run the commands using the PBS, 
they are NOT treated as comments. 
module load gcc/7.2.0 
#GCC version 7.2.0 allows proper calculations. 
module load gsl/2.3 
#subtract the MeC data in oxBS sample from the BS sample. Gives hmC result 
cd /home/tretyako/shared/Project_006/Analysis/2018-June-01 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/mlml -u $field[0] -m 
$field[1] -o $field[2] -H $field[2].counts 
#END"; 
$n++; 
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}  
A3.3. Determining sites with statistically different methylation and 
hydroxymethylation 
 This last code is contained in “METHFILTER.sh” and contains data filters and 
statistical calculations. Initially the various data files containing MeC or hmC are merged 
into a single file containing the coverage and methylated reads of each sample. These data 
are then filtered with a read cut-off of 200 reads across all samples to remove regions with 
little or no data because of RRBS preparation of samples. Differences in methylation are 
estimated using the FoldChangeFilter-05.pl which filters out sites that have less than a 5% 
difference between treated and control samples. The statistical differences were calculated 
using radmeth, and sites with a p-value less than 0.001 were moved to a new file to be 
included.   
Code for METHFILTER.sh: 
#!/bin/bash -l 
#PBS -l nodes=1:ppn=4,mem=5GB,walltime=24:00:00 
#PBS -m abe 
#PBS -M seile053@umn.edu 
#Merge the *.meth files together 
cd /home/tretyako/shared/Project_006/Analysis/2018-June-01 
module load gcc/7.2.0 
#Merge the multiple MethCount files together 
#Duration: 5-6 hours 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/merge-methcounts -t 
oxCtrl1.meth oxCtrl2.meth oxCtrl3.meth oxCtrl4.meth oxECS1.meth oxECS2.meth 
oxECS3.meth oxECS4.meth > MeCData.txt 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/merge-methcounts -t 
hmCtrl1.meth.counts hmCtrl2.meth.counts hmCtrl3.meth.counts hmCtrl4.meth.counts 
hmECS1.meth.counts hmECS2.meth.counts hmECS3.meth.counts hmECS4.meth.counts 
> hmCData.txt 
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# 
#Filter the merged files to ensure there is enough data for further comparisons and reduce 
statistical tests 
#Duration: 2 hours 
#Move the descriptor of the file to the new file and then perform the sort. 
head -n 1 MeCData.txt > MeCData_400.txt && awk '{sum=0; for(i=2; i<=NF; i++) sum 
+= $i; if (sum>400) print}' MeCData.txt >> MeCData_400.txt 
head -n 1 hmCData.txt > hmCData_500.txt && awk '{sum=0; for(i=2; i<=NF; i++) sum 
+= $i; if (sum>500) print}' hmCData.txt >> hmCData_500.txt 
# 
#Filter based on estimated fold change of at least 5%. Adjust this value according to 
depth and needs. Perl Script written by John Garbe, UMGC. 
#It is entirely possible that hmC and MeC need to have separate FC filters. 
perl /home/tretyako/shared/Project_006/FoldChangeFilter-05.pl MeCData_200.txt > 
MeCData_200_FC05.txt 
perl /home/tretyako/shared/Project_006/FoldChangeFilter-05.pl hmCData_200.txt > 
hmCData_200_FC05.txt 
# 
#After filters, statistical changes can be calculated. These have not been adjusted yet.  
#Use the header of the file to crease "Design_Matrix.txt" and "Design_Matrix2.txt" 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/radmeth regression -
factor case Design_Matrix.txt MeCData_200_FC05.txt > 200_FC05-MeC_CpGs.bed 
/home/tretyako/shared/MethPipeSoftware/methpipe-master/bin/radmeth regression -
factor case hDesign_Matrix.txt hmCData_200_FC05.txt > 200_FC05-hmC_CpGs.bed 
# 
#Filter the regression data. 
#First on values less than 0.001. Note the line stops reading at the 1, and the values 
included are actually less than 0.002. 
awk '$5 <= 0.001 "{print $0; $}"' 200_FC05-MeC_CpGs.bed > 200_FC05-
MeCintmed.bed 
awk '$5 <= 0.001 "{print $0; $}"' 200_FC05-hmC_CpGs.bed > 200_FC05-
hmCintmed.bed 
#Remove rows where statistics could not be calculated. We expect this to be few due to 
the earlier perl filtering. 
awk '$5 > -1 "{print $0; $}"' 200_FC05-MeCintmed.bed > 200_FC05-MeCintmed2.bed 
awk '$5 > -1 "{print $0; $}"' 200_FC05-hmCintmed.bed > 200_FC05-hmCintmed2.bed 
#Sort the output values based on the given p-value. 
sort -k 5n 200_FC05-MeCintmed2.bed > 200_FC05-MeCoutput.bed 
sort -k 5n 200_FC05-hmCintmed2.bed > 200_FC05-hmCoutput.bed 
#This list should be short enough to export into Excel and get the gene name.  
#END  
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Code for FoldChangeFilter.py: 
#!/usr/bin/perl -w 
die "USAGE: FoldChangeFilter.pl inputfile.txt\n" unless ($#ARGV == 0); 
# Assign the columns of data to groups for comparing the fold change 
%groups = ( 
    2 => 1,  
    3 => 2,  
    4 => 1, 
    5 => 2,  
    6 => 1,  
    7 => 2,  
    8 => 1, 
    9 => 2,  
    10 => 3, 
    11 => 4, 
    12 => 3, 
    13 => 4, 
    14 => 3, 
    15 => 4, 
    16 => 3, 
    17 => 4, 
);  
# open input file 
$ifile = shift @ARGV; 
open IFILE, "$ifile" or die "Cannot open $ifile: $!\n"; 
# first line is a header, grab it and print out 
$header = <IFILE>;  
print $header; 
# go through the rest of the input file line by line 
while ($line = <IFILE>) { 
    chomp $line; # remove newline character 
    next if ($line =~ /^#/); # ignore lines starting with # 
    next if ($line =~ /^\s*$/); # ignore empty lines 
    @line = split /\t/, $line; # split line by tabs 
    # Go through each column, calculate sum of each group 
    @sum = (0, 0, 0, 0, 0); # empty the sum array 
    for $index (0..$#line) { 
 $column = $index + 1; 
 if (defined($groups{$column})) { # if a group is defined for this column 
     $group = $groups{$column}; 
     $sum[$group] += $line[$index]; # add to the group sum 
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 } 
    } 
    # calculate foldchange 
    if (($sum[1] + $sum[2] == 0) or ($sum[3] + $sum[4] == 0) or ($sum[4] == 0)) { 
        $fc = 1.0  
    } 
    else { 
    $fc = ($sum[2] / ($sum[1])) / ($sum[4] / ($sum[3])); 
    $fc = abs($fc); 
    } 
    # print out the line if foldchange is greater than cutoff. As in it increased across the 
groups. 
    #Currently 10% change in either direction as below. 
    if ($fc > 1.05) {  
 print "$line\n"; 
    } 
    # reverse the equation in case methylation or hmC is lost in these sites. 
    if (($sum[2] == 0) or ($sum[3] + $sum[4] == 0)) { 
        $fc = 1.0  
    } 
    else { 
    $fc = ($sum[4] / ($sum[3])) / ($sum[2] / ($sum[1])) ; 
    $fc = abs($fc); 
    } 
    # print out the line if foldchange is less than a cutoff. This would show a decrease. 
    if ($fc > 1.05) { 
    print "$line\n"; 
    } 
} 
#END   
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A4. Chapter VI: Affinity Proteomics Protocols 
Biotin Capture: Reference: “Dynamic Readers of 5-(hydroxy)methylcytosine and its 
oxidized derivatives” Cell 2013. 
Protein Binding Buffer (PBB): 150 mM NaCl, 50 mM Tris-HCl, 1 mM DTT, 0.0025% 
NP40, pH 8.0. 
DNA Binding Buffer (DBB): 1M NaCl, 10 mM Tris-HCl, 1mM EDTA, 0.0005% NP40, 
pH 8.0. 
1. Resuspend the Streptavidin coated beads (Sepharose from GE healthcare).  
a. Note: To ensure bead homogeneity, mix the vial thoroughly by repeated 
inversion, gentle vortexing or using a rotating platform. 
2. Prepare an aliquot of beads with 30 μL per sample.  
a. Wash beads with 3x600N µL DBB.  
i. Where N = the total number of samples.  
b. Resuspend in 700N µL DBB and split into two equal aliquots.  
i. 1 aliquot for clearing non-specific binders and biotinylated 
molecules. 
ii. 1 aliquot for affinity purification. 
3. Clear non-specific binders from the samples:  
a. Note: Perform step 4 at the same time as the steps below. 
b. Separate one of the above aliquots (step 2b) from DBB and resuspend in 
600N µL PBB. 
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c. Add protein (800N µg, where n is the number of samples) to the beads in 
PBB. 
d. Incubate 2 hours at 4°C (cold room) while inverting samples with the 
Labroller. 
e. Separate beads from solution by centrifugation. 
f. Aliquot the supernatant to new tubes for affinity purification. 
4. For affinity purification: 
a. Add 6.5N nmol of DNA to the second aliquot of beads from step 2b. 
b. Incubate for 2 hours at 4 ℃ with inversion. 
c. Separate the beads from solution by centrifugation, discard DBB. 
d. Resuspend in 300N µL PBB. 
e. Transfer 300 µL resuspended beads to each sample from step 3f above. 
f. Incubate 2 hours at 4°C (cold room) while inverting samples with the 
Labroller. 
g. Wash beads from each sample 3x with 300 µLPBB, discarding the 
supernatant each time. 
5. Protein elution: 
a. Incubate beads from each sample in 0.1% SDS at 95°C for 10 minutes to 
disrupt protein-DNA interaction and elute proteins. 
b. Separate beads from solution by centrifugation and transfer supernatant to 
a pre-washed FASP filter as indicated below. 
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FASP Procedure (Using 50 mM HEPES pH: 8) 
1. Wash each FASP filter with 2 x 200 µL 50:50 water:ACN with 0.1% formic acid, 
followed by 2 x 200 µL wash with 0.1% formic acid in water. 
2. The supernatant (Step 5b) was transferred to an Amicon 3K filter and the salts 
were washed away by centrifugation at 14,000 x g for 10 minutes. 
3. Proteins were washed with 3x 100 µL of 50 mM HEPES to remove binding 
buffer and centrifuged at 14,000 x g for 10 minutes.  
4. The proteins were resuspended in 50 mM HEPES to a final volume of 100 µL 
5. Reduction: To the solution, 1 µL of the 200 mM DTT/0.1% SDS in 50 mM 
HEPES was added and the sample was incubated at 55 °C for 1 hour. 
6. Immediately before use, 9 mg of iodoacetamide was dissolved with 132 µL of 
water to make 375 mM iodoacetamide. 
7. Alkylation: To each solution, 1 µL of the 375 mM iodoacetamide was added and 
then incubated for 30 minutes at room temperature protected from light. 
8. Each tube was centrifuged at 14,000 x g for 10 minutes to remove excess reagent. 
9. Samples were washed 3x100 µL 50 mM HEPES with above centrifugation. 
10. The samples were suspended in 50 µL 50 mM HEPES and incubated with 1 µg 
trypsin overnight at 37 oC in a water bath.  
TMT Labeling of tryptic peptides 
1. The tryptic peptides were recovered by centrifugation at 14,000 x g for 10 
minutes into a clean tube.  
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2. The Amicon 3K filters had 3x 50 µL 0.1% formic acid added and centrifuged at 
14,000 x g for 10 minutes to wash peptides through the filter.  
3. One additional wash with 0.1% formic acid in 70% ACN was performed followed 
by centrifugation at 14,000 x g for 10 minutes. 
4. The collected washes for each sample were combined in a glass MS vial with 
insert, then concentrated to dryness under vacuum to remove the formic acid. 
5. Peptides were cleaned-up using C18 spin columns: 
i. Note: maximum loading of 30 µg per column. 
b. Each spin column was washed with 2x 200 µL 50% ACN to activate the 
resin. 
c. Columns were washed 2x 200 µL of 5% ACN/0.5% TFA to equilibrate 
the column. 
d. Reconstitute sample in 100 µL 5% ACN/0.5% TFA. 
i. Ensure sample acidity by checking pH is less than 3.  
e. Load sample on spin column and centrifuge to bind 
i. Collect Flow through and reload the flow through for more 
complete binding. 
f. Wash column with 2x 200 µL 5% ACN/0.5% TFA. 
i. Use 1-2 additional washes if samples contained large amounts of 
salts such as urea.  
g. Rinse collection tube with 0.1% FA in ACN to remove free plasticizers.  
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h. Elute peptides into the collection tube with 3x 20 µL 70% ACN. 
i. Dry the sample to remove ACN. 
6. Once dry, each sample was resuspended in 100 µL of water and quantified using 
Pierce BCA colorimetric peptide kit according to the manufacturer’s instructions. 
7. 2.5-10 µg of peptides for each sample was aliquoted to a new glass MS vial for 
TMT labeling and dried. 
a. If needed, a reference sample can be prepared by adding an equal amount 
of peptides from each sample to a single MS vial.  
i. Example: If 2 runs are needed to analyze all of the samples, then 
the total amount of peptide needed for the reference sample would 
be: Total Reference peptides = 2*(peptide amount for each sample) 
8. Once dry, each sample was reconstituted in 35 µL of 50 mM HEPES pH 8.0. 
9. To each solution, 5 µL of a TMT-sixplex (19.5 µg/µL)was added to the peptide 
solution. 
10. To the solution, 10 µL of ACN to yield a final solution of 50 µL, and 30% ACN. 
a. Note: 30% ACN is essential for effective TMT-labeling of peptides. 
11. Each solution was incubated at room temperature for 2 hours. 
12. Following the incubation, 4 µL of 5% hydroxylamine was added to each solution 
and incubated for 15 minutes. 
a. Note: This solution needs to be prepared fresh by diluting 50% 
hydroxylamine solution. 
378 
 
13. TMT-labeled samples were combined accordingly.  
14. The solutions were concentrated to dryness by speed vac to remove the 
acetonitrile.  
15. TMT-labeled peptides were then fractionated using the Pierce High pH 
Fractionation kit according the manufacturer’s directions for TMT-tagged 
samples.  
a. Note: The kit has fractionation solutions for unlabeled and for TMT-
tagged peptides. It is important to use the most appropriate method for the 
samples. 
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A5. Chapter VI: Description of Proteins Listed on Figure 5.4. 
The proteins here were identified in Experiment 4, Table 5.2 in Chapter V of this thesis. 
Protein descriptions were summarized from the Uniprot database.394  
Thioredoxin-TXN 
Binding preference for: MeC, hmC, fC, and caC 
TXN participates in redox reactions through the reversible oxidation of its active center 
dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions, including S-
nitrosylation of cysteine residues, for example CASP3. 
 
Protein CMSS1- CMSS1 
Binding preference for: MeC, hmC, fC, and caC 
CMSS1 function by binding poly(A) RNA. 
 
Pyruvate kinase PKM- PKM 
Binding preference for: MeC, hmC, fC, and caC 
PKM is a glycolytic enzyme that catalyzes the transfer of a phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP, generating ATP. Stimulates POU5F1-mediated 
transcriptional activation.  
 
Protein PRRC2A- PRRC2A 
Binding preference for: hmC, fC, and caC 
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PRRC2A may play a role in the regulation of pre-mRNA splicing and poly(A) RNA 
binding. 
 
Nuclear autoantigen Sp-100- SP100 
Binding preference for: MeC and fC 
SP100 is a tumor suppressor protein which together with PML is a major constituent of the 
PML bodies, a subnuclear organelle involved in a large number of physiological processes 
including cell growth, differentiation and apoptosis. May also regulate TP53-mediated 
transcription and through CASP8AP2, regulate FAS-mediated apoptosis.  
 
Filaggrin-2- FLG2 
Binding preference for: hmC and fC 
FLG2 is a calcium ion binding protein. 
 
Junction plakoglobin – JUP 
Binding preference for: hmC 
JUP is a common junctional plaque protein, which are needed to arrange and position the 
cytoskeleton and cells within the tissue.  
 
Cellular nucleic acid-binding protein – CNBP 
Binding preference for: hmC, fC, and caC 
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CNBP is a single-stranded DNA-binding protein, with specificity to the sterol regulatory 
element (SRE) and is involved in sterol-mediated repression. 
 
Myristoylated alanine-rich C-kinase substrate - MARCKS  
Binding preference for: C 
MARCKS is the most prominent cellular substrate for protein kinase C. This protein is 
mostly present in the cytoplasm, and binds calmodulin, actin, and synapsin. 
 
Poly(rC)-binding protein 3 - PCBP3 
Binding preference for: C 
PCBP3 is a single-stranded nucleic acid binding protein that binds preferentially to 
cytosine containing DNA.  
 
DAZ-associated protein 1 - DAZAP1 
Binding preference for: C 
DAZAP1 is a RNA-binding protein, which may be required during spermatogenesis. 
 
Far upstream element-binding protein 1 - FUBP1 
Binding preference for: C  
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FUBP1 regulates MYC expression by binding to a single-stranded far-upstream element 
(FUSE) upstream of the MYC promoter. May act both as activator and repressor of 
transcription. 
 
Far upstream element-binding protein 2 – KHSRP 
Binding preference for: C 
KHSRP binds to the dendritic targeting element and may play a role in mRNA trafficking. 
KHSRP also mediates exon inclusion in transcripts that are subject to tissue-specific 
alternative splicing and similar to FUBP1, KHSRP may interact with single-stranded DNA 
from the far-upstream element (FUSE).  
 
Far upstream element-binding protein 3 - FUBP3 
Binding preference for: C 
FUBP3 may interact with single-stranded DNA from the far-upstream element (FUSE) and 
activate gene expression. 
 
Heterogeneous nuclear ribonucleoproteins A2/B1 - HNRNPA2B1 
Binding preference for: C 
Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-
mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on 
nascent hnRNA is non-random and sequence-dependent and serves to condense and 
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stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in 
various processes such as transcription, pre-mRNA processing, RNA nuclear export, 
subcellular location, mRNA translation and stability of mature mRNAs.395-397  
 
Serine-threonine kinase receptor-associated protein – STRAP 
Binding preference for: C 
The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins 
(snRNPs), the building blocks of the spliceosome. STRAP plays a role in the cellular 
distribution of the SMN complex.  
 
Polymerase delta-interacting protein 3 - POLDIP3 
Binding preference for: C, fC, and caC 
POLDIP3 is involved in regulation of translation. Is preferentially associated with CBC-
bound spliced mRNA-protein complexes during the pioneer round of mRNA translation. 
Contributes to enhanced translational efficiency of spliced over nonspliced mRNAs. 
Recruits activated ribosomal protein S6 kinase beta-1 I/RPS6KB1 to newly synthesized 
mRNA. 
 
Heterogeneous nuclear ribonucleoprotein A1 - HNRNPA1 
Binding preference for: C 
384 
 
Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA 
from the nucleus to the cytoplasm and may modulate splice site selection. 
 
Nucleolysin TIAR - TIAL1 
Binding preference for: C 
TIAL1 is a RNA-binding protein and possesses nucleolytic activity against cytotoxic 
lymphocyte target cells. 
 
Replication protein A 70 kDa DNA-binding subunit - RPA1 
Binding preference for: C 
As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and 
stabilizes single-stranded DNA intermediates that form during DNA replication or upon 
DNA stress. It prevents their reannealing and in parallel, recruits and activates different 
proteins and complexes involved in DNA metabolism. Thereby RPA1 plays an essential 
role both in DNA replication and the cellular response to DNA damage.398  
 
Replication protein A 32 kDa subunit - RPA2 
Binding preference for: C 
RPA2 functions as part of the heterotrimeric replication protein A complex (RPA/RP-A) 
with RPA1 above to facilitate binding of ssDNA and its subsequent repair.  
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SAP domain-containing ribonucleoprotein – SARNP 
Binding preference for: C 
SARNP binds both single-stranded and double-stranded DNA with higher affinity for the 
single-stranded form. In addition, SARNP specifically binds to scaffold/matrix attachment 
regions of DNA.  
 
Exosome complex component MTR3 - EXOSC6 
Binding preference for: C and fC 
Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease 
activity and participates in a multitude of cellular RNA processing and degradation events. 
In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA 
species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-
products and non-coding 'pervasive' transcripts, such as antisense RNA species and 
promoter-upstream transcripts, and of mRNAs with processing defects, thereby limiting or 
excluding their export to the cytoplasm.  
 
Serine/arginine-rich splicing factor 8 - SRSF8 
Binding preference for: C  
Involved in pre-mRNA alternative splicing. 
 
Bifunctional polynucleotide phosphatase/kinase – PNKP 
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Binding preference for: fC 
Plays a key role in the repair of DNA damage, functioning as part of both the non-
homologous end-joining (NHEJ) and base excision repair (BER) pathways. Through its 
two catalytic activities, PNK ensures that DNA termini are compatible with extension and 
ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups 
on, the ribose sugar of the DNA backbone. 
 
Myosin-9 - MYH9 
Binding preference for: fC 
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized 
functions such as secretion and capping. During cell spreading, plays an important role in 
cytoskeleton reorganization, focal contacts formation. 
 
Zinc finger protein 185 - ZNF185 
Binding preference for: fC 
May be involved in the regulation of cellular proliferation and/or differentiation. 
 
Non-histone chromosomal protein HMG-17 - HMGN2 
Binding preference for: hmC, fC, and caC 
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Binds to nucleosomal DNA altering the interaction between the DNA and the histone 
octamer. May be involved in the process which maintains transcribable genes in a unique 
chromatin conformation (By similarity). 
 
High mobility group protein B2 - HMGB2 
Binding preference for: fC and caC 
In the nucleus, HMGB2 is an abundant chromatin-associated non-histone protein involved 
in transcription, chromatin remodeling and V(D)J recombination and probably other 
processes. Binds DNA with a preference to non-canonical DNA structures such as single-
stranded DNA. Can bend DNA and enhance DNA flexibility by looping thus providing a 
mechanism to promote activities on various gene promoters by enhancing transcription 
factor binding and/or bringing distant regulatory sequences into close proximity. 399-401  
 
Adipogenesis regulatory factor – ADIRF 
Binding preference for: C 
Plays a role in fat cell development; promotes adipogenic differentiation and stimulates 
transcription initiation of master adipogenesis factors like PPARG and CEBPA at early 
stages of preadipocyte differentiation. Its overexpression confers resistance to the 
anticancer chemotherapeutic drug cisplatin. 
 
Transcriptional enhancer factor TEF-4 - TEAD2 
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Binding preference for: C 
TEAD2 is a transcription factor which plays a key role in the Hippo signaling pathway, a 
pathway involved in organ size control and tumor suppression by restricting proliferation 
and promoting apoptosis. TEAD2 acts by mediating gene expression of YAP1 and 
WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal 
transition (EMT) induction.  
 
14-3-3 protein sigma – SFN 
Binding preference for: MeC and hmC 
SFN is an adapter protein implicated in the regulation of a large spectrum of both general 
and specialized signaling pathways. SFN binds to a large number of partners, usually by 
recognition of a phosphoserine or phosphothreonine motif resulting in the modulation of 
the activity of the binding partner. When SFN is bound to KRT17, it regulates protein 
synthesis and epithelial cell growth by stimulating Akt/mTOR pathway.  
 
E3 ubiquitin-protein ligase ZFP91 – ZFP91 
Binding preference for: MeC, hmC, and fC 
ZFP91 is an atypical E3 ubiquitin-protein ligase that mediates 'Lys-63'-linked 
ubiquitination of MAP3K14/NIK, leading to stabilized and activated MAP3K14/NIK. It 
thereby acts as an activator of the non-canonical NF-kappa-B2/NFKB2 pathway.  
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Non-histone chromosomal protein HMG-14 - HMGN1 
Binding preference for: hmC, fC, and caC 
HMGN1 binds to the inner side of the nucleosomal DNA thus altering the interaction 
between the DNA and the histone octamer. May be involved in the process which maintains 
transcribable genes in a unique chromatin conformation.  
 
Peroxiredoxin-1 - PRDX1 
Binding preference for: C and hmC 
PRDX1 is involved in redox regulation of the cell. PRDX1 reduces peroxides with 
reducing equivalents provided through the thioredoxin system but not from glutaredoxin 
and it may play an important role in eliminating peroxides generated during metabolism.  
 
Annexin A2 - ANXA2 
Binding preference for: C, hmC, and fC 
Calcium-regulated membrane-binding protein whose affinity for calcium is greatly 
enhanced by anionic phospholipids. It binds two calcium ions with high affinity.  
 
RNA-binding protein 4 - RBM4 
Binding preference for: C 
RBM4 in a RNA-binding factor involved in multiple aspects of cellular processes like 
alternative splicing of pre-mRNA and translation regulation. Modulates alternative 5'-
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splice site and exon selection. Exerts a suppressive activity on Cap-dependent translation 
via binding to CU-rich responsive elements within the 3'UTR of mRNAs, a process 
increased under stress conditions or during myocytes differentiation. Recruits EIF4A1 to 
stimulate IRES-dependent translation initiation in response to cellular stress. Associates to 
internal ribosome entry segment (IRES) in target mRNA species under stress conditions.  
 
Histone H2AX - H2AFX 
Binding preference for: C 
Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. 
Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the 
cellular machineries which require DNA as a template.  
